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α-Synuclein (α-syn), is a self-aggregating protein that has been identified as a 
pathologically important component in a number of diseases, such as Parkinson’s 
disease (PD). PD, a progressive neurological disorder affecting 1 in 500 people, 
results in motor dysfunction following the loss of dopaminergic neurones of the 
nigrastriatal pathway. A pathological hallmark of PD is the presence of α-syn 
containing Lewy bodies and Lewy neurites. Although α-syn has been linked to PD 
by both histology and genetic studies on familial PD, neither the physiological 
function nor the pathophysiological role of α-syn in PD has been fully elucidated. 
This thesis examines the cellular responses to exogenously applied recombinant  
α-syn under normal and disease-like conditions. Within this thesis large-scale 
expression and purification of α-syn was successfully established, reproducibly 
producing large quantities of pure recombinant α-syn that was utilised within in vitro 
experiments. In SHSY-5Y neuroblastoma cells, α-syn (10 and 30 µM) significantly 
decreased NAD(P)H levels after 48 h incubation, indicative of either cell death or 
disruption to energy metabolism of the cells. However, α-syn (0.1 - 30 µM) did not 
induce cell death, as determined by the LDH assay, even when the cells were 
exposed for 48 h. Therefore our studies show that under normal, physiological 
conditions, α-syn is not inherently toxic, but does result in a decrease of total cellular 
energy levels. 
 
The mitochondrial toxin, 1-methyl-4-phenylpyridinium ion (MPP+), induced cell 
death in SHSY-5Y cells that was both concentration- and time-dependent. α-Syn (30 
µM) significantly exacerbated MPP+-induced cell death in this model of PD. This 
suggests that while α-syn is normally non-toxic, under PD-like conditions it can 
exacerbate the cell death process. We identified that α-syn (30 µM) significantly 
increased cytosolic Ca2+ levels in a time-dependent manner as well as increasing the 
levels of the apoptotic mediator, cytochrome c (cyt c). The release of cyt c from the 
mitochondria into the cytosol is indicative of mitochondrial dysfunction and pore 
formation within mitochondrial membranes. However, α-syn-induced increase in 
cytosolic Ca2+ was not blocked by the mitochondrial pore inhibitor, cyclosporine A. 
This suggests that α-syn effects were not mediated through the mitochondrial pore 
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usually associated with dysfunction and cyt c release. α-Syn therefore releases cyt c 
and Ca2+ by a separate mechanism, such as the formation of α-syn protofibril pores. 
This was further compounded by data that showed that α-syn (30 µM) significantly 
decreased mitochondrial membrane potential after 48 h incubation. The loss of the 
mitochondrial membrane potential coincided with a decrease in NAD(P)H. These 
data would therefore suggest that physiologically α-syn induces a low, non-toxic 
effect on the mitochondrial membrane. Under pathological conditions similar to PD 
however, this mitochondrial stress mediated by α-syn acts to exacerbate cell death.
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Chapter 1: Introduction 
1.1 Synuclein Proteins 
1.1.1 Synucleins and the synuclein family. 
Synucleins are a small family of soluble proteins that potentially have a role in a 
number of disorders such as Parkinson’s disease (PD). Ranging in size from 127 to 
140 amino acids, the family consists of 4 members; α-, β-, γ-synuclein and synoretin. 
The family of proteins have a high level of sequence conservation and are also 
conserved across a number of animal species (Maroteaux and Scheller 1991; 
Buchman, 1998; Lavedan, 1998). α-Synuclein (α-syn) was first identified by 
Maroteaux et al. (1988) in the electric ray (torpedo californica). β-Synuclein (β-syn) 
was subsequently identified by Nakajo et al. (1990) and originally termed 
phosphoneuroprotein 14 (PNP 14), (Nakajo et al., 1990; Nakajo et al., 1993). 
However, PNP 14 was observed to share a high percentage of sequence homology 
and localisation with α-syn leading to its renaming to β-syn (Jakes et al., 1994; 
Shibayama-Imazu et al., 1998). A short while later γ-syn was discovered by Ji et al. 
in 1997, who isolated the γ-syn gene within breast cancer and originally named 
breast cancer-specific gene 1 (BCSG1) (Ji et al., 1997). The gene was quickly re-
classified after its homology to α-syn was characterised (Lavaden et al., 1998; 
Buchman et al., 1998). Synoretin was identified in the brain and retinal cells by 
Surguchov et al. (1999). Interestingly the synoretin protein shows more homology to 
γ-syn than α-syn (Surguchov et al., 1999). Since the identification of the synuclein 
family, the chromosomal loci for each of the synuclein genes has been identified; α-
syn is located at 4q21.3 (Spillantini et al., 1995; Shibasaki et al., 1995); β-syn at 
5q35 (Spillantini et al., 1995); γ-syn at 10q23 (Lavedan et al., 1998). However, the 
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chromosomal location for synoretin has not at present been identified (Murray et al., 
2001). 
 
Synuclein proteins are expressed throughout the body with highest expression levels 
in the central and peripheral nervous systems (CNS and PNS), especially in the brain 
(Jakes et al., 1994; Buchman et al., 1998; Lavedan, 1998). Immunohistochemical 
studies of α-, β- and γ-syn expression in the brain indicated that the synuclein 
proteins were expressed within similar regions of the brain, predominantly in the 
thalamus, substantia nigra (SN), hippocampus, caudate nucleus and amygdala 
(Lavedan, 1998), although β-syn was shown to have lower expression levels 
compared to α-syn and γ-syn (Shibayama-Imazu et al., 1993; Lavedan, 1998). 
 
Outwith the CNS further immunohistochemical studies have shown hetrogeneous 
expression of α-, β- and γ-syn in a diverse range of tissues and cells (Jakes et al., 
1994). γ-Syn has been shown to have considerable expression in the PNS (Buchman 
et al., 1998; Ninkina et al., 1999) as well as within skin and retinal cells (Ninkina et 
al., 1999). γ-Syn was, as mentioned previously, identified within breast cancer cells 
and has also been suggested to be over-expressed in ovarian tumours (Ji et al., 1997; 
Lavedan et al., 1998). α-Syn expression has been shown in platelets, haematopoietic 
cells, neuromuscular or junctions and cardiac tissue (Uéda et al., 1994; Li et al., 
2002; Michell et al., 2005). β-Syn has been shown to have localised expression in 
sertoli cells of the testis (Shibayama-Imazu et al., 1998). However, synoretin has 
only been shown to be expressed in the brain and retinal cells (Surguchov et al., 
1999) 
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1.1.2 Structure of α-syn. 
At the molecular level, all members of the synuclein family contain a phospholipid 
binding N-terminal and a negatively charged acidic C-terminal (Uversky et al., 
2002). They exhibit 55 – 62 % sequence conservation with similar domain 
organisation (Lavedan, 1998; Uversky et al., 2002), containing several repeats of an 
11 residue motif (containing variations of a “KTKEGV” residue sequence; see figure 
1.1) (Buchman et al., 1998; Ninkina et al., 1998; Murray et al., 2001). α-Syn and β-
syn have identical carboxyl termini (Lavedan, 1998) and very similar structures 
(Tsigelny et al., 2007). The C-terminal sequence of α-syn is highly conserved across 
species; human α-syn has been shown to be 95.3 % identical to the rodent sequence 
(Polymeropoulos et al., 1997). There are only 6 amino acid differences, one of these 
being the amino acid at position 53. This is normally an alanine (A) in humans and a 
threonine (T) in rodents. However, the substitution, A53T in humans, has been 
shown to be one of the mutations which is linked to a familial form of PD (Lavedan, 
1998). 
 
The organisation of synuclein sequences causes the formation of a random coil 
structure when in solution (Wienreb et al., 1996). The coils contain a hydrophobic 
region that interacts with membranes and allows penetration of synuclein proteins 
into the bilayer interior of the membranes and helps stabilise the lipid-protein 
interaction (Davidson et al., 1998). Within the α-syn sequence, amino acids 61 – 96 
are identical to the non-amyloid component (NAC) of amyloid plaques found in 
Alzheimer’s disease (AD) (Iwai et al., 1995; Weinreb et al., 1996). These residues 
are also thought to be important in phospholipid binding and 
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Figure 1.1: The comparison of synuclein family amino acid sequences.  
The total number of residues in α-, β-, γ-synuclein and synoretin proteins are 140, 134, 127 and 
127 respectively. The amino acid sequence alignments of human synucleins are compared above. 
The identification of the 11 residue repeats are indicated by orange lines. Residues that are shared 
by 2 synuclein family members are highlighted in grey and 3 or more are highlighted in black. 
Gaps within the sequences are indicated with dashes (adapted from Davidson et al., 1998 and 
Chandra et al., 2003). 
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chaperone properties of α-syn. With the isolation of NAC in amyloid plaques the 
NAC region of α-syn has been implicated in the capacity of α-syn to aggregate and 
form fibrils in diseases such as PD and dementia with Lewy bodies (DLB) (Weinreb 
et al., 1996). This has been further supported through the inability of β-syn to 
aggregate under physiological conditions; β-syn is almost identical to α-syn but does 
not contain the NAC region (Weinreb et al., 1996). This theory is however 
complicated by γ-syn, which contains the NAC region and forms dimers, but does 
not aggregate (Uversky et al., 2002). Studies have shown that although β-syn and γ-
syn do not aggregate they are able to reduce α-syn aggregation, possibly through 
binding to the dimerised and protofibril forms of α-syn, preventing completion of the 
aggregation process (Uversky et al., 2002; Tsigelny et al., 2007). 
 
α-Syn has been show to have a primarily random structure within the cytosol of cells, 
(Ischiropoulos, 2003). However, upon binding to phospholipid membranes, α-syn 
undergoes a conformational change converting to a predominantly α-helical structure 
(figure 1.2 and figure 1.3) (Davidson et al., 1998). The C-terminal (residues 96 - 
140) of α-syn appeared to remain unstructured upon α-syn binding to phospholipid 
membranes (Bussell and Eliezer 2003; Chandra et al., 2003; Ulmer et al., 2005). As 
α-syn is randomly structured in solution, the secondary structure only occurs after  
α-syn has bound to a phospholipid membrane. This secondary structure forms 








Figure 1.2: Helical wheel predication of α-syn secondary structure. 
An idealised α-helix wheel analysis of residues 1 to 96 containing 11 residue repeats producing a 5 
α-helical secondary structure within the N-terminal of α-syn. Non-polar residues are shaded black, 
polar residues are shaded grey, and charged residues are unshaded (adapted from Davidson et al., 
1998) Each of the five a-helices are shown: A) helix 1 composed of 1 – 15; B) helix 2 composed 
of 17 – 37; C) helix 3 composed of 39 – 48; D) helix 4 composed of 50 – 60; E) helix 5 composed 












Figure 1.3: Computer schematic of the structure of phospholipid bound α-syn.  
Using NMR the membrane bound structure of α-syn has been interpreted by Ulmer et al (2005), 
where A) shows the ensembly of twenty structures superimposed on top of each other. The N-
terminal forms two α-helices with a short linking region between the helices and the unstructured 
C-terminal (analysis by NMR by Ulmer et al., 2005). B) A side view of the average α-syn 
structure showing the curve α-helices when membrane bound (analysis by NMR by Ulmer et al., 
2005). C) Shows the structure within a phospholipid membrane with the N-terminal partially 
inserted into the membrane and the C-terminal unstructured which does not interact with the 
membrane. 
 25 
α-Syn preferentially binds to highly curved and acidic membranes (Davidson 
et al., 1998) as opposed to neutral or positively charged flatter membranes, giving 
evidence towards α-syn being involved in vesicle transport and regulations in cells 
(Davidson et al., 1998; Narayanan and Scarlata, 2001). The curvature of the bound 
phospholipid membrane appears to alter the position of the α-helices of α-syn such 
that the helices fold in on themselves becoming parallel (as opposed to relatively flat 
membranes where helices remain linear) (Bussell and Eliezer 2003; Chandra et al., 
2003; Ulmer et al., 2005). This implies that the linking region acts like a hinge 
between the two helices separating them depending on the curvature of the 
membrane to which α-syn is bound (Ulmer et al., 2005). 
 
1.1.2.1 α-Syn oligomer formation.  
Though primarily a soluble protein, α-syn has been shown to under go abnormal 
assembly that results in its oligermisation and the formation of fibrils. α-Syn fibrils 
have been identified with the formation of Lewy bodies (LB) and Lewy neurites 
(LN) within synucleinopathies such as PD. 
 
While α-syn has the potential to self-aggregate, the aggregation rate can be 
augmented by a number of cellular and environmental factors such as; metals (Al3+, 
Cu2+ and Fe2+) (Paik et al., 1999; Uversky et al., 2001; Golts et al., 2002), 
neurotoxins (1-methyl-4-phenylpyridine (MPP+) and rotenone) (Kalivendi et al., 
2004), cytochrome c (cyt c), calcium (Ca2+) and dopamine (DA) (Hashimoto et 
al.,1999; Lowe et al., 2004; Cappai et al., 2005). The aggregation of α-syn arises 
through α-syn undergoing a conformational change from a random α-helical 
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structure to β-sheet formation, leading to the formation of fibrils (El-Agnaf et al., 
1998). During the aggregation process α-syn forms homodimers, which could adopt 
non-propagating and propagating conformations (Tsigelny et al., 2007). The 
propagating dimers can consist of pentamers and hexamers that can form ring 
structures (Tsigelny et al., 2007). Further to this α-syn has been shown through 
atomic force microscopy and other methods, to form a number of intermediates 
including spheres, chains of spheres and rings, all of which are referred to as 
protofibrils (Conway et al., 2000a; Ding et al., 2002; Hoyer et al., 2004). The α-syn 
protofibril rings have been shown to bind to synthetic membranes and permeablise 
vesicles (Volles et al., 2001; Ding et al., 2002; Volles and Lansbury 2002; Tsigelny 
et al., 2007). This ability is similar to that observed by some bacterial toxins or a 
detergent-like mechanism, which perforate membranes through the insertion of pore-
like structures. This would indicate that the formation α-syn aggregates could induce 
a toxic effect upon cells through the possible formation of pores (Ding et al., 2002; 
Lashuel et al., 2002; Volles et al., 2002). Aggregation of α-syn could also lead to the 
loss of function of soluble α-syn (by virtue of its decreased levels) in cellular 
processes that include the regulation of synaptic plasticity (George et al., 1995), DA 
biosynthesis and regulation (Perez et al., 2002; Baptista et al., 2003; Wersinger and 
Sidhu, 2003a; Yavich et al., 2004) and regulation of vesicle transport (Yavich et al., 






1.1.3 Functional role of α-syn.   
The cellular role of α-syn has not yet been fully defined. α-Syn has however, been 
implicated in a number of different cellular processes within neurones which include 
the regulation of synaptic plasticity (George et al., 1995) and neuronal differentiation 
(Hashimoto et al., 1997; Satoh and Kuroda, 2001). Recently however, it seems to be 
emerging that primary roles of α-syn may lie in the regulation of synaptic vesicles, 
such as vesicle trafficking and recycling (see section 1.1.3.1.3) (Yavich et al., 2004; 
Wersinger and Sidhu, 2005; Roy et al., 2007). α-Syn has also been implicated in the 
regulation of DA, including DA biosynthesis, and regulation of DA transporters 
(DAT) (sections 1.1.3.2 and 1.1.3.3) (Perez et al., 2002; Baptista et al., 2003; 
Wersinger and Sidhu, 2003a; Yavich et al., 2004).  
 
1.1.3.1 Indication of α-syn functions through sequence homology. 
1.1.3.1.1 α-Syn as a chaperone protein. 
Homology studies on the sequence of α-syn have identified similarities to the 
chaperone proteins termed 14-3-3 proteins (Ostrervoa et al., 1999) (figure 1.4) and 
fatty acid binding proteins (FABP) (Sharon et al., 2001). Further support for a role as 
a chaperone protein is provided by structural studies that show α-syn interaction with 
phospholipid membranes (Davidson et al., 1998; Bussell and Eliezer 2003; Chandra 
et al., 2003; Ulmer et al., 2005) and other proteins such as 14-3-3 proteins, protein 
kinase C, phospholipase D2 and DAT (Ostrervoa et al., 1999; Wersinger and Sidhu, 








Figure 1.4: Sequence homology of α-syn and 14-3-3 proteins. 
The homology between α-syn N-terminal (amino acid 1 to 60) and amino acids 38 – 102 of 14-3-3 
proteins are compared. Regions in white letters on black background identify exact matches 
between the sequences; black letters on grey indicates amino acids with similar properties. (Taken 
from Ostrervoa et al., 1999)  
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While the homology between α-syn N-terminal and 14-3-3 proteins 
(Ostrerova et al., 1999) coincides with the highly conserved region of the N-terminus 
that is present in all the synuclein proteins (see figure 1.1) there is no report of 
similar 14-3-3 ligand binding for β- and γ-syn. 
 
1.1.3.1.2 α-Syn as a fatty acid-binding protein.  
Homology studies have highlighted sequence similarities between α-syn and FABP 
(Sharon et al., 2001). Sharon et al. (2001), demonstrated that two 18 residue regions 
in the α-syn sequence at the N- and C-termini share homology with a signature motif 
characteristic of FABP (55 % and 67 % respectively). As FABP are a diverse family 
of ~ 15 kDa cytosolic lipid transport proteins, α-syn may be involved in the 
transportation of fatty acids (FA) between aqueous and membrane phospholipid 
compartments. FABP expression has been shown to be tissue specific (Kurtz et al., 
1994; Sharon et al., 2001). For example in the brain, brain specific FABP ((B)-
FABP) was identified as a 14.5 kDa protein localised to glial cells (Kurtz et al., 
1994). α-Syn does not co-express with (B)-FABP in glial cells (Sharon et al., 2001), 
but is however, present in almost all other cell types within the brain (Uéda et al., 
1993; Jake et al., 1994). This has led to the suggestion that α-syn may be a novel 
brain specific FABP and associates with fatty acids such as oleic acid through the 
regions of homology (Sharon et al., 2001).  
 
It is important to note, that α-syn may not be a novel brain FABP, but rather a 
chaperone for vesicles including, but not limited to fatty acid-transport (Lücke et al., 
2006). This theory was borne out by Lücke et al. (2006), who showed that α-syn 
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bound to the negatively charged surface of oleic acid bilayers, but did not appear to 
bind other FA (Golovko et al., 2005, Lücke et al., 2006). Lücke et al. (2006) 
concluded that α-syn did not act as an intracellular FA carrier, but that the binding of 
α-syn to oleic acids was simply an intrinsic property to interact with negatively 
charged membranes (Lücke et al., 2006). The N-terminal sequence of β-syn is almost 
identical to α-syn (as shown in figure 1.5) (Sharon et al., 2001) and therefore would 
also share homology to the same FABP motif. While the N-terminal region of α-syn 
may or may not be involved in phospholipid binding, it may be the case, however, 
that the C-terminus of α-syn may also bind fatty acids and interact with proteins such 
as microtubulin and DAT (Wersinger and Sidhu, 2003a; Wersinger and Sidhu, 2005; 
Roy et al., 2007).  
 
 31 
        
     
Figure 1.5: Identification of fatty acid-binding motif within α-, β- and γ-syn sequences. 
The total number of residues in each protein is 140, 134, and 127 respectively.  Residues which are 
shared between 2 or all the synuclein sequences are highlighted in black. The green boxes indicate 
the regions of the synuclein sequences which show homology with the fatty acid-binding protein 
signature motif. Gaps in the β and γ sequences relative to α-syn are indicated with dashes (adapted 
using Sharon et al., 2001 and Chandra et al., 2003). 
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1.1.3.1.3 α-Syn involvement in vesicle trafficking. 
α-Syn has been shown to be a potent inhibitor of Phospholipase D (PLD) enzymes 
through in vitro studies by Jenco et al. (1998). PLD enzymes are a family of enzymes 
which are involved in lipid mediated signalling cascades and vesicle trafficking 
(Payton et al., 2004). The PLD family consist of two isoforms, PLD1 and PLD2 
(Colley et al., 1997). PLD1 and PLD2 are a phosphatidycholine-specific hydrolases 
that metabolise phosphatidylcholine to generate choline (used in the production of 
the neurotransmitter acetylcholine, and phoshatidic acid; PA (Colley et al., 1997). 
PA and its metabolites exhibit second messenger properties that are involved in the 
mediation of vesicular transport, mitogeneis, receptor-mediated endocytosis and 
cytoskeleton rearrangement (Colley et al., 1997). PA has also been associated with 
the recruitment of adaptor molecules that trigger the building of vesicles from donor 
membranes (Jenco et al., 1998). Furthermore, PA is metabolised by diacylglycerol 
kinase to produce diacylglycerol (DAG), which is involved in the activation of 
protein kinase C (PKC) and other diacylglycerol-dependent enzymes (Jenco et al., 
1998; Nishizuka, 1995). Activated PKC isoforms are involved in the activation of 
protein by phosphorylation, such as DAT (Chang et al., 2001). In summary, it would 
appear that PLDs are involved in the regulation of neurotransmitter generation 
through the production of choline and the regulation of DAT and the vesicle cycle 
(figure 1.6). PLD inhibition therefore suggests a role of α-syn in all these 
downstream events.  
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DAT activation and 
DA uptake 
Figure 1.6: A basic schematic of the PLD2 pathway and it’s inhibition by α-syn.  
The schematic shows the production of Phosphatidic acid (PA) from phosphatidylcholine by 
Phospholipase D2 (PLD2) and how PA and PA metabolites effect different cellular pathways; 
cytoskeleton rearrangement, vesicle recycling, dopamine (DA) uptake by dopamine transporter 
(DAT) activation. α-Syn inhibits PA metabolism and blocks the subsequent pathways. Key: DAG 
(Diacylglycerol), DAGK (Diacylglycerol kinase), PA (Phosphatidic acid), PAP (Phosphatidic acid 
phosphohydrolase), PKC (Protien kinase C) and PLD2 (Phospholipase D2). 
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α-Syn inhibition of PLD2 was shown to be modulated by the phosphorylation 
of α-syn at serine 129 (ser129), as well at tyrosine 125 or tyrosine 136 (Payton et al., 
2004). Within the cell, such phosphorylation of α-syn can be achieved by various 
seryl/threonyl proteins such as calmodulin kinase II (calcium-dependent manner), 
casein kinases (CK1 and CK2) and G protein-coupled receptor kinases (GRK) 
(Pronin et al., 2000). Activated G protein-coupled receptor kinase 5 (GRK5) showed 
the highest efficiency of phosphorylating α-syn specifically in the presence of 
phospholipids (Pronin et al., 2000; Martinez et al., 2003).  
 
The binding of α-syn to phospholipid membranes may enhance its phosphorylation 
due to a conformational change increasing the accessibility of ser129 residue (Pronin 
et al., 2000; Payton et al., 2004). Furthermore, the expression level of α-syn within 
neurones also appears to influence the phosphorylation of α-syn by the activation of 
GRK5 via the Ca2+-calmodulin complex (Chuang et al., 1996; Pronin et al., 2000; 
Martinez et al., 2003). In the absence of α-syn, the Ca2+-calmodulin complex inhibits 
GRK5 by preventing autophosphorylation, activation and the phosphorylation of 
other substrates. However, in the presence of α-syn, the complex stimulates GRK5 
autophoshorylation and increases the phosphorylation of α-syn (Martinez et al., 
2003). This would suggest that α-syn may act as a switch to convert the Ca2+-
calmodulin complex from inhibitor to an activator of GRK5 (Martinez et al., 2003). 
 
α-Syn has been further implicated in the regulation of vesicle trafficking by a study 
that showed α-syn increased vesicle-mediated α-granule secretion from platelets 
(Park et al., 2002). This suggests a role for α-syn that is not just limited to neuronal 
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synapses but, potentially many cell types (Uéda et al., 1994; Li et al., 2002; Michell 
et al., 2005).  
 
1.1.3.2 α-Syn regulation of DA biosynthesis.   
α-Syn has been implicated in a number of mechanisms, such as an interaction with 
DAT, inhibition of tyrosine hydroxylase (TH), PKC and extracellular signal-
regulated kinase (ERK), which directly regulate/modulate the biosynthesis of DA 
(Ostrerova et al., 1999; Perez et al., 2002).  
 
DA is a member of the catecholamine family of neurotransmitters belonging to the 
larger monoamines family (Kingsley, 2000; Longstaff, 2000). Catecholamines are 
found throughout both the CNS and PNS (Kingsley, 2000; Longstaff, 2000). In the 
CNS, the cell bodies of dopaminergic neurones are concentrated in the basal ganglia; 
primarily the substantia nigra pars compacta (SNpc) and dopaminergic neuronal 
terminals in stratum (York, 1970; Kingsley, 2000). DA is synthesised by the 
hydroxylation of tyrosine by TH to produce the 3,4-dihydroxyphenylalanine (L-
DOPA) intermediate, which is then decarboxylated to produce DA (figure 1.7) 
(Longstaff, 2000). The production of DA is regulated by the availability of TH, 
which acts as a rate-limiting step. In order for TH to convert tyrosine to L-DOPA, 
TH is phosphorylated at two serine residues, ser 19 and 40 (Haycock, 1990; Kumer 
and Vrana, 1996; Kleppe et al., 2001). 14-3-3 protein and Ca2+/calmodulin-
dependent protein kinase II have been shown to be the main enzymes that 
phosphorylate TH at theses serine residues (Haycock, 1990; Kumer and Vrana, 1996; 
Kleppe et al., 2001). 
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L-Aromatic amino acid 
decarboxylase 
Figure 1.7: DA synthesis from L-Tyrosine (adapted from Longstaff, 2000). 
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14-3-3 proteins interact and increases the active half life of a number of 
ligands including TH (Itagaki et al., 1999; Perez et al., 2002). α-Syn, by binding 
dephosphorylated TH, decreases DA synthesis and maintains TH deactivation (Perez 
et al., 2002). α-Syn also binds MAP kinase (inhibiting ERK activation) and 
inhibiting both Ca2+/calmodulin-dependent protein kinases (Ostrerova et al., 1999) 
and further decreasing TH activity (Perez et al., 2002). 
 
1.1.3.3 α-Syn regulation of DAT.  
A number of studies have implicated α-syn in the regulation of DA re-uptake from 
the presynaptic cleft through the ability of α-syn to associate with DAT and reduce 
DAT activity (Ostrervoa et al., 1999; Wersinger and Sidhu, 2003a; Sidhu et al., 
2004).  
 
DAT is a member of a large family of Na+- and Cl--dependent transporters that share 
a common topology of 12 putative transmembrane domains containing numerous 
consensus sequences for N-linked glycosylation. These transmembrane domains also 
contain recognised phosphorylation sites for PKA, PKC and calmodulin kinase II, 
which when phosphorylated, activate DAT and the uptake of DA from the synaptic 
cleft (Wersinger et al., 2004). It is speculated that the regulation of DAT is a crucial 
component in the maintenance of dopaminergic neurotransmission and the levels of 
intracellular DA (Lee et al., 2001; Wersinger et al., 2004). The rapid shuttling of 
DAT to and from the plasma membrane is thought to be one of the main mechanisms 
involved in the regulation of DAT activity and of DA cytosolic concentration (Sidhu 
et al., 2004 ; Wersinger and Sidhu, 2005). Within the presynaptic terminal, α-syn has 
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been implicated as one of the proteins involved in the transportation of DAT to and 
from the plasma membrane (Wersinger and Sidhu, 2005).  
 
α-Syn forms a heteromeric complex with DAT, with the last 22 residues of DAT 
associating with residues 58 – 107 of α-syn, a region that is in the NAC region (Lee 
et al., 2001; Wersinger and Sidhu, 2003a). Cells co-expressing α-syn and DAT, 
showed a 35 % reduction in DAT activity compared to cells transfected with DAT 
alone. α-Syn previously been shown to associate with a number of cytoskeletal 
protein such as tubulin, microtubulin, tau (Jensen et al., 1999; Zhou et al., 2004; 
Alim et al., 2004), and can also associate with α- and β-tubulin when in complex 
with DAT (Wersinger and Sidhu 2005). α-Syn has also been shown to increase DAT 
mobility and targeting to the plasma membrane, leading to the suggestion that it acts 
as an anchor tethering DAT to the microtubular network prior to its transportation 
across the cytoplasmic membrane (Wersinger and Sidhu, 2003a; Wersinger and 
Sidhu, 2005). This hypothesis was further strengthened by the suggestion of α-syn as 
a possible slow component-b protein of axonal transport (Roy et al., 2007), shuttling 
DAT to and from the cellular membrane.  
 
A consequence of α-syn regulating vesicle trafficking, DA biosynthesis and reuptake, 
is the increased exposure of the cell to the cytotoxic properties of DA (Wersinger and 
Sidhu, 2003b). This interaction between α-syn and DA may be important in the link 
between α-syn and neurodegenerative disorders such as PD (Rochet et al., 2004; 
Follmer et al., 2007). 
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1.2 Parkinson’s disease. 
While a physiological role of α-syn is only just beginning to emerge, an involvement 
in the pathophysiology of diseases such as PD has been recognised for decades. PD 
is a progressive neurological disorder first described in 1817 by Dr James Parkinson 
in the essay entitled “An Essay on the Shaking Palsy’’ (Parkinson J, 2002 (reprint)). 
While the majority of PD patients present with idiopathic PD, 5 - 10 % of PD 
patients have a pre-disposing genetic mutation for PD (Cordato and Chan, 2004; 
Gandhi and Wood, 2005). These genetic abnormalities all link directly or indirectly 
to α-syn. 
 
1.2.1 Symptoms and neuropathology of PD. 
PD is clinically a movement disorder with patients initially presenting with resting 
tremor, rigidity, loss of balance and bradykinesia (slowness of movement). With the 
development of the disease the symptoms increase in severity and the patient 
develops secondary symptoms including loss of dexterity, difficulties in co-
ordination, visual symptoms such as hallucinations or loss of vision, depression, pain 
and sensory discomfort, sexual difficulty, blood pressure changes, dermatological 
changes, gastrointestinal, and urinary difficulty (Duvoisin, 1978; Lieberman and 
Williams, 1993; Marsden and Fahn, 1995; Valls-sole and Valldeoriola, 2002). Many 
PD patients develop a characteristic walk of a fast-shuffling gait, finding it hard to 
start walking and once in motion finding it equally as difficult to change direction or 
stop quickly (Longstaff, 2000). The progression of symptoms are mirrored by 
degeneration of the dopaminergic cell bodies within the basal ganglia, specifically 
the SNpc, loss of the nigrostriatal projections from the SNpc and a substabtial 
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reduction in DA in the striatum. The terminal decline of these dopaminergic 
neurones and the loss of DA in the striatum results in abnormal regulation of the 
motor pathways within the cortex. This is speculated to be the mechanism 
responsible for the development of symptoms such as bradykinesia and rigidity 
within the PD sufferer (figure 1.8) (Hallett and Khoshbin, 1980; Dewaide et al., 
2000; Valls-Solé and Valldeoriola, 2002). 
 
Dopamine receptors are found on both the pre- and post-synaptic ends of neurones 
and are involved in regulating the activation and release of neurotransmitters. 
Different receptors modulate different reactions. D1 receptors are coupled with the 
adenyl cyclase 5’-adenosine (cAMP) second messenger system, enhancing the 
excitatory input and resulting in an increase cAMP synthesis. D2 receptors are 
coupled with G-proteins that inhibit adenyl cyclase, thus reducing cAMP synthesis 
and reducing the excitatory affect. D2 receptors are also auto-receptors on 
dopaminergic neurones in the SNpc and ventral tegmentum controlling DA synthesis 
(Herman et al., 1994; Jaber et al., 1996; Blandini et al., 2000; Longstaff, 2000; Onn 
et al., 2000) by reducing cAMP levels and inhibiting PKA-mediated TH synthesis 
(Jaber et al., 1996; Longstaff, 2000). When D3 auto-receptors are activated by DA 
binding, they signal the closure of pre-synaptic Ca+2 channels that in turn reduce the 
release of DA into the synaptic cleft (Jaber et al., 1996; Longstaff, 2000). Therefore, 
DA mainly acts in three mechanistic pathways. The first is the aforementioned SNpc 
pathway that is important in motor control (Jaber et al., 1996; Rang et al., 1999; 
Longstaff, 2000). Secondly, there are the mesolimbic/mesocortical pathways 
whereby dopaminergic cells based in the midbrain run axons through to the limbic 
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Figure 1.8: Schematic of the brain regions and pathways effected by PD. 
A schematic diagram showing the normal pathways and neurotransmitters linking between the 
brain regions and how PD affects the pathways and reduces the neurotransmitters within these 
brain regions. ACh = acetylcholine (neurotransmitter), DA = dopamine (neurotransmitter), GP = 
Globus Pallidus and GABA = γ-amino-butyric acid (neurotransmitter) (adapted from Blandini et 
al., 2000).  
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system (i.e. the cortex) and are involved in the control of emotions and drug-induced 
reward systems (Herman et al., 1994; Jaber et al., 1996). Finally, there are the 
tuberohypophyseal neurones located in the hypothalamus that are involved in the 
regulation of pituitary-gland secretions (Jaber et al., 1996; Rang et al., 1999). At 
present it is believed that, with PD-induced dopaminergic cell loss, the remaining 
neurones overproduce DA. The number of DA receptors and other neurones are also 
increased giving rise to a hypersensitive state (Herman and Abrous, 1994). These 
attempts by neuronal cells to preserve the integrity of DA transmission critically 
determine the effectiveness of drug treatments such as levodopa, which are designed 
to compensate for the lack of endogenously produced DA (Jaber et al., 1996).  
 
PD symptoms only present themselves when over 50 % of the dopaminergic 
neurones projecting into the striatum have been lost (Cornford et al., 1995; Zhang et 
al., 2000; Braak et al., 2003). A definitive diagnosis of PD can only be determined 
upon examination of the brain at post-mortem, as a number of other degenerative 
diseases of CNS present with parkinsonism (PD symptoms) such as Multisystem 
atrophy (MSA) (Cornford et al., 1995; Valls-Solé and Valldeoriola, 2002). A 
diagnosis of PD is confirmed by the observation of selective neuronal loss in the SN, 
along with the identification of characteristic α-syn containing LBs and LNs 
(Cornford et al., 1995; Forno, 1996; Mezey et al., 1998; Zhang et al., 2000; Wood-
Kaczmar et al., 2006). However neuronal loss is also observed in the dorsal motor 
nucleus of the vagus, the hypothalamus, cholingeric nucleus basalis Meynert, locus 
coeruleus (LC), midbrain, raphe nuclei, cerebral cortex and olfactory bulb (Cornford 
et al., 1995; Forno et al., 1996). The progression of PD has been suggested to start in 
 43 
the brainstem (dorsal motor neucleus of the vagal nerve) progressing into the 
midbrain and forebrain, and finally into the cerebral cortex (Braak et al., 2003; Braak 
et al., 2004). This is accompanied with gradual development of LBs (protein 
aggregates in the somata of cells) and LN (similar deposits in the axons and 
dendrites) of selective neurones in SN, LC, cerebral cortex, anterior thalamus, 
hypothalamus, amyygdala and basal forebrain (Cornford et al.,1995; Takahashi and 
Wakabayasgi., 2001; Wood-Kaczmar et al., 2006). Long axoned, partially or none 
myelinated neurones and melanin-containing dopaminergic neurones are 
predominately affected by the progression of PD, with short axoned cells appearing 
to be resistant to the pathology (Foley and Riederer, 2000; Braak et al., 2003; Braak 
and Del Tredici 2004; Braak et al., 2006).  
 
Mitochondrial dysfunction, specifically a decrease in the activity of complex I in the 
electron transport chain (ETC), has been identified as a main characteristic of PD 
(Schapira et al., 1989; Reichmann and Janetzky, 2000; Zhang et al., 2000) along 
with increase oxidative stress (Foley and Riederer, 2000). The decrease in complex I 
activity has been shown to be limited to the SNpc and neurones containing high 
levels of melanin (Janetzky et al., 1994; Reichmann and Janetzky, 2000). 
Interestingly, no mitochondrial dysfunction was identified within any other brain 
region, not even in the SNpr (Janetzky et al., 1994; Reichmann and Janetzky, 2000). 
Analysis of mitochondrial enzymes (eg. citrate synthetase and hydroxyacyl-CoA 
dehydrogenase) and cyoplasmic enzymes (eg. pyruvate kinase and lactate 
dehydrognease) from PD brains, revealed no change in the level or activity of other 
mitochondrial proteins within PD brains (Schapira et al., 1989; Mizuno et al., 1990; 
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Reichmann and Janetzky, 2000). The cause of the mitochondrial dysfunction by 
reduced complex I activity is still not fully understood however, it is thought 
increased oxidative stress, free radicals (Olanow, 1993; Foley and Riederer, 2000; 
Martin et al., 2003) and increased iron levels observed in PD patients brains, mainly 
in the SN (Dexter et al., 1987; Sofic et al., 1988; Sofic et al., 1991), may be linked.    
 
The underlying mechanisms involved in the causation of sporadic forms of PD 
remain obscure but a number of environmental causes have been implicated. These 
include, arteriosclerotic parkinsonism induced by multiple small strokes (Inzelberg et 
al., 1994, Rang et al., 1999), heavy metals (e.g. manganese or iron) (Graham, 1984; 
Sengstock et al., 1992; Nakano, 1993; Montgomery, 1995), carbon monoxide 
(Klawans et al., 1982) and neurotoxins such as MPP+, rotenone (Lee et al. 2002; 
Shimohama et al. 2003; Fernagut and Chesselet, 2004), paraquat (Fukushima et al., 
1993; Liou et al., 1996; Dinis-Oliveira et al., 2006) and 6-hydroxydopamine  
(6-OHDA) (Ungerstedt, 1968; Sachs and Jonsson, 1975; Soto-Otero et al., 2000) and 
certain drugs such as the psychiatric treatments chlorpromazine and haloperidol 
(Marsden and Fahn, 1995; Rang et al., 1999). 
 
Due to the progressive nature of the disease it has been suggested there is a 
predetermined sequence of disease progression which moves up from the brain stem 
and systematically progressing upwards into the cortex (figure 1.9) (Braak et al., 
2004). It has been suggested that a pathogen such as a neurotropic virus or a 
pathogen possessing unconventional, prion-like, properties could be involved in the 
pathogenesis of PD (Braak et al., 2004). It has been implied that such a pathogen 
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Braak’s stages of PD progression 
Figure 1.9: Schematic of the Braak’s stages of the progression of PD. 
Schematic representation of Braak’s stages of PD showing the progression of PD through the 
different regions of the brain from the brain stem up through the cortex. Symptoms only present 
once the neurodegeneration has reached the central nucleus or stage 3. The red graduated arrows 
and the white arrows located in the brain diagrams, indicates the progression of the increasing 
neurodegeneration through the brain (adapted from Braak et al., 2003). 
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could enter the body through the mucosa membrane of the stomach and pass into the 
PNS (Braak et al., 2003). A possible pathogen could then be transferred directly 
from neurone to neurone by species-specific, selective types of synapses or by 
receptor mediated endocytosis, up through the PNS into the brain stem (Braak et al., 
2003; Braak et al., 2004; Braak et al., 2006). The pathogen then causes specific 
neuronal cell death (Braak et al., 2003). This has been speculated through the 
observation of a large number of LBs within the PNS of the stomach (Wakabayashi 
et al., 1993; Braak et al., 2003). 
 
1.2.1.1 Lewy bodies and Lewy neurites. 
LBs and LNs were first identified and described by Fredrick Lewy (1912) (Lewy, 
1912). LBs are circular intracellular inclusions of approximately 5 – 25 µm in 
diameter and are composed of a dense granular core with filaments radiating out 
giving the impression of a halo (figure 1.10A and B) (Goedert et al., 1998; Mezey et 
al., 1998; Flint Beal, 2001). The primary components of LBs are α-syn and ubiquitin 
(Lowe et al., 1988; Cornford et al., 1995; Spillantini et al., 1997; Mezey et al., 
1998). LNs are very similar to LBs containing abnormal filaments, also primarily 
composed of α-syn and ubiquitin (Spillantini et al., 1997; Mezy et al., 1998; Goedert 
et al., 1998) within the axons and dendrites of neurones (figure 1.10C) (Spillantini et 
al., 1997; Spillantini et al., 1998a; Spillantini et al., 1998b).  
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Figure 1.10: Illustrations of LBs and LNs within neurones of the substantia nigra of PD 
patients. 
A) Transmission electron mircograph of a LB at 6,000 x magnification with arrows highlighting 
the core and halo of the LB (adapted from Forno, 1996). B) LB located in compact zone of the SN. 
Two colour image of the LB stained for ubiquitin (green) and α-syn (red), which identifies the core 
as being primarily ubiquitin,  with some α-syn (overlaying as orange) and the α-syn radiating out 
to form the periphery of the LB (red) (adapted from Mezey et al., 1998). C) LN double-stained for 
α-syn and ubiquitin in neurones located in the SN. The Bar = 90 mm and the red arrows indicate 
the LN (adapted from Spillantini et al., 1998b). 
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 1.2.2 Synucleinopathies. 
Through the identification of α-syn as the major protein involved in the formation of 
LBs (Spillantini et al., 1997), α-syn has been linked to a number of 
neurodegenerative disorders classified as synucleinopathies (see table 1.1) (Duda et 
al., 2000; Murray et al., 2001). Within this group of neurodegenerative disorders, 
disease progression sees the neurodegeneration of brain regions that contain 
selectively vulnerable populations of neurones (Murray et al., 2001) and the 
development of pathologic lesions composed of aggregated α-syn (Duda et al., 
2000). Diseases such as; PD, DBL, MSA (Spillantini et al., 1998a), LB variant of 
AD (Takeda et al., 1998; Wirths et al., 2000), and neurodegeneration with brain iron 
accumulation type I (Arawaka et al., 1998) have been classed as synucleinopathies 
(Duda et al., 2000; Galvin et al., 2001; Murray et al., 2001). With these disorders the 
patient develops either parkinson-like symptoms, dementia or a combination of both 
(Galvin et al., 2001). For example, in both LB variant of AD and DLB, progressive 
dementia is seen in the sufferer, with the presence of LB staining positive for α-syn 
in the cortex, senile plaques and neurofibrillary tangles also develop within both 
disorders (McKeith et al., 1996; Takeda et al., 1998; Spillantini et al., 1998a; 
Spillantini et al., 1998b; Wirths et al., 2000). In the case of LB variant AD the 
patients develop mild parkinsonism symptoms (increase in essential tremor, 
bradykinesia, mild neck rigidity, and slowing of rapid alternating movements) with 
progressive dementia indistinguishable from AD (Hansen et al., 1990). With DBL 
the patients develop similar parkinsonism symptoms to PD including bradykinesia 
and rigidity (but not resting tremors) and visual hallucinations (McKeith et al., 1996; 
Geser et al., 2005). However DLB patients also develop progressive late-onset 
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Examples of neurological disorders which are classed as synucleinopathies (adapted from Galvin et 
al., 2001) 
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AD-like dementia which is associated with the formation of cortical LBs (McKeith et 
al., 1996) as the number of cortical LBs correlates with the severity of dementia 
(Sameul et al., 1996). Through the investigation of one synucleinopathy it is hoped 
that this would help to understand the other neurodegenerative disorders and lead to 
the development of possible therapeutic treatments (Duda et al., 2000; Galvin et al., 
2001; Murray et al., 2001). 
 
1.2.3 Therapeutic interventions for PD. 
There are many treatments available to PD patients, from drug treatment through to 
surgical interventions. However, none of the available treatments at present are a 
cure and they do not stop the progression of the disease (Carlsson et al., 2007; Singh 
et al., 2007). The therapies for PD are symptomatic against the consequences of PD 
pathophysiology (Bittar, 2006; NCC-CC, 2006; Carlsson et al., 2007; Singh et al., 
2007). The main drugs initially used are the oral administration of either levodopa (a 
DA precursor), a DA agonist or a combination. (figure 1.11) (Carlsson et al., 2007; 
Singh et al., 2007). To reduce peripheral metabolism of levodopa, it is often 
combined with a peripheral dopa decarboxylase inhibitor, such as carbidopa or 
benserazide, increasing the amount of levodopa that crosses the blood-brain barrier 
(NCC-CC, 2006). The progression of the disease leads to increasing concentrations 
of levodopa required to maintain the levels of control over the motor symptoms 
which leads the development of motor complications caused by the levodopa, such 
as; involuntary movement or dyskinesias, dystonia, response fluctuations (‘wearing 
off’).  
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Figure 1.11: Schematic of dopaminergic synapse and examples of PD drugs that influence 
DA synthesis, degradation, uptake or mimic DA. 
The diagram shows examples drugs that are used to treat PD such as inhibitors of DA degradation 
by inhibiting Monoamine oxidase B (MAO-B) by selegiline and inhibition of catechol-Omethyl 
transferase (COMT) by entacapone, leading to increased levels of DA reuptake. Amantidine is 
speculated to inhibit DA uptake and increase DA release increasing activation of DA receptors. 
Levodopa increases DA synthesis and finally there are DA agonists that mimicking DA binding 
and activating DA receptors and finally (Adapted from Singh et al., 2007). 
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DA agonists mimic the effects of DA by binding directly to the posts-
synaptic DA receptors (figure 1.11). DA agonists are divided in to two categories; 
ergot-derivatives such as bromocriptine, pergolide, lisuride and cabergoline, and 
non-ergot derivatives including ropinirole, pramipexole, apomorphine and piribedil 
(Singh et al., 2007). 
 
Other therapies include monoamine Oxidase-B (MAO-B) inhibitors, such as 
selegiline and rasagiline (primarily used in later PD stages to decrease DA 
metabolism). Amantadine (possibly works by increasing DA release and reducing 
uptake), catechol-Omethyl transferase (COMT) inhibitors (e.g. entacapone and 
tolcapone that work similar to the MAO-B inhibitors by reducing the metabolism of 
DA increasing the half-life of levodopa by 30 - 50 %) (figure 1.11) (NCC-CC, 2006; 
Singh et al., 2007). 
   
There are also a number of different neurosurgical procedures that can be employed 
to alleviate individual symptoms of PD ranging from subthalamotomy to deep brain 
stimulation (NCC-CC, 2006). Such treatments for individual symptoms are 
extremely varied and tend to be viewed as a last resort for patients who respond to 
drugs, but have severe side-effects or severe fluctuations in response to medication 
(NCC-CC, 2006). The preferred surgeries tend to be deep brain stimulation (DBS) 
where a quadripolar electrode is inserted in to the subthalamic nucleus (STN), globus 
pallidus interna or the thalamus (Lozano, 2001; Hashimoto et al., 2002; Lopiano et 
al., 2002; NCC-CC, 2006; Singh et al., 2007). The more invasive surgery, 
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subthalamotomy, involves the destruction of the thalamus, globus pallidus or the 
STN (Weekly, 1995; NCC-CC, 2006). 
 
Stem cell transplantation is another approach to repair damaged areas of the brain, 
with the potential of long-term relief from symptoms and eventually the possibility 
of a cure (Storch and Schwarz, 2002; Lindvall and Kokaia, 2006). In principle, the 
experimental technique involves the implantation of dopaminergic neurones, derived 
from stem cells, into an adult living brain in order to replace and regenerate the 
damaged neuronal systems (e.g. by releasing growth factors) (Hynes and Rosenthal, 
2000; Storch and Schwarz, 2002; Lindvall and Kokaia, 2006). The stem cells used 
are primarily embryonic stem cells, but researchers are also looking into using stems 
cells isolated from; foetuses, the adult brain, bone marrow stoma, liver, skin and 
muscle (Hynes and Rosenthal, 2000; Lindvall and Kokaia, 2006; Singh et al., 2007). 
At present the approaches are still in the early stages of development with low cell 
survival and potentially fatal side effects in a few patients (Clarkson and Freed, 
1999; Kompoliti et al., 2007; Singh et al., 2007). 
 
1.2.4 Familial Parkinson’s Disease. 
Familial PD is attributed to rare mutations that cause autosomal recessive and 
dominant parkinsonism. Six gene loci have been fully characterised which contain 
PD inducing mutations; α-syn, Ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1), 
ubiqitin protein ligase (Parkin), PTEN-induced kinase 1 (PINK1), DJ-1 and Leucine-
rich repeat kinase 2 (LRRK2) (Polymeropoulos et al., 1997; Leroy et al., 1998; 
Alvarez et al., 2001; Abou-Sleiman et al., 2004; Paisán-Ruíz et al., 2004; Valente et 
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al., 2004; Sellbach et al., 2006). Further loci have been associated with familial PD, 
but the specific genes have not been isolated (table 1.2) (Le and Appel, 2004, and 
Sellbach et al., 2006). 
 
 
Table 1.2: Loci and genes which cause familial forms of PD.  
 
Locus  Chromosome Gene Inheritance Onset 
PARK1 4q21 - q23 α-synuclein AD Middle - late 
PARK2 6q25 - q27 parkin AR Early - juvenile 
PARK3 2p13 - AD Late 
PARK4 4p15 - AD Late 
PARK5 4p14 UCH-L1 AD Late 
PARK6 1p35 - p36 PINK1 AR Early 




LRRK2 AD Late 
PARK9 1p36 - AR Juvenile 
PARK10 1p32 - - Late 
NR4A2 2q - AD Late 
 
 
List of suspected genes and loci of familial forms of PD. AD and AR indicated whether the locus 
contains a mutation that causes autosomal dominant (AD) or autosomal recessive (AR) PD. (Adapted 




1.2.4.1 Structural mutations of α-syn.  
The involvement of α-syn in the pathophysiology of PD has been speculated since 
the identification of aggregated α-syn as the main LB protein (Spillantini et al., 
1997). Currently there are a number of possible theories as to this involvement of the 
α-syn protein in disease progression. Although the wild-type (wt), monomeric form 
of α-syn does not appear to be detrimental to the cell (and may have a physiological 
function) it has the potential to form aggregates as previously mentioned (Section 
1.1.2.1). Increases in α-syn concentration, oxidative stress and the presence of DA 
may all cause an increase in α-syn aggregation (Hashimoto et al.,1999; Lowe et al., 
2004; Cappai et al., 2005). The presence of the NAC region in α-syn is believed to 
increase the proteins ability to aggregate and form fibrils (via protofibril 
intermediates) (Uversky et al., 2002).  
 
The identification of α-syn ability to self-aggregate and α-syn presence in LB has 
lead to the hypothesis implicating aggregated α-syn as being toxic and involved in 
the progression of PD (El-Agnaf et al., 1998). However a number of alternative 
theories have since been suggested, such that the fibril formation of α-syn maybe a 
protective mechanism sequestering the potentially toxic intermediate (protofibril) 
form of α-syn (Conway et al., 2000a). This theory implies, therefore, that either the 
protofibril or monomeric form of α-syn is the pathogenic form. The discovery of 
three missense point mutations in α-syn has shed some light as to the mechanisms 
involved in PD progression in relation to the α-syn protein. The mutant forms of α-
syn, which have been linked to early onset PD, have been shown to have varying 
rates of aggregation that appears to affect their toxicity in cells compared to wt  
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α-syn. The A30P mutation was shown to form protofibrils quicker than wt α-syn, 
although full aggregation appears to be at the same rate (Narhi et al., 1999; 
Greenbaum et al., 2005). Therefore the A30P mutation promoted the formation of 
protofibrils but not fibrils. The A53T mutation promotes the formation of full fibrils 
removing α-syn from the cellular system and promoting an increase in α-syn 
expression, further aggregation and the presence of protofibrils. Triplication of the α-
syn gene increases α-syn protein expression and is linked to late onset PD, 
identifying the accumulation of α-syn promotes aggregation of α-syn and the 
formation of protofibrils (Section 1.1.2.1) (Singleton et al., 2003; Farrer et al., 2004; 
Miller et al., 2004; Singleton et al., 2004). However, this does not discount the 
soluble or the fibril form as being the pathogenic agent in PD, but highlights its 
involvement through its aggregation pathways. 
 
1.2.4.1.1 α-Syn A53T mutation. 
The A53T mutation in α-syn was first characterised in a cohorts of PD patients from 
the same Italian/Greek family by Polymeropoulos et al. (1997). This mutated form of 
the α-syn protein is indistinguishable from the wt protein in both its cytosolic and 
membrane bound conformations (Conway et al. 1998; Jo et al. 2002). However, the 
A53T mutation was seen to have an increased rate of aggregation compared to the wt 
(Conway et al. 1998). In vitro, the over expression of in A53T α-syn in cells 





1.2.4.1.2 α-Syn E46K mutation. 
The E46K mutation, first described by Zarranz et al. (2004), was isolated from a 
Spanish family. It was found that the mutation at residue 46 changed the polarity of 
the surrounding residues, resulting in an alteration of the function of this region of α-
syn (i.e. an increase in the proteins ability to bind negatively charged liposomes) 
(Choi et al. 2004). In a similar respect to the A53T mutation, the E46K mutation also 
has an increased rate of fibril formation (Choi et al. 2004; Greenbaum et al. 2005), 
where the formed filaments tend to be more tightly twisted than seen in the A53T 
mutation (Choi et al. 2004).  
 
1.2.4.1.3 α-Syn A30P mutation. 
The third α-syn mutation, in a German family, was first described by Krüger et al. 
(1998). Again, like the A53T mutation, the A30P mutation does not appear to affect 
the overall cytosolic structure of the protein (Conway et al. 1998). The mutated 
protein does, however, appear to have a reduced capacity for binding cellular 
vesicles via electrostatic interactions (Jensen et al. 1998). This has been suggested to 
lead to a build up of protein in neural cell bodies resulting in aggregation (Kahle et 
al. 2000). Interestingly, the A30P mutation has an increased rate of aggregation 
(albeit the slowest of the three mutations), but expresses the slowest rate of fibril 
formation (Narhi et al. 1999). This would suggest that the A30P mutant α-syn 
favours the formation of the protofibril intermediates rather than the full aggregated 
fibril form of α-syn. Furthermore, the A30P α-syn mutant is not able to undergo the 
conformational change required for the binding of the protein to lipid membranes 
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(i.e. the random coil to α-helix). This loss of function increases the cytosolic fraction 
of α-syn, further promoting fibril formation (Jo et al. 2002).   
 
Interestingly, Jo et al. 2002 expressed both the A53T and A30P mutant proteins in 
vitro. The A30P mutant was found to be dominant over the A53T mutant in terms of 
impairing membrane binding properties of α-syn. There was an overall increased rate 
in aggregation (Narhi et al. 1999).  
 
1.2.4.2 Familial PD through increased α-syn expression.  
Multiple copies of the α-syn gene were identified within a family, termed the Iowa 
kindred, which caused early onset of PD and increased the speculation that α-syn 
played a role in the pathogenesis of disease progression (Singleton et al., 2003; 
Farrer et al., 2004; Miller et al., 2004; Singleton et al., 2004). Within the Iowa 
kindred a triplication of the α-syn gene gave rise to four fully functional copies of the 
α-syn gene within the chromosome (Chr 4q) (Miller et al., 2004). The triplication of 
the gene does not appear to cause any alteration in the functional role of α-syn. 
However, as all four genes are fully functional this leads to an increased expression 
of α-syn protein and a doubling of the concentration of the protein and mRNA within 
the brain (Miller et al., 2004). The increased concentration of α-syn appears to 
increase the rate of α-syn aggregation and induces the early-onset of PD with an 
average age of approximately 34 years, and an increased likelihood of developing 
dementia (Farrer et al., 2004; Singleton et al., 2004). A duplication of the α-syn gene 
has also been identified in a separate family, but unlike the triplication of α-syn, this 
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induces late onset PD, which appears indistinguishable from idiopathic PD (Ibáñez, 
et al., 2004; Chartier-Harlin et al., 2004; Fuchs et al., 2007).  
 
1.2.4.3 Familial PD induced by UPS dysfunction. 
Mutations in two important enzymes involved in the Ubiquitin-proteasome system 
(UPS) have been identified (UCH-L1 and parkin, see below). These mutations can 
result in their loss of function and ultimately result in the development of autosomal 
PD. The UPS plays an essential role in the rapid degradation of abnormal proteins 
within cells, targeting mislocated, misfolded, mutant and damaged proteins for 
degradation (McNaught et al., 2001; Dev et al., 2003). The system consists of a 
series of enzyme-mediated reactions which identify and covalently bind multiple 
ubiquitin molecules to abnormal proteins marking the protein for degradation by 
20/26S proteasomes (figure 1.12). Initially, monomeric ubiquitin molecules are 
activated by ubiquitin-activation enzymes E1 through an adenosine triphosphate 
(ATP) mediated system (McNaught et al., 2001; Dev et al., 2003). The activated 
ubiquitin molecules are transferred to a substrate specific ubiquitin–conjugated 
enzyme (E2), and ubiquitin-protein ligase (E3) catalyses the ligation of the activated 
ubiquitin molecules on to lysine residues of the abnormal protein, marking it for 
degradation (McNaught et al., 2001; Dev et al., 2003). 20/26S proteasomes 
recognise the polyubiquitin tagged protein and break up the abnormal protein to 
produce short peptides chains and amino acids, which are subsequently recycled to 
produce new proteins (McNaught et al., 2001; Dev et al., 2003). The polyubiqitin 
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Figure 1.12: Flow diagram showing the ubiquitin-proteasome system and PD associated 
mutations. 
The ubiquitin-proteasome system (UPS) degrades proteins targeted with polyubiquitin chains. 
Monomeric ubiquitin molecules are activated by the ubiquitin-activation enzyme E1 and are then 
transferred to ubiquitin–conjugated enzyme E2 (McNaught et al.,2001; Dev et al., 2003). E2 
enzymes and ubiquitin-protein ligase E3 bind the activated ubiquitin molecules via lysine residues 
on the protein targeted for degradation. This can be repeated numerous times (grey arrow) until the 
target protein is recognised by the 26S proteasome and degraded. Degradation produces short 
peptide chains and amino acids, which are recycled back into the formation of new proteins. The 
polyubiqitin chains are released by the 26S proteasome and disassembled by ubiquitin carboxyl-
terminated hydrolases. The monomeric ubiquitin molecules are recycled in the UPS. Mutations in 
Parkin and UCHL-1 disrupt the pathways (marked by red crosses) and prevent the degradation of 
targeted proteins.   
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terminated hydrolases and re-enter the UPS (McNaught et al., 2001; Dev et al., 
2003). 
 
Ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) is a neuronal de-ubiquitination 
enzyme (Satoh and Kuroda, 2001) and is an essential part of the UPS (Leroy et al., 
1998; Satoh and Kuroda, 2001). The main role of this enzyme family is to 
disassemble polymeric ubiquitin to monomers by the hydrolysis of the bonds 
between ubiquitin molecules and small adducts (e.g. glutathione and cellular amines 
(McNaught et al., 2001)). The substitution of a methionine (M) for isoleucine (I) at 
amino acid position 93 (Leroy et al., 1998; Harhangi et al., 1999; MacDonald, 1999; 
Mellick and Silburn, 2000; Satoh and Kuroda, 2001) results in a truncated protein 
and dysfunction of the UPS. Ultimately, the pathway affected by the mutation results 
in the progressive accumulation of neuronal and glial inclusions composed of 
ubiquitinated protein aggregates including α-syn, which are implicated in 
neurodegeneration (figure 1.12) (Leroy et al., 1998; Harhangi et al., 1999; Satoh and 
Kuroda, 2001). 
 
Deletions within the 4th-exon of the parkin gene (which codes for the ubiquitin 
protein ligase (E3) parkin) have been linked to autosomal recessive juvenile 
parkinsonism (AR-JP) (Mizuno et al., 1999). Mutations in the parkin gene are the 
most common form of familial PD with ~ 50 % of familial cases of PD showing a 
parkin mutation and have been shown to range from single nucleotide deletions to 
hundreds of nucleotide deletions or missense mutations. The mutations in the parkin 
gene have been suggested to either affect the E2 enzyme binding region of parkin, 
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impairing the parkin protein interactions with the substrate protein, or reduce E3 
ligase activity, causing improper targeting of substrates for proteasomal degradation. 
The consequence of either mechanism is the accumulation of potentially neurotoxic 
proteins such as α-syn and aggregated α-syn (figure 1.12). 
 
1.2.4.4 Mitochondrial protein associated mutations.  
The PINK1 gene, located on chromosome 1p35-p36, encodes a putative protein 
kinase that shows a high level of sequence homology to serine-threonine kinases of 
the Ca2+/calmodulin family (Valente et al., 2004). The PINK1 protein is primarily 
located within mitochondria, more specifically the mitochondrial membrane. 
However, beyond helping in the protection of cells from oxidative stress (Tang et al. 
2006), its function is unknown.  
 
Similarly, the protein encoded by the DJ-1 gene is believed to have a primary role as 
an antioxidant (Abou-Sleiman et al., 2004), as it contains many readily oxidised 
residues (Kinumi et al., 2004). Furthermore, the DJ-1 protein is believed to act as a 
redox dependent chaperone, which sequesters free radicals from the mitochondria 
helping to protect it from oxidative stress (it is found in both, the mitochondrial 
matrix and inter-membrane space as well as the cytoplasm) (Gandhi and Wood 
2005). However, the exact role of this protein is still unclear and not well reported in 





1.2.4.5 Leucine-rich repeat kinase 2 (LRRK2) mutations. 
The Leucine-rich repeat kinase 2 (Lrrk2) protein is also known as dardarin. First 
termed by Paisán-Ruiz et al (2004), dardarin is a 286 kDa protein belonging to the 
family of protein kinases that has a similar sequence to the tyrosine and serine-
threonine kinases, a characteristic shared with the PINK1 protein. Lrrk2 is believed 
to be a predominately cytoplasmic protein and may co-express with parkin to 
increase cytoplasmic protein aggregates and enhance their ubiquitination (Smith et 
al. 2005).    
 
At least nine pathogenic mutations are known to exist in Lrrk2, where the mutation 
of the Lrrk2 protein is the most common known cause of late-onset, idiopathic and 
familial PD (Giasson et al. 2006). Two of the most common mutations in this 
protein, G2019S and I2020T, have been mapped to the protein kinase catalytic 
domain, where their presence seems to incur an increase in kinase activity (40 % in 
the case of the I2020T mutation) (Wood-Kaczmar et al. 2006). Considering the 
previous linking of Lrrk2 to an increase in cytoplasmic protein aggregates and their 
enhanced ubiquitination, it may be suggested that a mutation that leads to an increase 
in its kinase activity may result in an over accumulation of protein aggregates for 
degradation. This, with a lack of an increase in the UPS rate, may result in a backlog 
of protein aggregates, such as α-syn and ubiquitin leading to neurotoxicity. 
 
1.3 Models of Parkinson disease. 
To gain an understanding of the pathophysiology of PD, in vivo and in vitro models 
have been established using compounds such as 1-methyl 4-phenyl 1,2,3,6-
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tetrahydropyridine (MPTP) and rotenone, which induce PD-like symptoms (Lee et 
al. 2002; Shimohama et al. 2003; Fernagut and Chesselet, 2004). In vitro rotenone 
and the metabolite of MPTP (MPP+) inhibit complex I of the ETC resulting in 
mitochondrial dysfunction resulting in the loss of dopaminergic neurones in the 
substantial nigra in vivo, similar to that observed in PD patients (Lee et al. 2002; 
Shimohama et al. 2003). Mutant mice (null and over-expressing α-, β- and γ-syn 
(Fernagut and Chesselet, 2004)) and cells lines (such as human SHSY-5Y, rat PC12 
and BE-(2)-M17 human neuroblastoma dopaminergic cells) which can be genetically 
modified to over-express syn proteins, have enabled investigation into the interaction 
of the synucleins in PD (Shimohama et al. 2003).   
 
1.3.1 MPTP and MPP
+
. 
1.3.1.1 MPTP-induced PD. 
MPTP was identified in 1976 through the incorrect synthesis of a synthetic heroin,  
1-methyl 4-phenyl 4-propionoxypiperidine (MPPP) from meperidine (also known as 
Demerol) which resulted in a mixture of MPPP and MPTP (Davis et. al., 1979). The 
injection of MPTP contaminated MPPP caused the onset of PD-like symptoms which 
included; rigidity, tremors, state of muteness, flat facial expressions, hallucinations, 
slowness of and difficulty in moving, jerking limbs and a fixed stare (Davis et. al., 
1979; Langston et. al., 1983). The symptoms were speculated to be due to the loss 
and/or damage to dopaminergic neurones and alterations in the noradrenergic and 
serotoninergic systems. This was confirmed upon post-mortem analysis of one of the 
MPTP patients who died (Davis et. al., 1979). The analysis of the brain showed 
irregular patches of discolouration in ventricular lining, destruction of the SN and the 
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identification of a round eosinphilic intracytoplasmic inclusion characteristic of a LB 
found in PD patients (Davis et. al., 1979). For all the MPTP patients, symptoms were 
shown to be markedly improved and controlled with the use of PD treatments such as 
levodopa/carbidopa and DA agonists (benztropin and diazepam) (Davis et. al., 
1979). Reducing or the withdrawal of treatment lead to the reappearance of 
symptoms (Davis et. al., 1979; Langston et. al., 1983).  
 
The parkinsonism-like symptoms were suspected to be caused by the synthesised 
MPPP being contaminated with MPTP rather than the MPPP itself (Davis et al., 
1979; Langston et al., 1983). The method of MPPP synthesis documented by one of 
the MPTP patients was replicated and found to produce a mixture of MPPP and 
MPTP that was subsequently tested on rats, resulting in catatonia and rigidity (Davis 
et al., 1979). The discovery of MPTP as a chemical inducer of PD with identical 
symptoms and cellular damage sparked off the development of a wide variety of in 
vivo and in vitro models using MPTP (Frei and Richter, 1986). 
 
Primarily, MPTP was used in primates, but has since been demonstrated to exert 
similar effect on several rodent models (Burns et al., 1983; Langston et al., 1984; 
Heikkila et al., 1984a; Heikkila et al., 1984b; Mitchell et al., 1985; Fuller and 
Steranka, 1985; Chiba et al., 1985a; Forno et al., 1986; Cassarino et al., 1998). Initial 
studies used a variety of primates to investigate the specific effects of MPTP upon 
the brain. Burns et al. (1983) showed that rhesus monkeys intravenous treated with 
MPTP developed parkinsonism-like symptoms such as tremors rigidity, akinenia and 
postural instability (Burns et al., 1983). This was repeated with other studies in a 
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number of primate species (Langston et al., 1984; Eidelberg et al., 1986; Filion et al., 
1988). Burns et al. (1983) went on to show that the symptoms induced by MPTP 
could be reversed by treatment with L-DOPA, similar to PD patients. Histological 
and immunocytochemical analysis of MPTP-treated primate brains identified loss of 
pigmented neurones within the par compacta of the SN, neuronal loss in LC and 
raphe, reduced activity of the both pallidal segments and subthalamic nucleus and 
depletion of DA within the striatum and SN, although there were minimal effects on 
DA neurones in the ventral tegmental (Burns et al., 1983; Porrino et al., 1987; Filion 
et al., 1988). A further study identified the presence of inclusion bodies in the brains 
of MPTP-treated squirrel monkeys in the SN and LC similar to PD patients (Forno et 
al., 1986). The similarities of MPTP-induced symptoms and neurological damage to 
that of PD patients means MPTP models are useful for the investigation of PD, 
potentially elucidating pathways and mechanisms involved in the progression of the 
disease as well as for the identification of possible therapeutic methods and drug 
treatments. 
 
Rodent MPTP models initially showed varying effects with dose, route of 
administration, number and timing of injections, gender, age, strain, even variations 
in animals from suppliers (Speciale, 2002). The effects of MPTP were eventually 
clarified within the rodents once strain appropriate dosing and metabolic 
distributions of MPTP were characterised (Speciale, 2002). The rodent models 
showed varying susceptible to MPTP toxicity between rats and mice. Rats needed 
significantly higher doses of MPTP to induce any striatal DA reduction, SN neuronal 
loss and/or behavioural impairments compared to that needed for mice (Speciale, 
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2002). The rats’ resistance to systemic MPTP toxicity is thought to be due to unique 
enrichment of enzymes in the blood-brain barrier that efficiently metabolise MPTP to 
non-toxic metabolites and swiftly removes MPTP from the brain compared to mice 
and humans (Riachi et al., 1988; Riachi et al., 1990; Speciale, 2002). Compared to 
the rat, the mouse has a reduced ability to remove MPTP from their system, or 
convert to non-toxic metabolites (Riachi et al., 1988; Riachi et al., 1990). Variations 
between mice species to MPTP toxicity has also been shown, as C57 black mice 
have been shown to be more susceptible to MPTP than CF1 white mice, 
susceptibility correlated with an ability to convert MPTP to non-toxic metabolites 
(Riachi et al., 1988). However all strains are markedly more sensitive to MPTP 
compared to rats. 
 
There are however inconsistencies between the animal model and human idiopathic 
PD. Firstly the majority of studies noted that the toxic effects observed within the 
non-human primate and rodent models dissipates overtime unlike in humans where 
the effects are irreversible (Drolet et al., 2004). Secondly, inclusion formation is not 
normally observed following MPTP administration (Burns et al., 1983; Langston et 
al., 1984; Mitchell et al., 1985; Shimoji et al., 2005). However in the first case of 
human MPTP poisoning a rounded eosinophilic intracytoplasmic “Lewy body” was 
noted (Davis et al., 1979), and some other studies in primates and rodents have 
subsequently identified a few LB-like inclusion (Forno et al., 1986; Kowall et al., 
2000; Meredith et al., 2002).  
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It has been established that MPP+, a metabolite of MPTP is 100 times more 
toxic than the parent, is the toxic component (Harik et al., 1987). MPTP is a fat 
soluble compound that can freely penetrate cellular membranes, including the blood-
brain barrier (Markey et al 1984), and is accumulated in intracellular lysosomes in 
astrocytes (figure 1.13) (Riachi et al., 1988; Marini et al., 1992; Wong et al., 1999). 
MPTP is metabolised into 1-methyl-4-phenyl-2,3-dihydropyridine (MPDP+) by 
MAO-B which is predominantly located in astrocytes and serotonergic neurones 
(Castagnoli et al., 1985; Chiba et al., 1985a). MPDP+ is an unstable ion that 
spontaneously oxidises to form the toxic compound MPP+ (figure 1.14) (Javitch et 
al., 1985; Castagnoli et al., 1985; Chiba et al., 1985a; Brooks et al., 1989). In 
contrast MPP+ only poorly crosses the blood-brain barrier (Riachi et al., 1988) and as 
such is considerably less toxic than MPTP in vivo. In the brain, astrocyte metabolised 
MPP+ is released into the extracellular space where it is taken up into dopaminergic 
neurones, located in the striatum and specifically the SN, via the DAT system 
(Javitch et al., 1985; Chiba et al., 1985b; Brooks et al., 1988; Wong et al., 2004; 
Smeyne and Jackson-Lewis, 2005). This was shown with the use of mazindol, a DA 
uptake inhibitor, where DA and MPP+ uptake was blocked in mice mescenphalic 
neuronal primary culture (Schinelli et al., 1988). This was confirmed with further 
inhibition studies of the DA uptake system which showed the inhibition of DAT 
prevented MPP+-induced cell death (Javitch et al., 1985). The selective mechanism 
of MPP+ uptake via DAT explains the selective cell death observed in the MPTP 










Figure 1.13: Schematic of MPTP uptake and metabolism within the brain. 
Schematic of MPTP rapidly crossing the blood–brain barrier and metabolized to MPP+ (the active 
toxic compound). MPP+ is taken up by DA transporters, for which it has high affinity. Once inside 
DA neurones, MPP+ is concentrated by an active process within the mitochondria, where it impairs 
mitochondrial respiration by inhibiting complex I of the electron transport chain (From Vila and 
Przedborski, 2003). 

















Figure 1.14: Schematic of the formation of MPP+ from MPTP. 
Metabolism of MPTP to MPP+ by oxidation, catalysed by monoamine oxidase-B (MAO-B) and 
the intermediate step producing MPDP+. 
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Neuroprotection studies have also suggest a role for the catecholamine 
vesicular monoamine transporter (VMAT2) in regulating MPP+-induced toxicity 
(Reinhard, Jr. et al., 1988; Gainetdinov et al., 1998; Staal et al., 2000). In 
dopaminergic neurones VMAT2 is extensively localised to tubulovesicles that 
resemble saccules of the smooth endoplasmic reticulum, and to a much lesser extent 
to small synaptic vesicles or large dense-core vesicles (Nirenberg et al., 1996). 
VMAT2 normally sequesters DA to vesicles ready for release in response to stimuli 
(Nirenberg et al., 1996). It has been shown that VMAT2 also sequesters MPP+ into 
intracellular vesicles removing the MPP+ from the cytosol and reducing toxicity 
(Reinhard et al., 1988; Gainetdinov et al., 1998; Staal et al., 2000). The protective 
effects of VMAT2 against MPP+ toxicity has been shown to vary between different 
species in relation to VMAT2 levels in the brain (Reinhard et al., 1988). A study by 
Staal et. al. (2000) showed rats had a higher level of striatal VMAT2 compared to 
mice and as mentioned before rats have reduced susceptibility to MPP+ toxicity 
(Staal et al., 2000). The lower levels of VMAT2 in mice leads to less 
compartmentalisation of MPP+ and therefore increased cytosolic MPP+ and increased 
toxicity (Staal et al., 2000). This was confirmed with the use of heterozygous 
knockout VMAT2 mice that showed a significant increase in susceptibility to MPTP 
toxicity compared to normal homozygous VMAT2 mice (Gainetdinov et al., 1998). 
 
Through the multiple variations of MPTP administration in rodents and primates 
models have been established that closely resemble aspects of the pathophysiology of 
PD. These models are now being used to identify mechanisms involved in PD and 
future therapeutic strategies. 
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1.3.1.2 Mechanics of MPTP toxicity. 
MPP+ has many toxic effects in cells including mitochondrial dysfunction, increase 
in ROS and oxidative stress, which lead to cell death via apoptosis or necrosis 
depending on the severity of the insult (Nicotra and Parvez, 2002). MPP+ primarily 
acts by blocking mitochondrial respiration through inhibition NADH  
dehydrogenase, also known as complex I of the ETC (Ramsay et al., 1991; Vila and 
Przedborski, 2003). The ETC generating the majority of ATP along with glycolysis 
and the Kreb cycle, which also produce NADH that feeds in to the ETC to drive ATP 
production in cells (figure 1.15) (Hames and Hooper, 2000). MPP+ enters the 
mitochondrial matrix by ionic diffusion actively driven by electrochemical gradient 
of the inner membrane (Ramsay and Singer, 1986; Smeyne and Jackson-Lewis, 
2005). MPP+ inhibition of the ETC results in a decrease in ATP generation, (figure 
1.15), subsequently causing a loss of ATP-driven mitochondrial membrane potential 
and the generation of ROS, hydrogen peroxide and hydroxyl radicals (Wong et al., 
1999; Smeyne and Jackson-Lewis, 2005). Similar mitochondrial dysfunction is also 
observed in the post-mortem brain of PD patients (section 1.2). MPP+ also causes a 
breakdown in Ca2+ homeostasis (Frei and Richter, 1986) and an increase in nitric 
oxide synthase which increases nitric oxide levels (Przedborski et al., 1996). MPTP 
has also been shown to trigger pro-apoptotic signal, increasing phosphorylation of 
JNK leading to increased JNK activity; both are components of the stress-activated 
protein kinase system which inactivate the anti-apoptotic protein Bcl-2 (Srivastava et 
al., 1999). This was shown through the use a JNK blocker (CEP-1347/KT-7515) 
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Figure 1.15: Schematic of the energy pathways that generate NADH and ATP. 
Schematic of the glycolytic and Kreb cycles and the electron transport chain (ETC). The diagram 
shows the metabolism of glucose by glycolysis (dark red pathway) to acetyl CoA, generating 
NADH and ATP. Acetyl CoA feeds into the Krebs cycle within the mitochondria (purple pathway) 
generating NADH and FADH. NADH generated by glycolysis and the Kreb cycle is metabolised 
to NAD+ through the ETC (indicated in pale blue box) ultimately generating ATP from ADP. 
MPP+ inhibition is marked by a purple cross. Other Abbreviations: Flavin adenine dinucleotide 
(FAD), Cytochrome c (Cyto c), co-enzyme Q (Co Q).    
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1.4 Aims and objectives. 
The aims of this project are to investigate the physiological role of α-syn in normal 
and PD-like conditions. Initially protein-expression in a prokaryotic system will be 
established to express α-syn, A53T mutant α-syn and β-syn. This will allow for a 
constant and renewable source of protein throughout the project. The study will then 
characterise α-syn-mediated physiological effects in vitro (in both the soluble and 
aggregated form) using human SHSY-5Y neuroblastoma cells. Subseqentily the  
α-syn pathophysiological effects will be investigated in an in vitro MPP+ model of 
PD. Through these studies we aim to elucidate α-syn involvement in the 
pathophysiology of PD at a molecular level. Such studies will have important 





Chapter 2: Materials and Methods.  
2.1 General Materials. 
All chemicals were obtained from Sigma Chemical Co. (Pool, UK) unless otherwise 
stated. 
 
2.2 Molecular Biology. 
2.2.1.1 Preparation of agar culture plates. 
To produce 7 % stock volume of agar, 3.5 g Lennox L agar was added to 500 ml of 
deionised water and sterilised by autoclaving. The agar was cooled to ~ 50 oC and 
antibiotics were added to the 7 % agar solution; ampicillin (amp) plates contained 50 
µg/ml amp and amp and chloramphenicol (chlora) plates contained 50 µg/ml amp 
and 34 µg/ml chlora. The agar was poured into Petri dishes, filling each dish by 
approximately 2/3 and allowed to cool in a sterile hood. The set agar plates were 
stored at 4 oC for a maximum of 3 weeks.  
 
2.2.1.2 Preparation of LB and peptone broths. 
LB broth was produced similarly, where 25 g of LB broth powder was dissolved in  
1 L of deionised water and sterilised by autoclaving. Once cooled the LB broth was 
stored at 25 oC. On the addition of antibiotics, LB Broth containing antibiotics was 
stored at 4 oC for a maximum of 3 weeks.  
 
Peptone growth media consisted of 16 g of peptone and 5 g of sodium chloride 
(NaCl) dissolved in 1 L of deionised water and sterilised by autoclaving. Peptone 
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media was stored at 25 oC indefinitely, or on addition of antibiotics at 4 oC for a 
maximum of 3 weeks. 
 
2.2.2 Transformation of plasmids into library efficiency DH5α or JM109 
competent E.coli cells. 
Transformation protocol for DH5α and JM109 competent cells was the same for all 
types of DNA plasmid transformed into the cells. Plasmid was added to 250 µl of 
cells; each set of transformations contained two vials of cells transformed with either 
the supplied control plasmid DNA or sterile water (no addition DNA plasmid) as 
transformation controls. 
 
Vials of DH5α competent cells (Invitrogen, catalogue #18263-012) or JM109 
competent cells (Promega, catalogue #L2001), were stored at -70 oC, were thawed on 
ice for ~ 5 min. Once defrosted 2 µl of isolated syn-containing plasmid DNA was 
gently mixed with the cells by trituration. Two controls vials were set-up for the 
transformation; control plasmid DNA (2 µl) was added to one vial of cells and a 
further vial was left with no addition of DNA as control of the transformation 
protocol. All the cells were kept on ice for 30 min with gentle agitation to prevent the 
cells settling. The cells were then placed in a water bath for 45 sec at 42 oC and back 
on to ice for 2 min to shock the cells into taking up the plasmid DNA. To the heat-
shocked cells, 400 µl of pre-warmed LB broth was added and the cells incubated for 
1 h at 37 oC in a shaking incubator set to 225 rpm. Cell were centrifuged at 2,700 x g 
for 5 min and 200 µl of supernatant removed. The cells were gently re-suspended in 
the remaining supernatant. The cells were spread on to pre-warmed LB agar plates 
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containing ampicillin (50 µg/ml) using either 150 µl or 50 µl volume of cells. Control 
plates were also prepared which consisted of a blank plate, cells transformed with 
control plasmid DNA and non-transformed cells. All the plates were incubated 
overnight at 37 oC.  
 
2.2.3 Transformation of plasmids into BL21 (DE3) or BL21 (DE3)pLysS 
competent E.coli cells. 
The transformation protocol for BL21 (DE3) and BL21 (DE3)pLysS competent cells 
is the same for all the different DNA plasmids. Only one syn-containing plasmid was 
added to each 250 µl volume of cells. Each transformation contained two controls; 
control plasmid DNA supplied added to another vial of cells and a further vial with 
added sterile water, no addition of DNA. 
 
BL21 (DE3) competent cells (Invitrogen, catalogue #C6565-03) or BL21 
(DE3)pLysS competent cells (Invitrogen) in 250 µl volume were defrosted on ice for 
~ 5 min. 2 µl of isolated plasmid DNA (specified within results) was gently mixed 
with the cells by trituration. Two control vials were used for controls; one vial the 
cells were transformed with control plasmid DNA supplied with the cells and another 
vial had no DNA added to the cells. The cells were incubated on ice for 30 min and 
agitated every 5 min. The cells were heat-shocked by placing the tubes in to a water 
bath at 42 oC for 30 sec and then back onto ice for 2 min. 250 µl of pre-warmed LB 
broth was added to the cells and incubated for 1 h at 37 oC in a shaking incubator set 
to 225 rpm. At the end of the incubation, either 100 µl or 150 µl of the cells were 
spread on two pre-warmed LB agar plates containing ampicillin (50 µg/ml) and 
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chloramphenicol (34 µg/ml). Control plates were also prepared which consisted of a 
blank plate, cells transformed with control plasmid DNA and non-transformed cells. 
All the plates were incubated at 37 oC overnight. 
 
2.2.4 Miniprep of E.coli cultures. 
Plasmid DNA was isolated from transformed E.coli cells using a wizard® Plus SV 
Miniprep DNA purification system (Promega) following the manufactures 
instructions. Colonies were selected from transformation or stock plates and used to 
inoculate 6 – 10 ml pre-warmed LB broth (containing specific antibiotics for cell 
type) per colony within a 15 – 20 ml sterile tube and incubated at 37 oC in a shaking 
incubator overnight. Using a 2 ml micro centrifuge tube 2 ml of culture was 
transferred to the 2 ml tube and centrifuged at 7,400 x g for 2 min. The supernatant 
was gently removed and a further 2 ml of culture added prior to further 
centrifugation at 7,400 x g for 2 min. The supernatant was removed and a final 2 ml 
of culture transferred to the tube and centrifuged at 7,400 x g for 5 min. Excess 
media was removed. The cell pellets were re-suspended in 250 µl cell resuspension 
solution. 250 µl of cell lysis solution was added and the tube was inverted 4 – 6 
times. The cell suspension was incubated for a maximum of 5 min at room 
temperature, until partial clearing of the lysate was observed. Neutralising Solution 
(350 µl) was mixed by inverting the tube 4 – 6 times and then the tube was 
centrifuged at 14,500 x g for 10 min at room temperature (figure 2.1).  
 
Spin columns were inserted into a 2 ml collection tube and the clear lysate 
(supernatant) was transferred to the spin column, avoiding disturbing or transferring  
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Figure 2.1: Schematic of DNA mini prep from overnight culture.  
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any of the white precipitate. The spin column with lysate was centrifuged at  
14,500 x g for 1 min at room temperature. The spin column was removed from the 
collection tube and the flow through was discarded and the spin column re-inserted 
into the collection tube. The spin column was washed with 750 µl column wash 
solution and centrifuged at 14,500 x g for 1 min at room temperature. The collected 
wash through was discarded as before and the wash was repeated using 250 µl 
column wash solution. The wash through was discarded. The spin column was 
reinserted into the collection tube and centrifuged at 14,500 x g for 2 min at room 
temperature to remove any wash still present. The spin column was transferred to a 
sterile 2 ml micro centrifuge tube. Plasmid DNA was eluted from the spin column by 
adding 100 µl of sterile Nuclease-free water to the spin column and centrifuging at 
14,500 x g for 1 min at room temperature (figure 2.1). The eluted DNA was capped 
and stored at -20 oC or used immediately for DNA restriction digest. 
 
2.2.5 DNA restriction digests. 
To identify the presence of the synuclein gene inserts within the expression vectors 
the plasmids were cut using restriction enzymes that cut at specific nucleotide 
sequences. The restriction enzymes Nde I (Promega) and Hind III (Promega) were 
selected as both only cut once within the plasmid. Nde I cut the plasmid within a few 
nucleotides prior to the start codon of the gene insert and Hind III cut within a few 
nucleotides of the stop codon of gene inserts. Full digestion would therefore produce 




2.2.5.1 Combined restriction digest reactions. 
Initially, restriction digests used Nde I and Hind III in one restriction digest reaction 
to reduce DNA loss. For identification of the gene within a plasmid only small 
volumes of isolated plasmid were used in the digest. 2 µl of isolated plasmid DNA 
was mixed with 1 µl Multi-core buffer (Promega). 0.5 µl of both Nde I and Hind III 
was added and finally 6 µl of sterile milli-Q water was added. A control reaction was 
also prepared at the same time where the plasmid DNA was replaced with sterile 
milli-Q water. All the reactions were vortexed and incubated at 37 oC for 2 h within a 
water bath. To all the reactions 2 µl of loading buffer was added, vortexed, and 
loaded on to ethidium bromide (EtBr) 1 %  agarose gel (section 2.2.6) along with a 
specific DNA ladder specified for each gel. The agarose gel was run at 100 V for  
30 – 40 min (section 2.2.6). The gel was then visualised and photographed using a 
Multimager light cabinet (Alpha Innotech Corporation). 
 
This same DNA digest protocol was also used when digesting the α-syn gene 
produced by PCR, before ligation. For the removal of the insert from the expression 
vector, the volume of the restriction digest reactions were increased; DNA volume 
was increased to 25 µl, Multi-core buffer to 5 µl, each restriction enzymes to 2.5 µl 
and sterile milli-Q water to 20 µl. The in increase volume digest reactions were 






2.2.5.2 Individual restriction digest reactions.  
To increase the efficiency of the restriction enzyme reactions two separate reactions 
were performed using the specific reaction buffer for the enzymes.  
 
The gene insert isolated by PCR and the expression vector was initially cut using the 
resection enzyme Nde I and buffer D (Promega). The first reaction was setup using 
30 µl of DNA with 5.0 µl of Buffer D, 2.0 µl of Nde I and 13 µl of sterile milli-Q 
water to make the reaction volume up to 50 µl. The reaction was vortexed and 
incubated in a water bath at 37 oC for 3 h.  Reactions heated using a PCR machine 
were run overnight with the PCR machine programmed incubate at 37 oC for 2 h 
before dropping the temperature to 4 oC and holding the temperature. A sample (5 µl) 
of each reaction was run on a EtBr 2 % agarose gel at 100 V for 40 min along with 
uncut DNA to confirm if the restriction digest was successful (section 2.2.6). 
 
The remaining 45 µl of the digest were either run on EtBr 1 % low melting point 
(LMP) agarose gel and digested DNA extracted from the gel using QIAquick gel 
extraction kit (Qiagene) (section 2.2.7), or the Nde I cut DNA was collected via 
ethanol precipitation as described in section 2.2.8. For both extractions processes a  
2 µl sample of isolated DNA was run on a EtBr 1 % agarose gel (section 2.2.6). 
 
The isolated DNA was further digested by Hind III restriction enzyme to remove the 
gene insert from the now open expression vector. The seconded restriction enzyme 
reaction was setup using 30 µl of DNA (specified in results) with 5.0 µl of buffer E 
(Promega), 2.0 µl of Hind III and 13 µl of sterile milli-Q water to make the reaction 
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volume up to 50 µl. The reaction was vortexed and incubated in a water bath at 37 oC 
for 3 h. Again the restriction digests heated by PCR machine, the PCR machine was 
programmed to incubate the digest at 37 oC for 3 h, drop the temperature to 4 oC and 
hold.  
 
The restriction digests were collected by either gel extraction using QIAquick gel 
extraction kit, isolating the gene insert by band size from a EtBr 1 % LMP agarose 
gel, or by ethanol precipitation of the DNA. A sample of isolated DNA was run on a 
EtBr 1 % agarose gel (Section 2.2.6). The above restriction digest protocol opens the 
restriction sites of the gene insert and the expression vector ready for the use within a 
ligation reaction (Section 2.2.10). 
 
2.2.6 DNA ethidium bromide agarose gels. 
EtBr agarose gels and EtBr LMP agarose gels were prepared in the same way. The 
agarose was dissolved in TAE buffer (40 mM Tris acetate and 2 mM EDTA (pH 
8.3)) by heating agarose and TAE buffer to ~ 95 oC for 1 – 2 min without boiling. 
Once the agarose was dissolved it was cooled to 55 – 60 oC and 0.5 µg/ml EtBr 
solution was added to either agarose or LMP. The EtBr agarose or EtBr LMP was 
poured into a gel frame and the gel comb was inserted. Any bubbles within the gel 
were removed using the tip of a 200 µl pipette tip before the gel set. The ends of the 
gel frame and comb were removed before using the EtBr gel or EtBr LMP gel.  
 
All the agarose gels, independent of agarose percentage or type of agarose, were 
loaded into an electrophoresis agarose gel tank and completely covered with TAE 
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buffer. DNA samples (5 – 10 µl for EtBr 1 – 2 % gels and 40 – 50 µl for LMP EtBr 
gels) were loaded into the wells, the order for each run noted and stated with the gel 
results. The agarose gels were run at 100 – 150 V for 40 – 60 min at room 
temperature. The agarose gels were photographed using Multimager light cabinet 
(Alpha Innotech Corporation) containing a UV lamp to visualise the bands. 
 
2.2.7 DNA agarose gel extractions. 
DNA fragments produced by restriction digest (Section 2.2.5) were isolated and 
purified using a QIAquick gel extraction kit (Qiagen) and following manufacturer’s 
instructions. Restriction digests were run on EtBr 1 % LMP agarose gel (Section 
2.2.6) and the appropriated band was identified by comparing band size to a DNA 
molecular weight ladder marker. Once identified, the DNA fragment was cut out of 
the agarose gel and added to 3 times the volumes of buffer QG (weight/volume). The 
gel slice was solubilised in the buffer by incubation at 50 oC for 10 min in a water 
bath with occasional vortexing. Once dissolved, 1 volume of isopropanol was added 
to the sample and vortexed. A QIAquick spin column was inserted into a 2 ml 
collection tube and the sample loaded into the spin column. The spin column was 
centrifuged at 14,500 x g for 1 min. The flow through was discarded and the spin 
column inserted back in to the collection tube. The spin column was subsequently 
washed with 0.75 ml of buffer PE by centrifuging at 14,500 x g for 1 min. The flow 
through was discarded and the spin column was centrifuged for 1 min at 14,500 x g. 
The spin column was transferred to a sterile 2 ml micro centrifuge tube and the DNA 
fragment eluted from the spin column by the addition of 50 µl of sterile water prior to 
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centrifugation for 1 min at 14,500 x g. The eluted DNA fragment was either used 
immediately for ligation reaction or was stored at -20 oC. 
 
2.2.8 Ethanol precipitation of DNA.  
For DNA samples retrieved by ethanol precipitation, 2 volumes of 100 % ethanol 
and 1/10 volume of 3 M sodium acetate (NaAc) pH 5.2 was added to the finished 
restriction digest.  
 
The mixture was mixed by vortexing and incubated at -80 oC for 1 – 2 h. The 
reaction was centrifuged at 12,500 x g at 4 oC for 30 min. The supernatant was 
removed and the pellet was washed by gently adding 50 µl of 70 % ethanol without 
disturbing the pellet, centrifuging at 14,500 x g for 1 min and discarding the 
supernatant. The wash step was repeated and the pellet allowed to dry at room 
temperature for 5 – 10 min to allow the ethanol to evaporate. The DNA pellet was re-
suspended in sterile milli-Q water and either used immediately in further reactions or 
stored at -20 oC.  
 
2.2.9 Polymerase chain reaction (PCR) protocols. 
For all PCR reactions using α-synpRK172, forward primer sequences were designed 
to incorporate an Nde I restriction site into the α-syn start codon and a Hind III 
restriction site within the reverse primer directly after the α-syn stop codon. The 
primers were produced initially by MWG, but subsequently produced by Invitrogen, 




 5’- CCA TAT GGA TGT ATT CAT GAA AGG ACT T- 3’ 
Blue highlights the sequence for Nde I cutting site  
 
Alpha-reverse Primer: 
5’ – CAA GCT TTT AGG CTT CAG GTT CGT AGT C – 3’ 
 
Purple highlights the sequence for Hind III cutting site. 
 
These α-syn primers were also used in PCR reactions using α-synpET-22b(+) 
plasmid DNA to confirm the presence of the α-syn gene in the constructed plasmid. 
PCR was also used to confirm gene orientation within the α-synpET-22b(+), using a 
T7 forward primer and a reverse α-syn primer (Invitrogen). The PCR cycle program 
was unaltered by the change in primers. 
 
DNA isolated by mini prep was thawed on ice, pulse centrifuged and gently mixed 
by pipetting. PCR buffers and primers were warmed to room temperature, while 5 µl 
of target DNA was heated to 100 oC for 5 min. Immediately after heating the DNA 
the PCR reagents were added. A 50 µl PCR reaction included; 5.0 µl of 10 x PCR 
buffer, 0.4 µl of dNTPs each at 25 mM (Roche), 0.5 µl of the forward primer  
(1 pmol/µl) produced by either MWG or Invitrogen, 0.5 µl of reverse primer  
(1 pmol/µl) produced by either MWG or Invitrogen, 5.0 µl DNA (either α-
synpKR172 or α-synpET-22b(+)), 38.0 µl sterile deionised water and 0.75µl high 
affinity Taq (Roche). Concomitant controls used sterile water in place of DNA. Once 
reagents were added the reaction was briefly vortexed and pulsed centrifuged and the 
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tubes loaded onto a PCR machine (PCR express Thermo hybrid) and PCR cycles 
initiated as shown in figure 2.2. PCR products from the PCR reaction were identified 
by running 10 µl sample of each PCR reaction and control with 2 µl of loading 
buffer on a 1 % EtBr agarose gel (Section 2.2.6). 
 
2.2.9.1 PCR protocols for direct PCR from E.coli colonies. 
JM109 cells transformed with newly ligated α-synpET-22b(+) plasmid were 
constructed using PCR amplified α-syn using MWG primers (section 2.2.9).  
 
Individual colonies produced from JM109 cell transformated with α-synpET-22b(+) 
were selected and dipped into 50 µl of lysis buffer. The loop was then streaked across 
a 1 cm2 squares on an agar plate (amp 50 µg/ml). Remaining cells on the loop were 
removed by resuspending the cells in the 50 µl of lysis buffer. The lysis buffer 
containing colony cells was vortexed before incubating at 95 oC for 10 min. From the 
lysed sample 1 – 2 µl was taken and mixed with the following PCR reagents; 10 µl of 
Red Taq, 1 µl of α-syn forward primer (MWG), 1 µl of α-syn reverse primer (MWG) 
and 6 – 7 µl of sterile deionised water. The tubes were loaded onto a PCR machine 
(PCR express Thermo hybrid) and the PCR cycles initiated as described in figure 2.2. 
PCR products from the PCR reaction were identified by running a 10 µl sample of 
each PCR reaction (and control) with 2 µl of loading buffer on a EtBr 1 % agarose 
gel (section 2.2.6). 
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94 oC, 40 s 
50 oC, 30 s 




Figure 2.2: Schematic of the PCR temperature cycles.  
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2.2.10 Ligation of gene insert into expression vector. 
The α-synpET-22b(+) plasmid was constructed by inserting the α-syn gene generated 
by PCR from the α-synpRK172 plasmid (section 2.2.9)  into the commercially 
available pET-22b(+) vector (Invitrogen). Prior to the ligation reaction, the 
expression vector was opened by restriction digest using Nde I and Hind III (section 
2.2.5.2) and purified by either gel extraction (section 2.2.7) or ethanol precipitation 
(section 2.2.8). The ends of α-syn PCR products were also cut using Nde I and Hind 
III (section 2.2.5.2), priming the α-syn ends for insertion into the pET-22b(+) vector. 
For the ligation reaction; 1 µl of ligation T4 buffer (10 x), 1 µl of open pET-22b(+) 
vector, 3 µl of primed α-syn PCR product, 1 µl of Ligase T4 (enzyme) and 5 µl 
sterile milli-Q water were vortexed together and incubated overnight (12 – 16 h). The 
reaction was initially incubated at 16 oC with the temperature gradually reduced to  
4 oC. Once the reaction was finished the mix was used in a transformations of either 
DH5α or JM109 competent cells (section 2.2.2). The new constructed plasmid was 
confirmed by PCR (section 2.2.9) or restriction digest (section 2.2.5.1) of isolated 
plasmid DNA from colonies cultured from the transformation (section 2.2.4). 
 
2.3 Protein expression and purification. 
2.3.1 Protein expression. 
2.3.1.1 LB broth expression. 
BL21(DE3) competent colonies transformed with either α-synpRK172 or α-synpET-
22b(+) plasmids, were randomly selected and used to inoculate 6 – 10 ml LB broth 
containing both amp (50 µg/ml) and chlora (34 µg/ml) and incubated overnight at  
37 oC. Each overnight culture was then used to inoculate 100 ml pre-warmed LB 
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broth containing amp (50 µg/ml) and chlora (34 µg/ml) to an optical density of ~ 0.1 
(read at 560 – 600 nm (OD600)). The culture was incubated at 37 
oC, shaking until the 
OD600 reached 0.4 – 0.6 which took approximately 2 – 3 h. Once OD600 was reached, 
a 2 ml sample of the culture was collected and 0.001 M (final concentration) of 
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the culture to induce 
protein expression within the cells. After induction, 2 ml culture samples were taken 
at set times specified on expression gel in the results. All samples were centrifuged at 
14,500 x g for 2 min and the pellet re-suspended in 50 µl of milli-Q water and 50 µl 
of loading buffer (Section 2.3.2.1). The samples were stored at -20 oC prior to being 
run on an expression gel. 
 
The same protocol was used for protein expression in JM109 competent cells, 
however samples pellets were heat-treated rather than re-suspended in milli-Q water 
and loading buffer (Section 2.3.7). 
 
2.3.1.2 Peptone broth expression. 
BL21(DE3) competent colonies transformed with α-synpRK172 plasmid used in 
expression experiments using peptone media were performed in the same way as 
above (section 2.3.1.1), except instead of using LB broth, peptone media containing 
amp (50 µg/ml) and chlora (34 µg/ml) was used. 
 
2.3.1.3 LB broth single colony inoculation. 
Colonies of α-synpET-22b(+) transformed BL21(DE3)pLysS cells were selected 
from plates and used to directly inoculate 4 x 500 ml of pre-warmed LB broth 
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containing amp (50 µg/ml) and chlora (34 µg/ml). The cultures were incubated at  
37 oC, shaking until an OD600 of 0.4 – 0.6 was reached (at which point a 2 ml sample 
of the culture was collected and the remaining cultures were induced by the addition 
of 0.001 M IPTG). Then either time-course samples were then taken or all of the 
culture was collected 4 h after induction by IPTG. In both cases cultures were heat-
treated as described in section 2.3.7.1. 
 
2.3.1.4 10 L Fermentation  -  Scale-up of expression cultures. 
Plasmids were taken to the Edinburgh Protein Interaction Centre (EPIC) and 
Brunswick BioFlo4500s 5 – 15 L fermentors were used for culture growth. Pellets 
were collected from the EPIC and heat-treated as in section 2.3.7.2. 
 
2.3.2 Preparation of 16 % acrylamide SDS electrophoreses gels. 
Initial experiments used 16 % acrylamide, sodium dodecyl sulphate (SDS) gels 
prepared in-house. To produce two gels the following mix was prepared for the 16 % 
SDS gel: 2 ml milli-Q water, 5.3 ml 30 % acrylamide/bis-acrylamide, 2.5 ml 1.5 M 
Tris (8.8 pH) and 0.1 ml 10 % SDS, 0.1 ml ammonium persulphate and 10 µl 
TEMED. The stacking gel prepared contained: 3.3 ml milli-Q water, 1 ml 30 % 
acrylamide/bis-acrylamide, 0.62 ml 1.25 M Tris (6.8 pH), 0.05 ml 10 % SDS, 0.05 
ml ammonium persulphate and 10 µl TEMED.  
 
The gel was constructed by pipetting 3 ml of the 16 % SDS gel between two glass 
plates. 1ml of milli-Q water was gently pipetted on top of the 16 % gel to ensure a 
level top of the gel. Once set the water was removed and the stacking gel was 
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pipetted on top of the 16 % gel to the top of the glass plates, a well comb was 
inserted into the stacking gel and allowed to set. When set the comb was removed 
and the gels were ready use.   
 
2.3.2.1 Loading buffer for 16 % SDS gels.  
For the 16 % SDS gels, 2 x laemmli loading buffer was prepared in-house for sample 
loading. To produce 10 ml; 1 ml 125 M Tris (6.8 pH), 4 ml 10 % SDS, 71 µl 0.1 M 
β-mercaphothanol, 2 ml of glycerol and 2.93 ml of milli-Q water were mixed 
together.  
 
2.3.3 Electrophoresis of expression cell pellets using 16 % SDS gels.  
Cell pellets collected from the expression cultures were re-suspended in 50 µl of 
milli-Q water and 50 µl 2 x laemmli loading buffer. All the samples were heated to 
95 oC on a heat block for 5 min and allowed to cool. 
 
The electrophoresis box was prepared, containing 2 x 16 % SDS gels making a inner 
chamber which was filled with 1 x SDS running buffer and allowed to overflow to 
half fill the outer chamber. The wells were loaded with 20 µl of the samples and 10 
µl of specified marker with the order of loading noted for each individual run. The 
gels were run for 45 min at 200 V and 400 amps (figure 2.3).  
 
The 16 % SDS gels were removed from the electrophoresis box and removed from 
between the glass plates. The stacking gel containing the wells was removed and the 
remaining 16 % SDS gel was stained for 1 – 2 h with coomassie blue dye. The 
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excess staining was removed by washing the gel in 10 % acetic acid and 20 % 
methanol overnight on a rocking table. The gels were photographed using a 
Multimager light cabinet (Alpha Innotech Corporation) and analysed using FC 8000 
v3.04A FluroChem software. 
 
2.3.4 Electrophoresis of fraction samples using NuPAGE 4 – 12 % Bis –Tis gels.  
To all samples (normally ~ 37 µl) run on th NuPAGE 4 -12 % Bis –Tis 1.0 mm gels 
(Invitrogen), 12.5 µl of 10 x NuPAGE Sample buffer and 1.0 µl 0.1 mM DTT was 
added and the samples vortexed. All the samples were heated to 95 oC on a heat 
block for 5 min and allowed to cool. 
 
The electrophoresis box was prepared, containing NuPAGE 4 -12 % Bis –Tis 1.0 
mm gels (Invitrogen) making a inner chamber which was filled with 1 x NuPAGE® 
Mes SDS running buffer (Invitrogen) with 10 µl of NuPAGE antioxidant 
(Invitrogen) added once the chamber was full. NuPAGE® Mes SDS running buffer 
(Invitrogen) was also used to fill the outer chamber about 3/4 full. Samples were 
loaded in to the NuPAGE gels with 15 – 20 µl per well. The gels were run for 45 min 
at 200 V and 400 amps (figure 2.3).  
 
The NuPAGE gels were removed from the electrophoresis box and washed three 
times with distilled water for 15 min. SimpleBlue SafeStain (Invitrogen) was used to 
stain the gels. Enough stain was added to each gel to completely cover the gel 
(approx. 20 ml), and incubated at room temperature on a rocking plate for 1 – 8 h. 
The staining reagent was removed and the gels washed twice with distilled water for 
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NuPAGE gels 
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Figure 2.3: Schematic of NuPAGE gel electrophoresis setup.  
Front view Side view 
 95 
15 min. On the third wash the distilled water was left for a 1 h to remove any excess 
stain from the gel. The gels were photographed using a Multimager light cabinet 
(Alpha Innotech Corporation) and analysed using FC 8000 v3.04A FluroChem 
software.   
 
IMPORTANT NOTE 
Changing the gels from ‘homemade’ SDS-PAGE gels to pre-made NuPAGE gels 
(Invitrogen) showed that the α-syn protein ran differently between the two types of 
gel; on SDS-PAGE gels α-syn appears as a band at 17 - 19 kDa whereas on NuPAGE 
gels α-syn appears as a band at ~ 14 kDa. This was difference has been previously 
identified by (Moussa et al. 2004). 
 
2.3.5 Western blot positive control. 
Rat cerebrum was used as the positive control for the presence of syn proteins. 
Frozen rat cerebrums was thawed on ice while lysis buffer was prepared (10 mM 
Tris (pH 7.4), 1 % SDS, PMSF (1 µl per 100 µl), proteinase inhibitors (1 µl per 1000 
µl). A section of rat cerebrum weighing ~ 0.5 g was cut and homogenised using a 
loose fit (x 10) followed by a tight fit (x 20) homogeniser in 10 x the volume of lysis 
buffer (1 ml of lysis buffer to 0.1 g). The brain tissue was heated to 95 oC for 10 min 
and cooled on ice before centrifugation at 12,500 x g for 4 min at 4 oC. The 
supernatant was collected and total protein concentration was determined by BCA 
assay (Section 2.3.10). 
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A portion of the rat cerebrum supernatant was diluted to 5 mg/ml using 
NuPAGE loading buffer as follows; 200 µl of cerebrum sample, 2.8 ml of 10 x 
NuPAGE Sample buffer and 6 – 10 µl of DTT (10 mM). The cerebrum sample in 
loading buffer was aliquoted in to 50 µl volumes and stored at -70 oC. The remaining 
undiluted cerebrum supernatant was aliquoted into 0.5 ml volumes, stored at -70 oC.  
 
2.3.6 Western blotting. 
Proteins separated on either SDS-PAGE or NuPAGE gels can be detected using 
protein-specific antibodies by western blots. The protocol for each western blot is 
principally the same, with the only change being the specific primary antibodies used 
depending on the protein being identified on the blot. As all the primary antibodies I 
used were raised in mice the secondary antibody was anti mouse Ig for all western 
blot studies. Human α-syn (host: mouse) antibody (BD Biosciences) was used for the 
detection of α-syn and human β-syn (host: mouse) antibody (BD Biosciences) was 
used for the detection of β-syn. The dilution ratios all stayed the same irrespective of 
the antibody used. 
 
Initially protein samples were loaded on to either SDS-PAGE or NuPAGE gels, and 
run as described in sections 2.3.3 and 2.3.4 respectively. Magic marker standards 
(Invitrogen) and a control samples (section 2.3.5) were also run for each experiment. 
During the electrophoresis of the expression gels, 4 pieces of filter paper (Amersham 
Biosciences) and Hybond C membrane (Amersham Biosciences) were soaked in 1 x 
transfer buffer (25 mM Tris, 0.15 M glycine, 200 ml methanol 800 ml distilled 
water) along with 6 sponges. On conclusion of electrophoresis run, the gels were 
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removed from the electrophoresis tanks. The gels were layered as per figure 2.4. The 
produced sandwich was transferred into a transfer box and the box inserted into the 
electrophoresis tank and locked in place. Transfer buffer was poured into the top of 
the transfer box until the buffer level was just above the top of the gel and membrane 
sandwich. The gel transfer was run for 1 h at 30 V and 400 amps. 
 
At the end of the run the membrane was removed and washed in TBS/T (1 x Tris 
buffered saline (pH 8.0) containing 0.1 % Tween 20) for 5 min, three times. The 
membrane was then blocked with 4 % milk in TBS/T at room temperature on a 
rocking table for 1 h or at 4 oC overnight. The blocking solution was removed and 
the membrane incubated with primary antibody (1 : 5,000) in 4 % milk in TBS/T, at  
4 oC overnight on a rocking table. The antibody was removed and the membrane was 
washed in TBS/T for 5 min. The wash procedure was repeated a further 2 times. 
After the washes the membrane was incubated with the secondary antibody, (anti-
mouse Ig horseradish peroxidase-linked whole antibody; Amersham Biosciences,  
1 : 20,000) in 4 % milk in TBS/T for 1 h at room temperature and rocking. The 
secondary antibody was removed and the membrane washed in TBS/T for 10 min, 
three times. The membrane was developed using ECL Plus Western Blotting 
Detection reagents (Amersham Biosciences) by following manufacturer’s guidelines. 
In brief, detection reagents were mixed in 40 : 1 ration of reagent A and reagent B 
and protected from light. The excess buffer from the wash steps was drained from the 
membrane and the membrane was placed protein side up on to a piece of SaranWrap. 
The mixed detection reagents were pipetted directly on to the membrane ensure the 
whole membrane was covered. The membrane was incubated for 5 min at room 
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Figure 2.4: Schematic of the layers in a Western blot. 
Schematic of the order of layers in a western blot; sponge, filter paper, electrophoresis gel, 
Hybond-C extra membrane (marked on the side facing the gel), filter paper and sponge. 
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temperature. Excess detection reagents were drained off. The membrane wrapped 
again in SaranWrap and was exposed using Chemi display of the Multimager light 
cabinet (Alpha Innotech Corporation) for 1 min and the exposed membrane viewed 
using FC 8000 v3.04A FluroChem software. Exposure time was varied depending on 
initially intensity of protein blots viewed. 
 
2.3.7 Heat treatment of cell lysate. 
2.3.7.1 Heat treatment of expression time course samples. 
A 2 ml culture sample (from sections 2.3.1.1 to 2.3.1.3) was centrifuged at  
14,500 x g for 2 min, the supernatant discarded and cell pellet washed with 0.5 ml of 
cold 1 x PBS by centrifuging at 14,500 x g for 2 min or 2,700 x g for 5 min. PBS was 
discarded and the cell pellet re-suspended in 50 – 100 µl of cold lysis buffer (0.75 M 
NaCl, 0.1 M Tris pH 7.0, 1 mM EDTA and 1 protease inhibitor cocktail tablets 
(Roche) per 10 ml and milli-Q water) by vortexing. The lysed cells were heated for 
10 min at 100 oC in a water bath before cooling on ice and centrifuging at 12,500 x g 
for 30 min at 4 oC. The cell lysate was stored at -20 oC.  
 
2.3.7.2 Heat treatment of expression cultures. 
For 2 L expression culture, the culture was split into 4 x 500 ml centrifuge bottles 
and centrifuged at 4,000 x g for 15 min at 4 oC. The supernatant was discarded and 
each cell pellet was washed with 500 ml of cold 1 x PBS and centrifuge at 4,000 x g 
for 15 min at 4 oC. The 1 x PBS was discarded. Each pellet was re-suspended in the 
equivalent volume (approx. 5 – 10 ml) of cold lysis buffer (0.75 M NaCl, 0.1 M Tris 
pH 7.0, 1 mM EDTA and 1 Protease inhibitor cocktail tablets (Roche) per 10 ml and 
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milli-Q water) by trituration and vortexing. Once fully re-suspended, the lyised cells 
were heated for 10 min at 100 oC in a water bath and cooled on ice before 
centrifuging at 12,000 x g for 30 min at 4 oC. The cell lysate was removed to a sterile 
tube without disturbing the pellet. The pellet was discarded and the cell lysate was 
kept on ice ready for dialysis. 
 
2.3.8 Dialysis of protein samples. 
The cell lysate produced by heat treatment (section 2.3.7) was dialysed into 20 mM 
Tris (pH 8.2) using Slide-A-Lyzer® Dialysis cassettes with 3,500 MWCO (Pierce). 
The same dialysis protocol was also used for the dialysis of α-syn containing column 
fraction samples, although deionised water was used instead of 20 mM Tris (pH 8.2) 
(see sections 2.3.11). 
 
The cassettes were hydrated according to manufactures protocol immediately before 
use and used for one dialysis only. In brief, the cassette was immersed in dialysis 
buffer for 30 s to hydrate the dialysis membrane. The cell lysate was injected into the 
dialysis chamber and dialysed overnight with gentle stirring at 4 oC. The dialysed 
sample was removed and stored at either 4 oC for same day use or at -80 oC. 
 
2.3.9 Lyophilisation of α-syn protein.  
α-Syn fractions were pooled and dialysed overnight into deionised water (section 
2.3.8). After dialysis, the sample was sterilised by filtration (0.22 µm). A portion of 
the filtered sample was taken to determine protein concentration by BCA assay 
(section 2.3.10). Once the protein concentration was determined, the filtered α-syn 
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sample was aliquoted into ~ 1 mg quantities and frozen at -70 oC for 4 – 6 h before 
the tubes were freeze dried. The α-syn aliquots were kept under pressure overnight. 
Before being collected and stored at -70 oC. Two of the lyophilised α-syn samples 
were re-hydrated in 1 ml of deionised water each and the protein concentration was 
confirmed by BCA assay (section 2.3.10) with the BCA standards diluted in 
deionised water.  
 
2.3.10 BCA assay. 
All BCA assays (Pierce) were setup in a 96 well plate (Nunc) according to 
manufactures protocol. Test samples were analysed at appropriate dilutions and were 
run in triplicate. Concentration standards (Albumin, Pierce) were run concurrently 
(in duplicate), diluted in the same buffer as test samples. 10 µl of test sample or 20 µl 
of standards were loaded per well. 
 
The BCA reagents were then prepared by adding 11 ml of reagent A to 220 µl of 
reagent B and vortexed. 200 µl of the mixed reagents were added to each well used 
(standards and samples). The plate was wrapped in tin foil, incubated at 30 oC for 1 h 
and was then read using an optical density 96 well plate reader (Dynex revelation 
3.04) which read the plate at a wavelength of 560 nm. The protein concentration for 
each sample was calculated from the concentration curve produced by the standard 





2.3.11 Fast Protein Liquid Chromatography (FPLC). 
Recombinant syn proteins were purified by ion-exchange chromatography using 
either a Mono-Q column, a HiTrap Q HP column or a self-poured column using Q 
Sepharose High Performance matrix (all from Amersham Biosciences). All columns 
were equilibrated in 0.02 M Tris pH8.2 (buffer A). Protein samples were dialysed 
into buffer A, as described in section 2.3.8, and cell debris removed by centrifugation 
(12,500 x g for 5 min) using a micro centrifuge before being injected onto the 
column. Unbound material was eluted by washing with buffer A. The 1 ml Mono-Q 
column was run at a flow-rate of 1 ml/min with 1 M NaCl, 0.02 M Tris pH8.2 used 
as the elution buffer (buffer B). The elution of bound proteins from the column was 
achieved by increasing the buffer B gradient from 0 – 40 % over 10 min, before 
raising the gradient to 100 % for 5 min to wash the column. For the HiTrap Q HP 
column (1 ml and 5 ml), an extra 5 min of 20 % buffer B step prior to the start of the 
gradient was added to remove contaminants from the column prior to elution of the 
syn proteins. Bound protein was eluted by increasing the gradient 20 – 40 % over 10 
min. Buffer B gradient was then raised to 100 % for 4 min to wash the column. For 
the 1 ml HiTrap Q HP column, a 1 ml/min flow rate was used, whereas for the 5 ml 
HiTrap Q HP column, a 5 ml/min flow rate was used. 
 
Self-poured columns (using Q Sepharose High Performance matrix) were run at  
5 ml/min, with the increase of buffer B to 20 % gradient over 10 min. 4 ml volumes 
were collected over the 20 – 40 % gradient. For all the column runs the purified 
fractions collected were analysed by SDS-PAGE or NuPAGE gels as described in 
sections 2.3.3 and 2.3.4. 
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2.3.12 Mass Spectrometry of NuPAGE gel bands. 
Collected fractions from some of the FPLC purification runs (see section 2.3.11) 
were analysed by NuPAGE gels.  Bands from these gels were extracted and analysed 
by Dr Duncan Short of A.C.E. (University of Edinburgh) using mass spectrometry to 
identify the band corresponding to α-syn. Briefly, the bands of interest were excised 
from the gel and incubated with 300 µl of 200 mM ammonium bicarbonate in 50 % 
acetonitrile at 30 oC for 30 min to remove SDS. Supernatant was removed and the 
protein reduced in the presence of 20 mM dithiothreitol in 300 µl, 200 mM 
ammonium bicarbonate, 50 % acetonitrile and left at 30 oC for 1 h. Separate gel 
pieces were washed with 300 µl of 200 mM ammonium bicarbonate, 50% 
acetonitrile three times before the protein band was alkylated by the addition of  
100 µl 50 mM iodoacetamide, 200 mM ammonium bicarbonate and 50% acetonitrile 
at room temperature in the dark for 20 min. Gel pieces were allowed to air dry before 
being reconstituted in acetonitrile. Reduced and alkylated protein gel pieces were 
digested with 20 µl of 12.5 µg/ml trypsin in 20 mM ammonium bicarbonate 
overnight at 30 oC (after a short period of gel swelling at 4 oC). Samples were spotted 
directly onto the MALDI sample plate utilising the dry drop method (0.5 µl each, 1:1 
mix with matrix solution consisting of saturated alpha-cyano-4-hydroxy cinamic acid 
in 0.1 – 0.3 % TFA, 50 % MeCN,) and allowed to air dry.  
 
2.4 Tissue Culture. 
The SHSY-5Y human neuroblastoma cells (cell line No. 94030304) were obtained 
from the ECACC (European Collection of Cell Cultures, Salisbury, Wiltshire, UK). 
SHSY-5Y cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
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with 10 % foetal calf serum (FCS) (Gibco), 2 mM L-glutamine and 1 % penicillin 
and streptomycin. The cells were not cultured beyond 6 weeks or passage 18.  
 
2.4.1 Passage of SHSY-5Y cells into 250 cm
2
 flasks. 
Once the cells were 80 % confluent on the bottom of the 250 cm2 flask, they were 
split into new flasks. The growth media was removed and the cells washed with pre-
warmed Hank’s balanced salt solution (Hanks). The Hanks was removed and 5 ml of 
0.25 % Trypsin-EDTA solution was added to the cells and incubated at 37 oC and  
5 % CO2 for maximum of 10 min. This causes the cells to rise off the bottom of the 
flask to be enabling collection. Trypsin was neutralised by the addition of 5 ml of 
pre-warmed DMEM containing 2 mM L-glutamine and 1 % penicillin, streptomycin 
and 10 % FCS (growth media). The cells were then centrifuged for 5 min at 200 x g 
at 37 oC. The supernatant was removed and 2 ml of fresh media was added. The cell 
pellet was re-suspended by gently pipetting the cells in growth media. A further  
18 ml of growth media was added to the cells. 10 µl of the re-suspended cells were 
counted using a haemocytometer. 
 
The re-suspended cells were transferred to new sterile 250 cm2 flasks to a density of 
approximately 1 x 106 cells per flask. Growth media was added to each flask to give 
a final volume of 25 ml. The flasks were incubated at 37 oC, 5 % CO2, the media was 





2.4.2 Media change of SHSY-5Y culture flasks. 
The media change was similar to the passage described above but the cells were not 
removed from the flasks. The growth media was removed from the cells and the cells 
washed with pre-warmed Hanks. To each flask, 25 ml of pre-warmed growth media 
was added and the cells returned to incubator until the confluence reached ~ 80 % 
(typically achieved after a further 3 days). 
  
2.4.3 Seeding of SHSY-5Y on to 96 well plates. 
For in vitro studies, cells were passaged as previously described in Section 2.4.1 and, 
after counting, were plated on to poly-D-lysine treated 96-well plates (NUNC) at a 
density of 1 x 105 cells per well. Cells were incubated at 37 oC with 5 % CO2 
overnight to allow cells to adhere to the wells. Growth media was removed and the 
cells were washed twice with DMEM containing 2 mM L-glutamine. After the final 
wash, cells were available for experimental use. 
 
2.4.4 Aggregating of α-syn protein. 
α-Syn WT and A53T proteins produced commercially (rPeptide) or in-house were 
aggregated by re-suspending 1 mg of lyophilized α-syn (either WT or A53T) in 1 ml 
sterile filtered milli-Q water to give a final concentration of 69.1 µM based on 
molecular weight. The resuspended α-syn was aliquoted in to 55 µl volumes and 
incubated at 37 oC for 7 days. After the 7 day incubation the aggregated WT or A53T 
α-syn was used immediately. Thioflavin T is a dye which fluoresces at the excitation 
and emission of 450 and 482 nm, respectively, in the presence of α-syn fibrils (but 
not in the presence of soluble α-syn) (Conway et al., 2000; Hoyer et al,. 2002). 
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Thioflavin T was used to monitor and confirm α-syn aggregation by a method 
adapted from Yoshiike et al., 2003. 
 
2.4.5 Preparation of MPP
+
 stocks. 
MPP+ was dissolved in a sterile filtered milli-Q water to give a stock solution of 1 M, 
and used immediately used. All tips and containers with had come in to contact with 
MPP+ and any unused MPP+ solutions were disposed of in separate labelled waste 
containers, and incinerated. 
 
2.4.6 MTS assay. 
CellTiter 96® AQueous One Solution Reagent (Promega) (MTS assay) contains a 
novel tetrazolium compound that is reduced by NAD(P)H (released from 
metabolically active cells) to produce a coloured formazan product. The colour 
change induced by the reduction of MTS is monitored by reading the light absorption 
at 490 nm. A decrease in MTS signal is indicative of cytotoxicity and cell death.  
 
The assay was used according to the manufactures protocol (Promega Technical 
bulletin TB245 – General Protocol). The cells were plated as described in section 
2.4.3. Cell treatments and controls were set up in triplicate to a final volume of  
100 µl. Background controls of all treatments were plated in wells not containing 
cells. The plates were incubated for the specified time for experiment (stated in 
results section 4.1). 
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At the end of the treatment incubation, 20 µl of pre-warmed CellTiter 96® AQueous 
One Solution Reagent (Promega) was added directly to all the wells giving a 1 in 6 
dilution. The plates were incubated for a further 1 h at 37 °C and 5 % CO2. After 
incubation, the plates were read using an optical density 96 well plate reader (Dynex 
revelation 3.04) at 490 nm wavelength. The plate reader was setup to automatically 
subtract the appropriate background from the treatment wells according to the 
experimental template. The data was analysed using SigmaPlot and SigmaStat and 
errors bars on all subsequent graphs show standard error of mean (SEM).  
 
2.4.7 LDH assay. 
CytoTox96® Non-Radioactive Cytotoxicity assay (Promega) (LDH assay) quantified 
cell death by measuring the release of the enzyme lactate dehydrogenase (LDH) from 
lysed cells. Released LDH metabolises tretrazolium salt to produce a red formazan 
produce. The amount of colour change is proportional to the number of lysed cells 
and the colour change can be detected using a visible wavelength plate reader.  
 
The LDH assay was used according to the manufactures protocol (Promega 
Technical bulletin TB163 – LDH measurement). The cells were plated as described 
in section 2.4.3. Cell treatments (or vehicle) were performed in triplicate at a final 
volume of 100 µl. Triplicate wells of all treatments (each 100 µl) were also prepared 
in wells devoid of cells to be used as background control. Plates were incubated for 
the time specified for each experiment (stated in results chapter 4). Irrespective of 
incubation times, 90 min prior to the end of incubation, 15 µl of 10 x lysis solution 
(supplied with LDH assay) was added to the positive control cells (to generate 
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measurable cell death signal). At the end of the incubation, 50 µl of the supernatant 
(media) of each well was transferred to a fresh 96-well plate. 
 
12 ml of assay buffer (supplied within the LDH assay, Promega) was added to one 
bottle of substrate mix (supplied within the LDH assay, Promega). Once resuspended 
the substrate was protected from the light and used immediately. The reconstituted 
substrate mix was added at 50 µl per well to all the wells of the treatment plate. The 
treatment plate was covered with tin foil (to protect the plate from light), incubated 
for 30 min at room temperature before the addition of 50 µl of stop solution 
(supplied within the LDH assay) to each well. The plate was run using optical 
density 96 well plate reader (Dynex revelation 3.04) at 490nm and analysed using 
Revel software within 1 h of the addition of the stop solution. The Revel software 
was programmed, to subtract the appropriate background from each treatment 
reading.  
 
The average of the treatment, controls and lysed cells was determined and used to 
calculate the percentage of cytotoxicity. The percentage of cell death was calculated 
by the below equation (figure 2.5). The resultant data was analysed using SigmaPlot 
and SigmaStats, with errors bars on all subsequent graphs showing SEM.  
 
         
 
Figure 2.5: Percentage of cell death calculated from LDH assay. 
% Cell Death = x 100 
Lysied Cells – Vehicle Control 
Treatment – Vehicle Control 
 109 
2.4.8 Cytochrome c ELISA. 
2.4.8.1 Cytochrome c sample preparation. 
The cells were plated as described in section 2.4.3. Cells were treated according to 
the concentration and incubation time stated in the results (section 4.2) in sets of 
triplicate wells with final volume of 100 µl per well. 
 
At the end of the treatment incubation, the treatments were removed and the cells 
were washed with 100 µl of Hanks solution. The wash was removed and the cells 
incubated for 1 h at room temperature with 70 µl of either digitinon extraction buffer 
(removes cellular membrane but not vesicle or organelle membranes) or  3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) extraction buffer 
(removes all membranes). Thirty min into the incubation the cells were triturated and 
then incubated for a further 30 min at room temperature. Lysed cells from each 
triplicate were combined and centrifuged at 2,500 x g for 5 min. The supernatant was 
collected and stored at either -20 oC overnight or -70 oC if longer. 
 
2.4.8.2 Solution for cytochrome c cell sample preparation. 
10 x stock of 1.5 M NaCl + 100 mM HEPES-(Na/K)OH, pH 7.6:  Dissolved 8.8 g 
NaCl (1.5 M) and 2.4 g HEPES into 80 ml of water, corrected pH to 7.6 with NaOH 






Digitonin Extraction Buffer:  
150 mM NaCl + 10 mM HEPES – (Na/K)OH pH 7.6 (use a 10x stock)  
1 % PMSF  
1 % protease inhibitor cocktail 
3.1 µM digitonin 
 
CHAPS Extraction Buffer:  
150 mM NaCl + 10 mM HEPES-(Na/K)OH, pH 7.6 (in a 10 x stock) 
1 % PMSF 
1 % protease inhibitor cocktail 
1 % CHAPS detergent 
 
2.4.8.3 Cytochrome c ELISA – Protocol. 
The ELISA kit used as described within the manufactures manual (Bender 
MedSystems working protocol for the human Cytochrome c Module set 
BMS263MST). Initially, plates were coated with 100 µl/well of coating solution  
(1 µg/ml; 1 in 100 dilution in PBS of supplied stock solution). The plates were 
incubated at 2 - 8 oC overnight. The coating solution was removed and the plates 
were washed with 250 – 300 µl of 1 x PBS with 0.1 % tween 20 (repeated twice). On 
the last wash the plates were tapped dry. The coated plates were blocked with 250 µl 
1 x Assay buffer per well (supplied with kit as 5 x stock and diluted with milli-Q 
water) and incubated for either 2 h at room temperature or overnight at 2 – 8 oC.  
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The samples prepared in section 2.4.8.1 were diluted in 1 x Assay buffer 
(1/10, 1/20, 1/50 or 1/100) and cyctochrome c standard (100 ng/ml, supplied with 
kit) was prepared at 0.16 ng/ml, 0.32 ng/ml, 0.63 ng/ml, 1.25 ng/ml, 2.5 ng/ml, 5.0 
ng/ml and 10 ng/ml.  
 
The blocked plates were washed twice with 1 x PBS with 0.1 % tween 20 before 100 
µl of the diluted sample and standard were added to the plate. Biotin-conjugate was 
diluted by a ratio of 1 : 2,000 in assay buffer and 50 µl of the diluted biotin-conjugate 
was added to each wells, the plate was covered and incubated for 2 h at room 
temperature. The plate was washed three times with 1 x PBS with 0.1 % tween 20. 
On the final wash the plate was tapped dry. 
 
To each well 100 µl of Streptavidin-HRP (supplied in kit and diluted to a ratio of  
1 : 10,000 in 1 x assay buffer prior to use) was added. The plate was covered and 
incubated for a 1 h at room temperature. The plate was washed three times with 1 x 
PBS with 0.1 % tween 20 and tapped dry. Substrate solution was prepared 
(tetramethylbenzidine in milli-Q water, 2 : 1 v/v) and 100 µl added to all the wells. 
The plate was incubated in the dark at room temperature for 15 min. The reaction 
was stopped by the addition of 100 µl 4 N Sulphuric acid and the plate was read 
using the optical density 96 well plate reader (Dynex revelation 3.04) at 450 nm. The 
plate was analysed using the Revel software according to experimental template.  
The results were analysed using SigmaPlot and SigmaStat, with errors bars on all 
subsequent graphs showing SEM. 
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2.4.9 FLIPR Plus Ca
2+
 assay. 
The FLIPR Plus calcium assay kit (Molecular Devices Corporation) is a 
fluorescence-based assay which utilises a cytoplasmic dye to detect changes in 
intracellular calcium. 
 
The cells were plated as described in section 2.4.3. Cells were treated with specified 
treatments or controls in triplicate, with a final volume of 75 µl. An hour prior to the 
termination of the incubation time, the original cell treatments at 5 x the 
concentration of the original treatment and the cytoplasmic dye were prepared.  
 
Cytoplasmic dye was prepared by warming one vial of component A (supplied with 
kit) to room temperature and dissolving in 10 ml of 1 x calcium buffer (diluted from 
x 10 Hanks buffer with Ca2+/Mg2+ and 200 mM HEPES). To the reconstituted dye, 
200 µl of 25 mM (±) sulfinpyranzone in 1 M NaOH was added. To each well, 25 µl 
of the treatment (to give appoperiate concentration in final volume) and 100 µl of the 
cytoplasmic dye was added. The cell plate was covered in tin foil and incubated for 
an hour at 37 oC in 5 % CO2 before reading. Digitonin treated cells were used as a 
positive control. Wells allocated as positive controls were incubated initially with 75 
µl serum-free media and an hour prior to termination, of digitonin (10 µM final 
concentration; prepared in serum-free media) and 100 µl of the dye was added to the 
wells. 
 
After incubation the plate was transferred directly a Flexstation (Molecular devices) 
set to read at an excitation wavelength of 485 nm and emission wavelength of  
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527 nm (with emission cut-off at 515 nm). The generated results were analysed using 





 Mitochondrial permeability transition detection kit.  
The MitoPTTM Mitochondrial permeability transition detection kit (B-Bridge 
international, Inc.) was used to detect changes in mitochondrial membrane potential 
within SHSY-5Y cells treated with α-syn, using the manufacturers protocol 
(MitoPTTM Mitochondrial permeability transition detection kit user manual UM-
MPT01, B-Bridge international, Inc.). Changes in the mitochondrial membrane 
potential were detected by using the fluorescent cationic dye, 5,5’,6,6’-tetrachloro-
1,1’,3,3’-tetraethyl-benzamidazolocarbocyanin iodide, (JC-1). 
 
For the MitoPTTM assay, SHSY-5Y cells were cultured and plated as described in 
section 2.4.3, to a density of 1 x 105 cell per well (100 µl), using black 96-well plates 
with clear bottom and lid (Corning Incorporated). The plated cells were treated in 
triplicate well sets with α-syn (30 µM) in serum-free media or appropriate controls 
and incubated for 0 – 48 h. STS (1 µM) was used as a positive control and serum-
free media was used a negative control.  
 
At the end of the incubations, the treatments were removed. The cells were washed 
with 100 µl Hanks salt solution, pre-warmed to 37 oC. The Hanks was gently 
removed and 50 µl of the prepared 1 x MitoPTTM solution (section 2.4.10.1) was 
added to each well. The plate was gently rocked to ensure the cells were completely 
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covered. The cells were incubated for 15 min at 37 °C, 5 % CO2 before the  
1 x MitoPTTM solution was removed. The cells were washed with 200 µl of prepared 
1 x assay buffer warmed to 37 oC (section 2.4.10.1). The wash was discarded and 
100 µl of fresh 1 x assay buffer was added to each well. The plate was read using a 
Flexstation (Molecular devices) in combination with softmax Pro computer software 
set to read at an excitation wavelength of 485 nm and the emission wavelength of 
527 nm to detect green fluorescence followed by a second read with emission 
wavelength of 595 nm for the identification of red fluorescence. The results 
generated with analysed using SigmaPlot and SigmaStats software, with subsequent 
errors bars on all graphs showing SEM. 
 
2.4.10.1 Preparation of MitoPT
TM
 reagents.   
Reconstitution of MitoPT
TM: all the MitoPTTM powder was dissolved in DMSO 
according to manufactures protocol to form 100 x stock, which was frozen 
immediately and protected from light at all times. 
 
Working solution of MitoPT
TM: The 100 x Stock MitoPTTM was diluted 1 : 100 
with 1 x assay buffer pre-warmed to 37 oC to give 1 x MitoPTTM solution. 
 
1 x Assay buffer: pre-warmed 10 x assay buffer was diluted in a ratio of 1 : 10 in 
deionised water. 
 
E.g. 60 ml 10 x Assay buffer + 540 ml Deionised water. 
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Chapter 3: Expression, generation and purification of synuclein proteins.  
3.1 Creation of recombinant synuclein proteins. 
3.1.1 Determination of synuclein gene expression in pRK172 plasmid. 
The expression plasmids pRK172 containing α-syn, β-syn or A53T α-syn were kindly 
gifted to the group through our collaboration with Professor Vladimir Buchman. 
Initially, the quantity of each plasmid had to be increased to establish usable 
amounts. This was achieved by transforming each plasmid into DH5α E.coli cells 
cultured on LB amp agar plates as described in section 2.2.2. From each plate, 
colonies were picked and grown overnight on LB broth with amp. The plasmids were 
isolated from the overnight cultures as described in section 2.2.4. Initially, syn genes 
were inserted into the pRK172 expression vector using Nde I and Hind III restriction 
enzymes. Using these restriction enzymes the isolated plasmids were digested and 
run on 1 % agarose EthBr gels (section 2.2.5.1 and 2.2.6) to determine the presence 
and orientation of the syn gene (figure 3.1).  
 
Three bands were produced by DNA digest for each plasmid (figure 3.1). All digests 
observed a band of approximately 4 Kb and another of approximately 3 Kb. The 3 
Kb band was the correct size for pKR172 vector minus syn insert, whereas the 4 Kb 
bands were the correct size for partially digested plasmid where only one restriction 
enzyme successfully cut the plasmid. The plasmid digests of 500 bp in lanes 2 and 4 
is consistent for either α-syn or A53T α-syn (figure 3.1; lanes 2 and 4 respectively). 
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Figure 3.1: Restriction digest of syn containing pRK172 plasmids. 
Plasmids were digested using Nde I and Hind III restriction enzymes and run on 1 % agarose 
EthBr gel. The figure identifies the presence of syn genes within the pRK172 vectors, with 
schematic of plasmid indicting band orientation and cutting sites (red line Hind III and blue lines 
Nde I cutting sites). EthBr gel Lane order was as followed; 1) HyperLadder I marker, 2) α-syn 
pRK172, 3) β-syn pRK172, 4) A53T pRK172. The 3 digest show three bands. As shown in the 
diagram, the band at ~ 4000bp is full plasmid as indicated by the purple arrows, showing only 
partial enzyme digestion. The ~ 3000 bp band is pRK172 vector minus insert, as indicated by the 
black arrows, and the bands at 500 – 700 bp are the syn inserts.   
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The β-syn plasmid gave a band that corresponds with the expected weight of 
the β-syn gene (approximately 700 bp) (figure 3.1; lane 3). From the DNA digest the 
presence of syn genes were identified with the correct orientation within the pRK172 
vector. 
 
3.1.2 Small scale production of protein expression of β-syn but not α-syn or 
A53T α-syn. 
After identifying the correct inserts and increasing quantities of each syn plasmid, 
small scale expressions were carried out to discover the optimum condition and 
induction times for each protein expression. Initially, each plasmid was transformed 
into the competent cell line BL21 (DE3) and streaked on to amp and chlora 
containing agar plates (section 2.2.3). Colonies were picked for each plasmid and 
grown overnight in 10 ml LB with amp and chlora. The overnight cultures were used 
to inoculate 100 ml volumes of LB with amp and chlora which were grown to an 
OD600 of between 0.4 – 0.6 (growth medium used as a blank) (section 2.3.1). The 
OD600 reading of the culture was used as an indication of the cells entering the 
stationary phase of growth, the optimum growth phase for protein expression. Protein 
expression was then induced by the addition of IPTG to the culture (section 2.3.1). 
Full cell samples from each expression cultures were taken at 0, 0.5 h, 1 h, 2 h, 4 h 
and overnight for α-syn and β-syn expression cultures and at 0, 1 h, 2 h and overnight 
for A53T α-syn expression cultures. The cell samples were centrifuged and the 
pellets re-suspended in milli-Q water and laemmli loading buffer (1:1 v/v) (section 
2.3.2.1) and run on SDS-PAGE gels to determine protein expression levels (section 
2.3.2 and 2.3.3).  
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No expression was identified for either α-syn or A53T α-syn at any time of 
the points investigated (figure 3.2 A and B). β-Syn, however, was expressed with the 
intensity of the gel band increasing up to 4 h after induction of the expression 
culture. However, when the culture was left overnight the intensity of the β-syn band 
was severely reduced compared to earlier time points (figure 3.2 C). From this 
expression study we showed that α-syn and A53T α-syn expression was not induced 
under the conditions used. β-syn expression was successfully induced, with optimum 
expression at 4 h after induction (figure 3.2). The lack of α-syn and A53T α-syn 
expression could either suggest that the growth conditions were not optimum or 
indicative of a problem within α-syn and A53T expression vector, preventing the 
induction of protein expression.  
 
3.1.3 Lack of expression of α-syn and A53T α-syn with increased stationary 
phase. 
Although expression of β-syn was successful, similar conditions did not lead to 
expression of either α-syn or A53T α-syn. This could be due to the growth conditions 
used. The LB broth used for the culturing of the E.coli could be promoting a rapid 
increase in cell growth, reducing the length of time the cells are in stationary phase 
before entering the death phase of the growth cycle and therefore producing little or 
no protein. This would show as minimal levels of protein expression, if any at all. To 
determine if this was the case, we used peptone with the addition of sodium chloride 
as the growth media with the intention of reducing available glucose, thereby 
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Figure 3.2: Expression trails for α-syn, β-syn and A53T α-syn proteins overtime. 
SDS-PAGE expression gels were used to analyse protein levels of α-syn, β-syn and A53T from 
BL21 cells to determine optimum incubation time. Kaleidoscope pre-stained standards were used 
as marker, with red arrows marking the location of the correct band size for the syn proteins (17 - 
19 kDa) on each gel. No expression was induced for either α-syn (A) or A53T α-syn (B) cultures 
at any time point. β-syn (C) expression was induced with increasing band intensity overtime up to 
4 h. β-Syn expression was reduced with overnight incubation 
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reducing cell growth and increasing the stationary phase of the cell (the phase in 
where and increasing protein expression occurs) (section 2.3.1). 
 
α-Syn and A53T α-syn BL21 glycerol stocks were used to establish colonies on amp 
and chlora containing agar plates. As described previously (section 3.1.2), colonies 
were picked and cultured overnight in either LB broth or peptone with amp and 
chlora. The appropriate overnight culture was used to inoculate either 100 ml 
volumes of LB broth or peptone, containing amp and chlora. As before, cultures 
were grown to an OD600 of 0.4 – 0.6 before inducing with IPTG. Samples of each 
expression culture were taken at 0, 0.5 h, 1 h, 2 h and overnight after induction, with 
an extra sample taken at 4 h from the α-syn culture in LB both. All samples were 
prepared as described previously by harvesting the cells and re-suspending the cells  
1 : 1 ratio of water and laemmli loading buffer (section 2.3.4 and 3.1.2). All samples 
were run on NuPAGE gels as described in section 2.3.4. 
 
The use of the peptone media reduced the total amount of cellular protein for both α-
syn and A53T α-syn at all time points when compared to the amount of cellular 
protein from cultures grown in LB broth (figure 3.3). However, no obvious induction 
of expression for α-syn was observed with either growth media (figure 3.3 A and B). 
In slight contrast, low levels of expression were seen 30 min after induction for 
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A) α-Syn LB broth 
C) A53T LB broth 
B) α-Syn Peptone 
D) A53T Peptone 
  M       0h        0.5h       1h         2h          4h  M        0h       0.5h        1h        2h         o/n 
M         0h       0.5h      1h         2h         o/n  M        0h       0.5h       1h          2h       o/n 
Figure 3.3: Comparison of expression of α-syn and A53T α-syn in LB broth or peptone. 
NuPAGE expression gels were used to analyse expression levels of α-syn and A53T α-syn in 
BL21 cells over time. Kaleidoscope pre-stained standards was used as a marker, red arrows 
indicating the approximate band size for either α-syn or A53T α-syn on each gel. No expression 
was observed for α-syn cultured in either LB broth (A) or peptone (B) at any time point post-
induction.  Low levels of expression were observed with A53T α-syn cultured in LB broth (C) 
and peptone (D), where low level expression was observed after 0.5h induction. 
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From this study we showed that low level expression of A53T α-syn could be 
induced under normal conditions (in LB broth) or with an increased stationary phase 
(in peptone media). The low or lack of expression for both proteins could suggest 
that the issue may not be related to the media conditions, but due to a problem with 
the expression vector itself, restricting the induction of expression. However, levels 
of expression were still very low and α-syn did not show any expression at all. 
 
3.1.4 Validation of low syn expression levels using immunochemical 
identification. 
To determine the expression of α-syn, A53T α-syn and β-syn accurately and to 
analyse α-syn expression with greater sensitivity we used western blotting to identify 
if there was any α-syn expression present within the samples.  
 
For all western blots, rat cerebrum was used as a positive control for syn proteins 
(section 2.3.5). Using an antibody targeted against α-syn, A53T α-syn was identified 
in all the A53T α-syn samples (figure 3.4 A). However, similar expression was not 
observed for α-syn (figure 3.4 A). Expression of β-syn was shown to increase over 
time (0 – 4 h) (figure 3.4 B). A53T α-syn samples, run on the β-syn western blot as 
negative controls, showed no expression.  
 
Using this more sensitive method, specific expression was confirmed for both β-Syn 
and A53T α-syn by western blot, but not for α-syn. As for the previous study, this 
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Figure 3.4: Western blots of α-syn, A53T α-syn and β-syn expression. 
The western blots were run using either α-syn or β-syn antibodies with protein expression samples. 
A) α-syn antibody: lane order; 1) kaleidoscope pre-stained standards, 2) positive control of rat 
cerebrum. 3) α-syn 4 h after induction in LB broth. 4) A53T α-syn overnight after induction in 
peptone, 5) A53T α-syn expression overnight in peptone and 6) A53T α-syn 4 h after induction in 
LB. No expression was observed for α-syn, A53T α-syn samples suggest high levels of expression 
with all samples this is due to exposure time used on the film. B) β-syn antibody: lane order; 1) 
Precision plus Protein dual colour standards, 2) positive control of rat cerebrum, 3) β-Syn 
expression at 0 h after induction in LB, 4) β-Syn 4 h after induction in LB, 5) A53T α-syn 
overnight after induction in peptone and 6) A53T α-syn 4 h after induction in LB. β-Syn was seen 
to be expressed within both β-syn samples and no expression of A53T α-syn was detected.  
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 transformation into the cells lines used or with the expression vector itself (figure 
3.4). 
 
3.2 Induction of α-syn expression. 
Initial studies showed the presence of the α-syn gene in the α-syn plasmid (section 
3.1.1); however, expression of α-syn could not be induced (section 3.1). This could 
suggest a problem either through poor transformation of the α-syn plasmid into the 
cell lines used or a problem in the pRK172 expression vector. To investigate these 
two possibilities, two studies were run in parallel. Firstly the originally gifted α-syn 
plasmid was transformed directly into competent BL21 (DE3) expression cells, 
where the expression was monitored. Secondly, the α-syn gene was removed from 
the pRK172 vector and inserted into a pRK172 vector isolated from the β-syn 
plasmid (section 3.2.4). 
 
3.2.1 Transformation of α-syn plasmid into BL21 cells. 
To investigate whether the lack of expression with α-syn was due to a problem with 
the transformation of the α-syn plasmid into BL21 (DE3) cells, the original sample of 
α-syn plasmid gifted to us was transformed directly into expression BL21 (DE3) cells 
(section 2.2.3 and 3.1.1). The BL21 (DE3) cells containing α-syn plasmid from the 
previous study (section 3.1.2), where the plasmid was transformed into DH5α cells 
before transforming into BL21 (DE3) expression cells, were also plated and grown as 
a control. Colonies were picked at random from each plate and cultured overnight in 
6 ml LB with amp and chlora. Plasmid DNA was isolated from the overnight cultures 
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and digested using Nde I and Hind III DNA restriction enzymes. The digested 
samples were run on 1 % agarose EthBr gel.  
 
From the EthBr gel (figure 3.5) three bands were seen for each sample. In each case 
a band with the apparent base pair size of ~ 500 bp, the correct size for the α-syn 
gene, was observed. However, this was seen to be markedly reduced within the α-syn 
plasmid isolated from the BL21 (DE3) cells taken from the previous study (figure 
3.5). This, taken with the fact that a strong α-syn gene band was seen in the freshly 
transformed cells, would imply that the lack of α-syn expression seen previously was 
due to possible low levels of α-syn plasmid transformation.       
 
3.2.2 Expression trials for the newly transformed α-syn plasmids. 
The lack of α-syn expression, previously observed in sections 3.1.2 and 3.1.3, was 
suggested to be through low levels of α-syn plasmid transformation. It was observed 
that newly transformed BL21 (DE3) cells with α-syn plasmid showed relatively 
higher levels of α-syn plasmid present in the cells. The present study was preformed 
to observe if the increased presence of α-syn plasmid would lead to subsequent 
protein expression. 
 
The BL21 (DE3) cells transformed with α-syn plasmid, from the previous study 
(section 3.2.1), were streaked on to amp and chlora agar plates. Colonies were 
randomly picked and cultured overnight in either peptone or LB broth containing 
amp and chlora (section 2.3.1). The overnight cultures (grown in the appropriate 
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Figure 3.5: α-Syn plasmid DNA digest. 
The digested plasmids (using Nde I and Hind III restriction enzymes) were run on a 1 % agarose 
gel. The gels identified the presence of the α-syn gene within the pRK172 vectors for all samples. 
Lane; 1) HyperLadder I marker, 2 – 3) α-syn plasmid isolated from newly transformed BL21 cells,  
4 – 6) α-syn plasmid isolated from previous α-syn BL21 stocks. Three bands were identified in 
digest with no variation in band size across samples. The band at  
~ 4 Kb is the correct size for full plasmid where only one enzyme digest has occurred. The band at 
~ 3 Kb is consistent for pRK172 vector minus insert and the final band at 500 bp is consistent for 
isolated α-syn gene insert.  
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media) were used to inoculate 100 ml of either LB broth or peptone containing amp 
and chlora. As described previously (section 3.1.2) the expression cultures were 
grown to an OD600 between 0.4 – 0.6 before inducing with IPTG. Two samples were 
collected at each time point (0 h, 2 h, 4 h and overnight) for all the expressions. The 
samples were either re-suspended (1:1 ratio) in water and laemmli loading buffer or 
the samples were lysed and heat-treated as described in section 2.3.7. The 
supernatants were collected and mixed with laemmli loading buffer in a ratio of 1 : 1. 
All the samples were run on 16 % SDS-PAGE gels. 
 
The use of LB broth expression cultures was shown to increase the expression level 
of α-syn compared to expression levels cultured in peptone (figure 3.6). The lysed 
and heat treated expression samples showed significant α-syn expression within LB 
and peptone samples after induction as well as a reduction in the majority of cellular 
proteins compared to the untreated samples (figure 3.6). Within both LB and peptone 
cultures, α-syn expression does not appear to increase beyond 2 h (figure 3.6 B). This 
could imply that the rate of α-syn production is the same as degradation rate of the  
α-syn.  
 
α-Syn expression was successfully induced with the best expression levels observed 
using LB broth compared to peptone media. It was also established that lysing and 
heat treating the samples removed the majority of other cellular proteins without 
affecting the quantity of α-syn collected. 
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Figure 3.6: Comparison of expression of α-syn expression in LB broth or peptone. 
SDS-PAGE expression gels were used to analyse the expression levels of α-syn protein within 
BL21 cells over time and comparing expression within LB broth and peptone growth medium. The 
red arrows indicate α-syn band size (~19 kDa). A) α-Syn, full cells: lane: 1) Kaleidoscope pre-
stained standards, 2) was empty,  3) α-syn at 2 h after induction in LB, 4) α-syn at 4 h after 
induction in LB, and 5) α-syn overnight after induction in LB, 6) α-syn overnight after induction in 
peptone, 7) α-syn at 4 h after induction in peptone, 8) α-syn at 2 h after induction in peptone 9) α-
syn at 0 h after induction in peptone. B) α-Syn, heat treated: lane; 1) Precision plus Protein dual 
colour standards, 2) α-syn at 0 h after induction in LB, 3) α-syn at 2 h after induction in LB, 4) α-
syn at 4 h after induction in LB, 5) α-syn overnight after induction in LB, Lanes 6 – 9 were α-syn 
expression in peptone: 6) α-syn at 0 h after induction in peptone, 7) α-syn at 2 h after induction in 
peptone, 8) α-syn at 4 h after induction in peptone 9) α-syn overnight after induction in peptone. 
Both gels show α-syn expression in cultures grown in either LB or peptone media.   
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3.2.3 α-Syn expression confirmed by western blot. 
To confirm the identity of the potential α-syn band observed in the previous 
expression (section 3.2.2), western blot was used to identify α-syn protein (section 
3.1.4). The α-syn BL21 cells were plated and colonies grown overnight. The 
overnight cultures were used to inoculate 500 ml volumes of LB with amp and chlora 
and cultures grown to an OD600 of between 0.4 – 0.6 before inducing with IPTG. 
Expression samples were then collected from each culture at 0 h, 2 h, 4 h and 
overnight after induction. All the samples were lysed and heat treated as described in 
section 2.3.7 and run on a 16 % SDS-PAGE gel. The SDS-PAGE gel was then used 
within a western blot using a α-syn antibody (section 2.3.6). 
 
From the western blot (figure 3.7), expression of α-syn and A53T α-syn can clearly 
be seen at all time points, appearing to increase from 2 h to 4 h after induction, and 
subsequently diminishing with longer incubation (figure 3.7). This profile of 
expression was mirrored with the A53T α-syn study (figure 3.7).  
 
From these expression studies it has been shown that re-transforming the original  
α-syn plasmid directly into BL21 (DE3) cells resulted in successful induction of 
protein expression. This would suggest that the problem in expression observed in 
earlier expressions was due to the original α-syn plasmid transformation into DH5α 
cells subsequently effecting expression in BL21 (DE3) cells. 
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Figure 3.7: Western blots of α-syn and A53T α-syn expression. 
The western blot, from SDS-PAGE gel and using a α-syn antibody, shows expression of α-syn and 
A53T overtime after induction. Lanes; 1) kaleidoscope pre-stained standards, 2) rat cerebrum 
positive control, 3) α-syn at 0 h after induction, 4) α-syn at 2 h after induction, 5) α-syn at 4 h after 
induction, 6) α-syn overnight after induction, 7) A53T α-syn at 0 h after induction, 8) A53T α-syn 
at 2 h after induction,  9) A53T α-syn at 4 h after induction, 10) A53T α-syn overnight after 
induction. α-Syn expression can been in all α-syn samples with increasing expression up to 4h, 
however expression is seen to diminish overnight. Expression was also seen for A53T α-syn in all 
A53T α-syn samples.  
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3.2.4 Concomitant study expressing α-syn using β-syn vector. 
The β-syn plasmid has been shown to successfully express β-syn when transformed 
into BL21 (DE3) E.coli cells. To further investigate if the α-syn vector is responsible 
for the level of protein expression, the pRK172 vector from the β-syn plasmid would 
be extracted and used to construct a new plasmid with α-syn. The newly constructed 
plasmid would then be transformed into DH5α and BL21 (DE3) cells. 
 
β-syn plasmid was cut using Nde I and Hind III and run on 1 % LMP agarose gel. 
From the gel the pRK172 vector band was identified and was cut out of the agarose 
gel. The pRK172 vector was purified using the QIAquick Gel extraction kit and a 
sample of the extracted vector was run on an agarose gel to confirm the successful 
isolation of the pRK172 vector band (figure 3.8A). The procedure was repeated with 
the α-syn plasmid to extract the α-syn gene from the plasmid (figure 3.8B). The 
purified pRK172 vector and α-syn were ligated together overnight. The newly 
formed α-syn plasmid was transformed into DH5α cells. Colonies were selected at 
random and cultured overnight. The overnight culture was used to isolated plasmid 
DNA. The isolated DNA was checked by DNA digest using Nde I and Hind III and 
run on 1 % agarose EthBr gel (figure 3.8C).  
 
The agarose gel identified that all the samples tested contained plasmid containing  
α-syn. These studies along with those in the preceding sections (section 3.2.2 and 
3.2.3) suggested the previous lack of expression was due to a fault of the α-syn 
pRK172 vector. 
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Figure 3.8: Agarose gels of the reconstruction of the α-syn plasmid. 
All DNA samples were run on 1 % agarose EthBr gel. A) Shows only one band at ~3000 bp 
correct for the size of purified pRK172 vector cut using Nde I and Hind III from the β-syn 
plasmid, lane 1 contains 1 Kb marker, lane 2 Sample. B) Shows two samples both of which only 
show one band at ~ 500 bp are correct for purified α-syn gene cut using Nde I and Hind III from α-
syn plasmid; lane 1 contains HyperLadder I. C) Shows restriction digest using Nde I and Hind III 
of the newly constructed α-syn plasmids, all contain 2 bands one of ~ 3000 bp and one  
~ 500 bp; lane 1 containing HyperLadder I  
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3.3 Purification of synuclein proteins by FPLC. 
From the previous studies, expression was induced for α-syn, A53T α-syn and β-syn 
(section 3.1 and 3.2). Denaturing the generated proteins with heat treatment appeared 
to remove the majority of the contaminating cellular proteins from the expression 
samples (section 2.3.7 and 3.2). However, a number of contaminating proteins were 
still present within the collected syn protein. To further purify the isolated syn 
proteins, fast protein liquid chromatography (FPLC) was utilised, using an anion 
exchange column to isolate syn protein from the remaining contaminates. The anion 
exchange column separates the proteins based on their surface charge and was 
selected due to the negative charge of synucleins. 
 
3.3.1 Insufficient purification with FPLC using Mono-Q column. 
β-syn expression achieved using the protocols established in section 3.1.2, using  
β-syn BL21 cells from glycerol stocks. The culture was induced and grown for 6 h. 
The cells were lysed and heat treated, as previous, for initial isolation of β-syn within 
the supernatant (section 2.3.7). β-syn supernatant was dialysed into 0.02 M Tris 
pH8.2 overnight using Cellu.Sep regenerated cellulose tubular membrane dialysis 
tubing (MWCO 4,000 – 6,000) (section 2.3.8). While the Mono-Q, 1 ml anion 
exchange column was hydrated and equilibrated with 0.02 M Tris pH 8.2, the 
dialysed β-syn protein was centrifuged and sample of the dialysed protein was used 
to determine protein concentration (~ 9.8 mg of β-syn as determined by BCA assay). 
By using 0.02 M Tris pH 8.2 with 1 M NaCl an ion gradient was produced with the 
mobile phase where the gradient was initiated 12 min into the column run. The 
gradient started at 0 % and was raised to 40 % NaCl over 10 min. To elute the 
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remaining proteins the NaCl gradient was increased to 100 % for 5 min before 
dropping to 0 % NaCl (section 2.3.11 and figure 3.9 A). The mobile phase from the 
column was analysed by UV at 280 nm, to indicate at which time proteins were 
eluted from the column, and indicating which fraction(s) may contain β-syn. A 
representative of each fraction was mixed with NuPAGE loading buffer and run on 
NuPAGE gel to analyse the fractions (figure 3.9 B).  
 
From analysis of the gel, the majority of β-syn was eluted from the column into 
fractions 14 and 15. The two β-syn containing fractions were combined and the 
amount of protein contained was shown to be 2.5 mg, using the BCA assay (section 
2.3.10). However, as other protein bands were observed in the β-syn fractions, this 
protocol did not generate a purity suitable for use in further experiments  
(figure 3.9 A). 
 
3.3.2 High synuclein purification with FPLC using HiTrap Q HP column. 
This study investigated if the replacement of the previous Mono-Q column to a 
HiTrap HP anion exchange column would generate purer syn product. The HiTrap Q 
HP column contains sepharose beads which are stronger anion exchangers than the 
beads in the Mono-Q anion exchange column. The FPLC protocol was also adapted 
from the previous study (section 3.3.1).  
 
β-Syn produced and dialysed from the previous study (section 3.3.1) was used within 
the FPLC. The dialysed β-syn sample (~ 4.9 mg of protein) was centrifuged and 
loaded on to a 1 ml HiTrap Q HP anion exchange column. A 20 % NaCl step was 
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Figure 3.9: Analysis of β-syn fractions produced from column run. 
A) Schematic of β-syn column run: Shows a schematic of purification of β-syn by FPLC using a 
mono-Q 1 ml column. The number and volume of factions are indicated within the diagram.  
B) NuPAGE gel of selected fractions: lane order; 1) Precision plus Protein unstained standards, 
2) pre-column β-syn sample, 3) fraction 2, 4) fraction 8, 5) fraction 9, 6) fraction 10, 7) fraction 
11, 8) fraction 12,  9) fraction 13, 10) fraction 14, 11) fraction 15, 12) fraction 16. β-syn was 
identified to be eluted primarily in to fraction 14 and 15, with a reduction in contaminant proteins. 
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added prior to the start of the gradient, such that the gradient started at 20 % NaCl 
and increased to 40 % NaCl over 10 min (figure 3.10A). The elution of the mobile 
phase from the column was monitored by UV at 280 nm throughout the run. Due to 
the UV monitoring specific stages of the column run were held longer than 
programmed (figure 3.10A). All the mobile phase was collected in fractions as 
shown in figure 3.10A. A sample of each fraction was analysed by gels fractionation 
(figure 3.10B). 
 
Analysis of the fractions indicated β-syn protein was eluted mainly into fractions 18 
and 19 with no other protein bands present (figure 3.10B). Fractions 18 and 19 were 
combined and the quantity of β-syn was shown to be 0.6 mg, determined by BCA 
assay.  
 
Here we have shown that the eluted β-syn from the column contained no 
contaminating protein bands. By changing the column and adapting the protocol we 
have not only successfully increased the purity of our β-syn sample but have also 
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Figure 3.10: Analysis of β-syn fractions produced using a HiTrap Q HP column. 
A) Schematic of the β-syn column run: shows the protocols used for the purification of β-syn by 
FPLC using a HiTrap Q HP 1 ml column, the alteration to the column run are overlaid on to the 
programmed run and the actual number of fraction and volumes collected are stated below. B) 
NUPAGE gel analysis of fractions: representative number of the fractions collected, lane order; 
1) Precision plus Protein unstained standards, 2) Pre-column β-syn sample, 3) Fraction 2, 4) 
Fraction 3, 5) Fraction 4, 6) Fraction 6, 7) Fraction 7, 8) Fraction 8,  9) Fraction 9, 10) Fraction 18, 
11) Fraction 19, 12) Fraction 22, 13) Fraction 23, 14) Fraction 24. The majority of β-syn was 
eluted into fractions 18 and 19.  
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3.3.3 Purification of α-syn using optimised FPLC protocol. 
We investigated whether using a similar protocol to above (section 3.3.2) would 
similarly purify α-syn.  
 
α-Syn expression was established using BL21 cells transformed with α-syn plasmid 
produced in section 3.3.2. The α-syn BL21 cells were plated on to amp and chlora 
containing agar plates. Colonies randomly selected were cultured overnight and used 
to inoculate 1 L volume of LB with amp and chlora. The expression culture was 
grown to an OD600 of 0.4 – 0.6 and induced with IPTG. The cells were harvested 4 h 
after induction and heat treated as described in section 2.3.7. The supernatant which 
contained the isolated α-syn was dialysed overnight into 0.02 M Tris pH 8.2. 
Dialysed α-syn was analysed by BCA assay to establish the total protein 
concentration (0.97 mg/ml) and 1 ml of the α-syn sample was centrifuged and loaded 
on to 1 ml HiTrap Q HP anion exchange column, hydrated and equilibrated with 0.02 
M Tris pH 8.2. The column run was executed as previously described in section 3.3.2 
(figure 3.11A). The elution of the fractions was monitored by UV at 280 nm reading 
throughout the run. Representatives of the fractions were run on a NuPAGE gel to 
analyse the protein content of the fractions (figure 3.11B).  
 
Analysis of the gel showed that α-syn was highly purified, with no other 
contaminating bands (figure 3.11B). Combining α-syn-containing fractions and 
analysing by BCS assay, showed a protein concentration of 0.13 – 0.15 mg/ml. This 
was between 13 - 16 % of the original concentration of total protein loaded on to the 
column. 
 139 
         
 
 


























           5 ml 
 
           1 ml 
100 % 
Fractions:  
















1    2   3   4    5    6    7   8   9  10   11  12 13 14  15  
B) NuPAGE gel analysis of fractions  
Lane numbers 
kDa 
A) Schematic of α-syn column run 
Figure 3.11: Analysis of α-syn fractions produced using a HiTrap Q HP column. 
A) Schematic of the α-syn column run: illustration of the method used to purification α-syn by 
FPLC using a HiTrap Q HP column with the number of fractions and volumes of each showed 
along the bottom of the diagram. B) NuPAGE gel analysis of fractions: representative of the 
fractions collected from the column run, order of lanes; 1) Fraction 3, 2) Fraction 4, 3) Fraction 5, 4) 
Fraction 6, 5) Fraction 11, 6) Fraction 12, 7) Fraction 13, 8) Fraction 14, 9) Fraction 15, 10) Fraction 16, 11) 
Fraction 17, 12) Fraction 18, 13) Fraction 19, 14) Fraction 20, 15) Precision plus Protein unstained standards. 
α-Syn was eluted within to fraction 12 and 13. No contaminating protein appears to be present in any α-syn 
fractions. 
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3.4 Analysis of α-syn expression yield. 
With each expression it appeared that the total concentration of pre-column protein 
was decreasing with each expression run, which resulted in a decrease in the yield of 
purified α-syn protein. To establish whether there was a decrease in protein 
expression and if so was it affecting the percentage of α-syn yield, the concentration 
of protein loaded on to the column (as measured by BSA assay) and the percentage 
of purified α-syn produced per expression was compared across expression runs.  
 
Analysis of the expression runs suggested that the concentration of the pre-column 
protein decreased. This was confirmed for two separate 1 L culture runs (table 3.1) 
where the concentration decreased from 0.972 to 0.842. Increasing the culture size 
did not significantly increase total protein concentration (table 3.1), but did result in a 
decrease in the percentage of purified α-syn protein (table 3.1). This decrease in 
percentage yield of α-syn is indicative of a decrease in the expression of α-syn. The 
greater loss of yield with each subsequent experiment could suggest that the 











Total protein loaded 




α-Syn % of total 
protein 
19/04/2004 1.0 0.972 0.972 0.134 13.80 % 
21/05/2004 1.0 0.842 5.05 0.975 19.30 % 
30/06/2004 2.5 0.890 12.02 1.04 8.65 % 
Table 3.1: Analysis of α-syn yield from individual α-syn expression. 
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3.4.1 Analysis of expression levels from stock cells. 
To determine if the decrease in the yield of α-syn was (section 3.4) due to issues 
surrounding storage, the expression levels of all the BL21 cells in glycerol stocks 
were analysed. 
 
Glycerol stocks of α-syn BL21 cells were spread onto amp and chlora agar plates and 
colonies were randomly picked and cultured overnight in LB broth containing amp 
and chlora. The overnight cultures were used to inoculate 100 ml volumes of LB and 
were grown to an OD600 of between 0.4 – 0.5. The cultures were induced with IPTG 
and samples taken at 0, 1, 2, 3, 4 and 5 h after induction. All the samples were 
centrifuged and re-suspended in water and loading buffer (1:1 v/v). A second 5h 
sample was heat-treated and the supernatant prepared with loading buffer. All the 
samples were run on NuPAGE gels for analysis. 
 
Analysis of the NuPAGE gels showed that there was no expression of α-syn within 
any of the cultures (figure 3.12). This would indicate that the α-syn plasmid is being 
rejected by the BL21 (DE3) cells with time. 
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Figure 3.12: Analysis of α-syn expression overtime by NuPAGE gel. 
The NuPAGE gel is representative of all the α-syn plasmid-containing stock cells. The red arrow 
indicates where α-syn expression should be present on the gels. Lane order: 1) Precision plus 
Protein unstained standards, 2) 0 h after induction, 3) 1 h after induction, 4) 2 h after induction, 5) 
3 h after induction, 6) 4 h after induction, 7) 4 h after induction with sample heat treated,  
8) 0 h after induction, 9) Precision plus Protein unstained standards, 10) 1 h after induction,  
11) 2 h after induction, 12) 3 h after induction, 13) 4 h after induction, 14) 5 h after induction, 15) 
5 h after induction with sample heat treated.  No α-syn expression can be seen in any of the 
samples.  
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3.4.2 Analysis of plasmid levels in glycerol stocks. 
The previous study (section 3.4.1) showed that there was no expression of α-syn 
from any of the glycerol stocks of BL21 cells containing α-syn plasmid. This 
suggests that the BL21 cells are a mixed population containing cells which have 
plasmid without the α-syn gene. These cells may out grow the BL21 cells still 
containing the plasmid with α-syn gene. To establish whether this is the case, the 
presence of the α-syn plasmid was investigated. 
 
Overnight cultures of α-syn BL21 cells, A53T α-syn BL21 cells or β-syn BL21 cells 
were used to isolate α-syn, A53T α-syn or β-syn plasmid DNA as described in section 
2.2.4. The isolated plasmid DNA was digested using Nde I and Hind III at 37 oC for 
an hour and then loaded on to EthBr 1 % agarose gel.  
 
Analysis of the agarose gel showed a reduction in the amount of α-syn plasmid 
present within the BL21 cells. Specifically there was a reduction in the level of α-syn 
gene, rather than pRK172 vector. In comparison to the faint α-syn gene band, A53T 
α-syn and β-syn showed large bands. This implies that α-syn stocks cells contain a 
mixture of α-syn plasmid and pRK172 vector without the α-syn gene. The intensity 
of the pRK172 band at ~ 3 Kb within the α-syn plasmid samples does not appear to 
be reduced compared to the pRK172 band within the A53T α-syn or β-syn samples. 
The reduction in presence of the α-syn gene would explain the loss of α-syn 
expression observed in section 3.4.1, and would suggest the BL21 (DE3) cells are 
rejecting the α-syn plasmid (figure 3.13). However the A53T α-syn and β-syn plasmid 
containing BL21 cells do not appear to be affected to the same extent (figure 3.13). 
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Figure 3.13: Analysis of syn plasmids by DNA restriction digest. 
α-Syn, β-syn and A53T plasmids digested using Nde I and Hind III restriction enzymes and run on 
a 1 % agarose gel. The lane order was as followed; 1) Marker; HyperLadder I, 2) Water control, 3) 
β-syn plasmid, 4) β-syn plasmid, 5) A53T plasmid 6) A53T plasmid, Lanes 7 – 14) α-Syn plasmid. 
Three bands were identified in digest with one exception in lane 8 of α-syn plasmid which 
contained an extra band ~ 5 Kb which is likely to be undigested plasmid. All the samples show 
bands at ~ 4 Kb which full plasmid with insert, band at ~ 3 Kb which is correct size for pRK172 
minus gene insert. The β-syn samples show band at ~ 550 bp correct for size for β-syn gene and 
the A53T samples show a band at ~ 400 bp correct for A53T α-syn gene. All the α-syn samples 
show only a very faint band at ~ 400 bp, correct for α-syn gene.  
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3.5 Construction of a new α-syn expression plasmid. 
Our earlier studies showed expression of α-syn was being lost due to the BL21 (DE3) 
cells rejecting the α-syn plasmid (section 3.4). The most efficient way of restoring 
and increasing the expression levels of α-syn would be to reconstruct a new α-syn 
plasmid. Re-constructing the α-syn plasmid using a more up-to-date expression 
vector, such as pET-22b(+) (figure 3.14), has a number of advantages over using the 
pRK172, some of which are listed in table 3.2. Importantly, by using the commercial 
pET-22b(+) vector, we would have a fully sequenced vector map and therefore 
would be less likely to contain abnormalities that may lead to reduced expression or 





Expression vector Combination of two vectors 
Fully published vector map Full vector map not published 
Option of tagging protein -- 
Contains T promoters Contains T promoters 
Contains Lac z gene to reduce leakage of gene 
expression 
-- 
Renewable and reliable source 
Gifted from labs. Multiple replication and 
restriction digests caused alteration in sequence 
and cutting sites. 
 
 






Figure 3.14: Schematic of pET-22b(+) vector showing restriction enzyme sites.  
Diagram adapted from the Novagen pET-22b(+) vector manual (version TB038 12/98).   
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3.5.1 Isolation of α-syn from pRK172 plasmid by DNA digest. 
To construct a new α-syn plasmid the α-syn gene had to be isolated from the original 
α-syn plasmid. The α-syn gene was isolated by restriction digest using Nde I and 
Hind III restriction enzymes. The α-syn DNA was extracted and purified from EthBr 
gel, and A53T α-syn and β-syn plasmids were used as controls.  
 
The original α-syn plasmid was transformed into DH5α cells and grown on amp agar 
plates. Colonies were randomly selected from the plates and cultured overnight and 
the plasmid DNA isolated. Plasmid DNA was digested using Nde I and Hind III 
restriction enzymes (section 2.2.5.1) and analysed on 1 % agarose EthBr gel. One of 
the α-syn, A53T α-syn and β-syn plasmid DNA digests were run on a  
1 % LMP agarose gel as described in section 2.2.6. The bands that corresponded with 
the syn gene were extracted from the gel as described in section 2.2.7 and the isolated 
syn genes were confirmed by running a sample of the purified DNA on a 1 % 
agarose EthBr gel. 
 
As can be seen from the EthBr gel (shown in figure 3.15), the DNA digests of α-syn 
plasmid produced two bands, one at approximately 3 Kbp (consistent with the 
pRK172 vector) and a band at approximately 500 bp (consistent with the size of the 
α-syn gene of ~ 400 bp) (figure 3.15A).  
 
The A53T α-syn and β-syn genes were successfully removed and purified from their 
respective plasmids, with the appearance of a 500 and 700 bp band respectively, on a 
1 % EthBr gel used to check the gene were removed (figure 3.15 B). However, the 
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 Figure 3.15: Restriction digest and isolation of α-syn from pRK172 plasmids. 
The EthBr gels show the presence of α-syn gene and isolation of the syn gene from the plasmid. A) 
Digest gel: shows 1 % agarose EthBr gel of the restriction digests of α-syn plasmid samples using 
Nde I and Hind III restriction enzyme, where lane 1) 1000 bp marker, 2) α-syn 1.1, 3) α-syn 1.2, 4) 
α-syn 1.3, 5) α-syn 1.4, 6) α-syn 2.1, 7) α-syn 2.2, 8) α-syn 2.3, 9) α-syn 2.4, 10) α-syn 2.5, 11) α-
syn 2.6, 12) α-syn 2.7, 13) α-syn 2.8, 14) 100 bp marker. The sample in lane 11 does not to contain 
α-syn plasmid. The remaining samples all contained α-syn plasmid with the digest producing 2 
bands at either ~ 3000 bp correct size for pRK172 minus α-syn, and a band at ~ 500 bp correct for 
α-syn gene. B) Extraction gel: shows the isolated syn gene after being extracted and purified from 
LMP agarose. Lane order; 1) 100 bp marker, 2) A53T  α-syn, 3) β-syn, 4) α-syn. A35T and β-syn 
shows correct size band after isolation and purification, the α-syn extraction sample produced a ~ 
1000 bp band that is not consistent with the α-syn gene (~ 500 bp).  
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α- syn gene sample did not show a band at 500 bp, representative for the α-syn gene, 
but did have a band at ~ 1000 bp. This would imply the DNA of the α-syn genes 
were ligating during the purification process, rendering the extracted DNA unusable 
(figure 3.15 B). 
 
3.5.2 Changing the culture growth protocol did not increase α-syn plasmid.  
From the previous study (section 3.5.1), only a low level of α-syn plasmid was 
present within DH5α cells compared to the amount of pRK172 vector without the α-
syn gene. The low level of α-syn-containing plasmid resulted in a reduction in the 
effectiveness of isolating the α-syn gene from pRK172 vector. We speculated that by 
altering the growth conditions used, we should be able to increase the amount of α-
syn plasmid expressed within the cells and therefore increase the efficiency of the 
DNA digests used to remove the α-syn gene from the pRK172 vector. 
 
Glycerol stocks of DH5α cells and BL21 cells, transformed previously with the 
original α-syn plasmid, were plated on agar plates containing either amp or both amp 
and chlora. Colonies were randomly selected and cultured in LB broth with the 
relevant antibiotics at which point the cultures were grown to an OD600 of ~ 0.1 
before being pelleted, re-suspended in fresh LB broth (containing either amp or both 
amp and chlora) and grown for a further 3 h, whereas in previous experiments the 
cultures would have been grown overnight. Cells were then harvested and α-syn 
plasmid DNA was isolated as described in section 2.2.4. The isolated α-syn plasmids 
were digested using Nde I and Hind III restriction enzymes and run on a 1 % agarose 
EthBr gel (sections 2.2.5 and 2.2.6). 
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As can be seen from the EthBr gel (figure 3.16), only one band at ~ 3000 bp 
is present from the digestion of the α-syn plasmid DNA isolated from DH5α cells. 
This would indicate that the plasmid does not contain the α-syn gene. Whereas DNA 
digests of the α-syn plasmid isolated from BL21 cells produced three bands; one 
band of very low intensity at 500 bp, which is coincides with the α-syn gene, a strong 
band at ~ 3000 bp consistent with pRk172 vector and a stronger band at ~ 4000 bp 
consistent with linearised plasmid (figure 3.16). This would suggest the efficiency of 
the DNA digest is very low and the α-syn gene is not effectively being removed from 
the pRK172 vector.  
 
Altering the growth conditions in an attempt to increase the quantity of α-syn 
plasmid did not successfully increase the plasmid concentration. However, the 
quantity of pRK172 vector without insert did increase. Interestingly, BL21 cells 
transformed with α-syn plasmid were not affected by the alteration in growth 
conditions. The experiment highlighted the low efficiency of DNA digest at 
removing the α-syn gene from the pRK172 vector. 
 
3.5.3 MWG primers successfully isolated α-syn from pRK172 plasmid. 
From the previous studies (sections 3.5.1 and 3.5.2) the α-syn plasmid was shown to 
be rejected from E.coli cells used. To prevent the loss of the α-syn gene, we 
attempted to isolate the α-syn gene and reconstruct the α-syn plasmid using a 
commercial expression vector. However, initial attempts at removing α-syn gene by 
DNA digest identified too insufficient an amount of the α-syn plasmid was present 
within the cells to successfully remove α-syn gene by this method (sections 3.5.1  
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Figure 3.16: Restriction digest of α-synpRK172 plasmids isolated from DH5α and BL21 
(DE3) cells. 
Agarose EthBr gel showed DNA bands from the α-syn plasmid digests. A schematic diagram 
illustrating the band orientation and cutting sites (red line Hind III and blue lines Nde I cutting 
sites) is also shown. Lane order; 1) HyperLadder I marker, lanes 2 – 10) digests of α-syn plasmid 
isolated from DH5α cells, 11 – 13) digests of α-syn plasmid isolated from BL21. None of α-syn 
plasmid isolated from DH5α cells contained a band consistent with α-syn gene (~ 500 bp). α-Syn 
plasmid isolated from BL21 cells show 3 bands, very low intensity band at  ~ 500 bp consistent 
with α-syn gene, a band at ~ 3000 bp consistent with pRK172 minus α-syn gene and a band at ~ 
4000 bp consistent with uncut α-syn plasmid.  
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and 3.5.2). This study attempted to amplify and remove the α-syn gene from the 
pRK172 vector using specifically designed primers. The PCR primers were used to 
add specific restriction cutting sites immediately in front of the start codon and 
immediately after the stop codon of the α-syn gene (section 2.2.9).   
   
α-Syn plasmid was transformed into DH5α cells and cultured on agar plates 
containing amp (section 2.2.2). Colonies were randomly selected and cultured 
overnight in LB broth with amp. α-Syn plasmid was isolated from the cells as 
described in section 2.2.4. The isolated α-syn plasmid was then utilised within a PCR 
reaction using specifically designed primers (MWG) as described in section 2.2.9. A 
sample of the PCR products was analysed by 1 % agarose EthBr gel (figure 3.17). 
 
As can be seen from the EthBr gel, a band of ~ 400 bp (consistent with the α-syn 
gene size) was identified in half of the α-syn PCR products (figure 3.17). This 
indicates the PCR successful amplified the α-syn gene.  
 
3.5.4 Isolated α-syn gene did not successfully ligated into pET-22b(+) expression 
plasmid. 
The earlier study showed the successful amplification and removal of the α-syn gene 
from the pRK172 vector by PCR (section 3.5.3). To construct the new α-syn plasmid 
the isolated α-syn gene was ligated into the pET-22b(+) commercial vector. Using 
colony growth of JM109 cells transformed with the newly constructed α-syn plasmid 
would indicate whether the new α-syn plasmid was successfully constructed and 
transformed. The colonies produced were cultured overnight and the α-syn plasmid 
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Figure 3.17: Amplification of α-syn by PCR. 
The EthBr gel showed the PCR products of α-syn plasmid isolated from DH5α cells. Lane order; 
1) HyperLadder I marker, 2) water control, 3) α-syn 1, 4) α-syn 2, 5) α-syn 3, 6) α-syn 4. Two out 
of the four α-syn plasmid samples show a band at ~ 500 bp consistent with α-syn gene. 
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 isolated and assessed by restriction digests and PCR.  
 
The isolated α-syn gene from section 3.5.3 along with the commercial pET-22b(+) 
vector was digested using Nde I and Hind III restriction enzymes and extracted from 
the 1 % LMP agarose EthBr gel (sections 2.2.5.1 and  2.2.7; figure 3.18). This digest 
produces sticky ends on the α-syn gene and opens the pET-22b(+) plasmid ready to 
for the ligation.  The α-syn gene and pET-22b(+) vector were ligated overnight and 
transformed into JM109 E.coli cells (sections 2.2.2 and 2.2.10). The transformed 
JM109 cells were grown on amp containing agar plates. 
 
Although the positive control transformation were successful, no colonies were seen 
on plates spread with the α-syn plasmid-transformed JM109 cells, suggesting that the 
ligation of the α-syn gene into the pET-22b(+) vector was not successful. 
 
3.5.5.1 Comparison of DNA purification protocols after digestion of either the α-
syn gene or pET-22b(+) vector. 
From the previous studies we successfully isolated the α-syn gene from the pRK172 
vector by PCR, however the isolated α-syn gene was not successfully inserted into 
the pET-22b(+) vector (sections and 3.5.3 and 3.5.4). This could be due to 
insufficient amounts of α-syn gene with sticky ends and open pET-22b(+) vector 
produced by restriction digest preventing the ligation reaction (section 3.5.2), or the 
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Figure 3.18: Restriction digest and purification of α-syn PCR products. 
Agarose EthBr gel showed ~ 400bp bands for all α-syn samples. A) Gel 1 Restriction Digest 
shows comparison of uncut and cut α-syn PCR products. Loading order; 1) HyperLadder I marker,  
2) α-syn 1 cut, 3) α-syn 1 uncut, 4) α-syn 2 cut, 5) α-syn 2 uncut. B) Gel 2 Purification of 
restriction digest samples. Loading order; 1) HyperLadder I marker, 2) α-syn 1, 3) α-syn 2 the gels 
show that there are no alterations to the α-syn PCR products by restriction digests or purification.  
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To investigate why the α-syn gene did not successfully insert into the pET-
22b(+) vector we altered the protocol for the restriction digest from a combined 
restriction digest to two independent digestions. By performing the restriction digest 
independently, we speculated that each restriction enzyme cutting efficiency would 
be increased. To assess these two purification protocols, gel extraction and ethanol 
precipitation, were compared.      
 
The α-syn gene isolated by PCR in section 3.5.3 was utilised for the experiment and 
labelled α-syn 1 and α-syn 2, along with two samples of the pET-22b(+) vector which 
were labelled vector 1 and vector 2. Each sample of α-syn and vector were digested 
with Nde I restriction enzymes. The α-syn and pET-22b(+) digests were purified 
either by gel extraction, α-syn 1 and vector 1 (section 2.2.7), or ethanol precipitation, 
α-syn 2 and vector 2 (section 2.2.8). The α-syn and pET-22b(+) samples were then 
digested with Hind III and were purified as previously. The digested α-syn and vector 
samples were analysed by 1 % agarose (figure 3.19 A and B). 
 
From the EthBr gels the α-syn sample purified by gel extraction showed a reduction 
in the quantity α-syn after Nde I digestion and no DNA appeared to be left after the 
final purification by gel extraction (figure 3.19 A). In comparison, purification by 
ethanol precipitation did not appear to reduce levels of α-syn between stages (figure 
3.19 A). This was mirrored by the digestion and purification of pET-22(+) which 








10000  ― 
 
2000  ― 
 
1500  ― 
 
1000  ― 
800  ― 
 
600  ― 
 




200  ― 
 
1           2          3           4           5           6          7 
 
10000  ― 
 
 
2000  ― 
 
1500  ― 
 
1000  ― 
800  ― 
 
600  ― 
 
400  ― 
 
 
200  ― 
 
   1          2           3          4           5         6 







EtOH                               Gel 
precipitate                   extraction 
Figure 3.19: Comparison of gel and ethanol purification of α-syn PCR products and  
pET-22b(+). 
Agarose EthBr gels show a comparison of purification of α-syn and pET-22b(+) by gel extraction 
or ethanol precipitation. A) α-Syn Gel: shows purification by gel extraction in lanes 2- 4 and 
ethanol (EtOH) precipitation in lanes 5 -7. Loading order; 1) HyperLadder I marker, 2) α-syn 1 
PCR, 3) α-syn 1 Nde I, 4) α-syn 1 Nde I and Hind III, 5) α-syn 2 PCR, 6) α-syn 2 Nde I, 7) α-syn 2 
Nde I and Hind III,. B) pET-22b(+) Gel: shows purification by gel extraction in lanes 3- 4 and 
ethanol precipitation in lanes 5-6. Loading order; 1) HyperLadder I marker, 2) pET-22b(+) 1 
uncut, 3) pET-22b(+) 1 Nde I, 4) pET-22b(+) 1 Nde I and Hind III 5) pET-22b(+) 2 Nde I, 6) pET-
22b(+) 2 Nde I and Hind III. Both A) and B) show that ethanol precipitation does not reduce DNA 
levels as much as DNA purification by gel extraction.  
EtOH              Gel   
 precipitate        extraction 
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3.5.5.2 Separate restriction digests did not increase success of ligation. 
From the previous study, using separate restriction digest reactions and ethanol 
precipitated purification, digested α-syn gene and digested pET-22b(+) vector 
concentrations were not diminished by the purification protocol. To verify whether 
the alternative protocol improved the ligation reaction, the ethanol precipitated 
samples were ligated and transformed in to E.coli cells. As previously colonies 
growths was used to indicate successful ligation with PCR confirmation.  
 
The newly constructed α-syn plasmid was transformed into JM109 cells and grown 
on amp containing agar plates. Plates streaked with JM109 cells transformed with the 
new α-syn plasmid showed good colony coverage. From these plates, 87 colonies 
containing the new α-syn plasmid were selected and used directly in PCR reactions 
(section 2.29.1). The PCR products were run on 1 % agarose EthBr gel (figure 3.20).  
 
None of the colonies used contained the α-syn gene (figure 3.20). The absence of any 
bands for any of the PCR reactions showed that the α-syn gene was not inserted into 
the pET-22b(+) vector. This would imply the isolation of the α-syn gene by PCR did 
not correctly add the restriction cutting sites onto the ends of the α-syn gene 
preventing correct restriction digest and insertion into pET-22b(+) vector.  
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Figure 3.20: EthBr gel identifying the presence of the α-syn gene within JM109 cells 
transformed with α-synpET-22b(+) plasmid. 
The EthBr gels show all 87 JM109 cell colonies used in PCR reactions to identify the presence of 
plasmids containing the α-syn gene. The green arrow indicates where the α-syn band should be 
located. M marks the HyperLadder I marker lanes. No bands were seen within any of the colonies 
tested. 
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3.5.6 Invitrogen primers successfully isolated α-syn from pRK172 vector. 
In earlier studies, construction of a new α-syn plasmid failed due to errors with PCR 
replication of the α-syn gene from the original α-synpRK172 plasmid (section 3.5.5). 
Our results imply that the primers did not successfully add the additional restriction 
cutting sites to the start and terminus of the α-syn gene. This prevented the insertion 
of the α-syn gene into the pET-22b(+) expression vector. To investigate whether the 
lack of insertion was due to the PCR primers used, this study used primers (with the 
same sequence) from an alternative source.    
 
The original α-synpRK172 plasmid was transformed into DH5α cells and cultured on 
agar plates containing amp (section 2.2.2). Colonies were randomly selected and 
cultured overnight in LB broth with amp. The α-syn plasmid was isolated from the 
cells as described in section 2.2.4 and utilised within a PCR reaction using our 
designed primer produced by Invitrogen (section 2.2.9). The PCR reactions were 
analysed by 1 % agarose EthBr gel (figure 3.21). 
 
As can be seen from the EthBr gel, a band at ~ 400bp was seen in all the lanes 
containing α-syn PCR samples, consistent with the size α-syn gene (figure 3.21). 
Invitrogen primers are therefore capable of amplifying and removing α-syn gene 
from pRK172 vector. 
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Figure 3.21: Amplification of α-syn by PCR. 
The EthBr gel shows the amplification of the α-syn gene from the α-syn plasmids by PCR. Lane 
order; 1) α-syn 1.1, 2) α-syn 1.2 3) α-syn 2.1, 4) α-syn 2.2, 5) α-syn 3.1, 6) α-syn 3.2, 7) α-syn 4.1, 
8) α-syn 4.2, 9) water control, 10) HyperLadder I marker. A band at ~ 400 bp was seen in all α-syn 
plasmid samples, which is consistent with the size of the α-syn gene. 
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3.5.6.1 Evaluation of α-syn inserts produced by Invitrogen primers. 
Our previous studies showed that the α-syn gene could be isolated and amplified by 
PCR using primers produced by Invitrogen (section 3.5.6). The α-syn gene and  
pET-22b(+) vector were digested by the restriction enzymes Nde I and Hind III in 
individual reactions and purified by ethanol precipitation as previously described in 
sections 2.2.5.2, 2.2.8 and 3.5.5.1. The α-syn gene was then inserted into the  
pET-22b(+) vector and transformed in to JM109 cells. As described previously, the 
number of colonies on the plate was used as an indication of the number of α-syn 
plasmid containing cells. Confirmation was provided by PCR (section 3.5.5.2).  
 
A huge number of colonies were apparent in plates of JM109 cells after 
transformation with α-synpET-22b(+) plasmid. From these plates, 43 colonies were 
selected and used directly in PCR assays (section 2.2.9.1). Analysis after PCR was 
by running the PCR products on 1 % agarose EthBr gel (figure 3.22). 
 
From the EthBr gels 35 colonies used in the PCR reactions showed a band at  
~ 400 bp (figure 3.22). This would implies that the α-syn gene, generated with 
Invitrogen primers, was successfully inserted into the pET-22b(+) vector and that the 
new α-syn plasmid was transformed into the JM109 cells. 
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Figure 3.22: Identification of α-syn within α-synpET-22b(+)-transformed JM109 cells by 
PCR. 
EthBr gels identifies JM109 colonies transformed with new α-syn plasmid containing the α-syn 
gene. Out of the 43 colonies used in the PCR, 36 colonies showed a band  
~ 400 bp, consistent with the α-syn gene size. Colony numbers are located at the top of each gel 
row. M = HyperLadder I marker and C = water control. The red circles identify the colonies that 
exhibited the highest intensity of ~ 400 bp band. 
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3.5.6.2 Assessment of the orientation of the α-syn gene within the α-syn 
pET-22b(+) plasmid. 
Within the previous study we identified colonies that contained our newly 
constructed α-syn plasmid. Although we showed successful ligation, the orientation 
and the sequence of the α-syn gene is unknown. By using our reverse α-syn primer 
and a T7 PCR primer in a PCR, the orientation of the α-syn gene can be established 
by examining the band size produced. In α-syn plasmids, which show the correct 
orientation, the α-syn DNA would be confirmed by DNA sequencing using our 
designed primers.  
 
To investigate the orientation and sequence of the α-syn gene, colonies showing the 
highest amplification of α-syn gene were selected from the previous study (section 
3.5.6.1), and grown overnight in LB both containing amp. The new α-syn plasmid 
was isolated from the cells (section 2.2.4). The isolated α-syn plasmid was used in 
the PCR, using T7 primer and α-syn reverse primer (section 2.2.9.1). The PCR 
products were analysed using 1 % agarose EthBr gel (figure 3.23).  
 
From the EthBr gel, four of the α-syn plasmids showed a band at ~ 400 bp (figure 
3.23) and are therefore in the correct orientation. The α-syn plasmids which were 
identified to have the correct orientation where sent for DNA sequencing using 
reverse T7 primer and our designed reverse α-syn primer to MWG. The DNA 
sequence for all the α-syn pET-22b(+) plasmids were shown to contain the correct 
DNA sequence for α-syn gene. 
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Figure 3.23: α-Syn orientation within pET-22b(+). 
The EthBr gel showed the PCR products produced by the PCR reactions of selected 5 α-syn pET-
22b(+) plasmids isolated from JM109 cells using T7 reverse primer and reverse α-syn primer. 
Lane order; 1) HyperLadder I marker, 2) water control, 3) α-syn 5, 4) α-syn 34, 5) α-syn 35, 6) α-
syn 38, 7) α-syn 42. A band at ~ 400 bp was seen for four of the five α-syn pET-22b(+) plasmids, 
this consistent with the size of the α-syn gene. No bands with observed for the α-syn pET-22b(+) 
plasmid within lane 3.   
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3.6 Failure of validation of the newly constructed α-synpET-22b(+) expression 
plasmid in JM109 cells. 
From the previous study, we successfully constructed a new expression vector by 
removing the α-syn gene from the original pRK172 plasmid and successfully 
inserting the α-syn gene into the commercial pET-22b(+) expression vector (section 
3.5). To validate both the correct orientation of plasmid and ability of this system to 
produce α-syn protein a small scale expression experiment was preformed. 
 
From the previous experiment colony 35 (which contained the new α-syn plasmid 
with the correct α-syn gene; sections 3.5.6.1 and 3.5.6.2), was streaked onto an amp 
agar plate. Colonies from the plate were randomly selected and grown overnight in 
LB broth with amp. The overnight cultures were used to inoculate two 100 ml 
volumes of LB broth with amp and grown to an OD600 of 0.5 – 0.6, protein 
expression induced by the addition of IPTG. For one culture, cell samples were 
collected at 0 h, 30 min, 1 h, 2 h, 4 h, 6 h and overnight after induction. The cells 
from each time point were centrifuged and resuspended in 1:1 ratio of water and SDS 
loading buffer. For the second expression culture, a cell sample was taken at 0 h and 
all the cells were harvested 4 h after induction, lysed and heat treated as described in 
section 2.3.8. All the time-point samples and heat-treated samples were analysed by 
NuPAGE gel. 
  
The NuPAGE gel showed no expression for either of the cultures (figure 3.24). This 
indicates that this system is not suitable for α-syn protein production. In hindsight the 
JM109 E.coli cells were a poor choice of cell line as they are not designed to
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Figure 3.24: Analysis of α-syn expression from α-synpET-22b(+) transformed in JM109. 
The gels show two α-syn expressions analysed by NuPAGE gel. The red arrow indicates the 
correct size for the α-syn protein band (~ 14 kDa). Lane order; 1) 0 h after induction, 2) 30 min 
after induction, 3) 1 h after induction, 4) 2 h, after induction 5) 4 h after induction, 6) 6 h after 
induction, 7) incubation overnight after induction, 8) Precision plus Protein unstained standards. 9) 
0 h after induction for heat treated sample, 10) heat-treated sample 4 h after induction. No obvious 
band at ~ 14 kDa was observed for either expression culture. 
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accommodate the pET-22b(+) vector. JM109 cells do not contain T7 phage RNA 
polymerase which is required for the expression of the target gene in the pET-22b(+) 
vector. However, the BL21(DE3)pLysS E.coli cells contain λDE3 lysogen which 
carries T7 phage RNA polymerase under the control of the lacUV5 promoter (which 
requires IPTG for activation), for the expression of the target gene. 
 
3.6.1 Successful α-syn production with alternative expression system. 
The unsuccessful system in the previous study used JM109 cells (section 3.6). As 
these cells are primarily used for plasmid storage rather than expression, this study 
investigated whether using BL21 (DE3)pLySs E.coli cells (specifically designed for 
protein expression) would enable α-syn expression.   
 
Colony 38, (validated in sections 3.5.6.1 and 3.5.6.2), was streaked onto an amp agar 
plate. Colonies from the plate were randomly selected and grown overnight in LB 
broth with amp and the α-syn plasmid was isolated from the cells as described in 
section 2.2.4. The isolated α-syn plasmid was transformed into BL21 (DE3)pLySs 
cells as described in section 2.2.3. Colonies were randomly selected and grown 
overnight in LB broth with amp and chlora. The overnight cultures were used to 
inoculate 100 ml volumes of LB broth with amp and chlora. BL21 (DE3)pLySs 
expression cultures were grown to an OD600 of 0.2 before inducing with IPTG and 
cell samples were collected at 0 h, 0.5 h, 2.5 h, 4.5 h and overnight after induction. 
All the cell samples were lysed, heat-treated and run on a NuPAGE gel. 
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Samples taken from the BL21 (DE3)pLySs cells show a band at ~ 14 kDa on 
the NuPAGE gel increases in intensity with time but is diminished with overnight 
incubation (figure 3.25). This shows that α-syn plasmid can be successfully used to 
express α-syn once transformed into expression specific BL21 (DE3)pLySs cells. 
 
3.6.2 Optimisation of expression protocol. 
Initial studies using the original α-synpRK172 plasmid (section 3.2), suggested that 
high expression levels of or prolonged exposure to α-syn, induced toxicity. The  
pET-22b(+) vector, which has been used to construct the new plasmid, contains the 
Lac z gene that reduces the expression of α-syn prior to induction with IPTG. The 
BL21(DE3)pLySs cells produce T7 lysozymes which further reduce the basal levels 
of α-syn expression. Reducing the production of α-syn before induction should 
decrease any toxicity due to prolonged exposure. In the previous study (section 3.6.1) 
however, high basal levels of protein expression was observed within the time zero 
sample. This study investigated whether prevention of ‘pre-induction’ protein 
expression could increase yields. By altering the inoculation protocol to use only one 
colony, direct from the culture plate, we speculated this would lower the basal level 
of α-syn. 
 
Glycerol stocks of BL21 (DE3)pLySs cells transformed with α-syn plasmid 
(produced in section 3.6.1) were grown on agar plates containing amp and chlora. 
Colonies were randomly selected and used to directly inoculate 100 ml volumes of 
LB broth with amp and chlora. The cultures were grown to an OD600 between 0.4 – 
0.6 before inducing with IPTG. For one culture, cell samples were taken at 0 h, 1 h,  
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Figure 3.25: Analysis of α-syn expression from α-synpET-22b(+) transformed into BL21 
(DE3)pLysS cells. 
The gel shows α-syn expression overtime in BL21 (DE3)pLysS cells on a NUPAGE gel. The red 
arrow indicates α-syn protein at 14 – 15 KDa. Loading order; 1) Precision plus Protein unstained 
standards, 2) 0 h before induction of expression, 3) 0.5 h after induction of expression, 4) 2.5 h, 5) 
4.5 h, 6) overnight. Expression of α-syn can be seen in all samples. 
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2h, 4 h, 5 h and overnight after induction. From the second culture, a cell sample was 
taken at 0 h and the remaining cells harvested 4 h after induction. For both cultures, 
the cell samples and the harvested cells, were lysed, heat-treated and run on a 
NuPAGE gel. 
 
A reduction in the basal levels of α-syn expression was seen at time zero (see figures 
3.25 and 3.26) and expression of α-syn was seen in both cultures (figure 3.26). The 
α-syn expression increased over time, but still decreased with overnight incubation 
(figure 3.26). Reduced level of basal protein expression, does not appear to affect the 
level of protein expression. 
 
3.6.3 Generation of purified α-syn. 
The current study evaluated the FPLC method (section 3.3.3) of protein purification 
for α-syn generated by the new protocol. Now the α-synpET-22b(+) plasmid has 
been optimised and shown to successfully express α-syn in BL21 (DE3)pLySs cells, 
we needed to establish if similar quantities of α-syn protein can be collected and 
purified by FPLC as seen with the previous α-synpRK172 plasmid (section 3.3.3).   
 
BL21 (DE3)pLySs cells containing α-synpET-22b(+) (see section 3.6.1) were plated 
onto agar plates containing amp and chlora and incubated overnight. A colony was 
randomly selected and used to inoculate 2 L of expression media directly. The 
culture was grown to an OD600 0.4 – 0.6 and induced with IPTG. The culture was 
incubated for 4 h and the whole culture harvested, the cells lysed, heat treated and  
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Figure 3.26: Increasing α-syn expression with increasing incubation periods within BL21 
(DE3)pLysS cells. 
The NUPAGE gel shows the expression of α-syn in BL21 (DE3) pLySs cells. The red arrow 
indicates the location of α-syn protein (14 – 15 KDa). Lane order; 1) 0 h after induction α-syn 
expression 2) 4 h after induction of expression culture which was harvested, 3) Precision plus 
Protein unstained standards, 4) 0 h after induction, 5) 1 h after induction, 6) 2 h after induction, 7) 
4 h after induction, 8) 4 h after induction, 9) 5 h after induction, 10) incubation overnight after 
induction. The α-syn was observed within all the samples, with α-syn expression increasing over 
time, however α-syn expression was reduced when incubated overnight. 
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centrifuged to remove debris. The supernatant was dialysed overnight into  
0.02 M Tris pH 8.2. 
 
As described previously (section 3.3) a HiTrap Q HP anion exchange column was 
used, although for these studies the columns were scaled-up to 5ml. The column was 
equilibrated with 0.02 M Tris pH 8.2. Dialysed α-syn was analysed by BCA assay to 
establish the total protein concentration of ~ 2.9 mg/ml (data not shown). 9 ml of the 
α-syn sample was centrifuged and loaded directly onto the column. The same 
protocol was used previously (section 3.4), taking into account the larger column 
volume by increasing the flow rate to 5 ml/min (figure 3.27A). Elution of the 
proteins was monitored by UV at 280 nm reading during the run (data not shown). 
Samples were taken from each fraction and run on a NuPAGE gel for analysis 
(figure 3.27B). 
 
Analysis of the fractions from the column run showed that α-syn was eluted into 
more fractions than previous, with the majority of α-syn in fractions 14 to 18 (figure 
3.27B). Fractions 14 to 18 were pooled together and dialysed overnight into water. 
The concentration of protein in the dialysed sample was 1.4 mg/ml (quantified using 
the BCA assay), approximately ~ 48 % of the total protein loaded. α-Syn was divided 
into 1 mg aliquotes (714 µl), snap-frozen using liquid nitrogen and lyophilised 
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A) Schematic of α-syn column run 
B) NuPAGE gel of selected fractions  
Figure 3.27: FPLC run and NuPAGE of selected fractions containing α-syn. 
A) Schematic of α-syn column run: using a 5 ml HiTrap Q HP column. The percentage NaCl 
elution gradient is shown with the fraction numbers and volumes listed below. B) NuPAGE gel of 
selected fractions. The gel shows fractions containing α-syn purified from the FPLC run. The red 
arrow indicates the location of the band for α-syn protein at 14 – 15 KDa. Loading order (fraction 
numbers); 1) 14, 2) 15, 3) 16, 4) 17, 5) 18, 6) 19, 7) 20, 8) 21 9) 22, 10) Precision plus Protein 
unstained standards, 11) 27, 12) 28, 13) pre-column sample. Fractions 14 to 18 were pooled 
together for use in further experiments.  
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3.7 Scale up of α-syn expression using 10 L fermentation. 
This study investigated whether increasing culture volumes and scaling up the 
purification protocol could produce larger amounts of α-syn protein. 
 
Through our collaboration with Dr. White (EPIC) and using a Brunswick 
BioFlo4500s fermentor, expression cultures were scaled up from 2L to 10 L. The α-
synpET-22b(+) plasmid was transformed directly into E.coli expression cells for 
every fermentation run (section 2.3.1.4). Using the same growth condition as for the 
2 L cultures, the 10 L growth cultures were grown to an OD600 of 0.4 – 0.6 before 
inducing with IPTG. A sample was taken prior to induction to check expression. The 
fermentation was then allowed to incubate for 4 – 5 h at which point the cells were 
harvested, pelleted and stored at -20 oC.  
 
A large increase in α-syn expression can be seen after a 4 h incubation (figure 3.28), 
compared with time zero. Once expression was confirmed, cell pellets were de-
frosted and the cells lysed and heat-treated as previously. The supernatant was 
dialysed into 0.02 M Tris pH 8.2 overnight. The concentration of total protein was 
~5.5 mg/ml dialysed (determined by BCA assay). The sample (~ 20 – 30 ml) was 
then centrifuged to remove any debris and loaded directly onto an in house prepared 









0 h          4 h 
α-syn 
14 kDa 
Figure 3.28: α-Syn expression produced from a 10 L fermentation. 
The gel shows α-syn expression 4 h after induction of expression with IPTG with compared to 
expression at time of induction. Red arrow marks the α-syn 14 kDa protein band.  
 177 
The protocol from section 3.3 and section 3.6.3 was adapted for the increase in 
column and sample size. Although the flow rate was maintained at 5 ml/min the 
fraction volumes were increase to 3 ml. The elution of the proteins was monitored by 
UV at 280 nm throughout the column run (data not shown). Samples were taken 
from each fraction and run on a NuPAGE gel (figure 3.29). 
 
The majority of α-syn was eluted in fractions 23, 24 and 25 with no apparent 
contamination from other proteins (figure 3.29). As the bands produced by these 
fractions were large, samples of the bands were cut from the gel and analysed by 
mass spectrometry (Dr. D Short, A.C.E.) as shown in figure 3.30.  The results from 
the mass spectrometry determined the gel samples contained α-syn and no 
contaminating proteins. Figure 3.30 shows an example of the mass spectrometry 
reading for the expression gel in figure 3.29. This was repeated on a number of other 
expression runs and the same results were obtained. 
 
Fractions 23, 24 and 25 were pooled together and dialysed overnight into water. The 
concentration of protein in the dialysed sample was quantified using the BCA assay 
showing the pooled fractions of α-syn to contain ~ 11.5 mg/ml, a total of 99 mg of 
purified α-syn from one 10 L expression culture. Scaling the culture up has increased 
the quantity of α-syn by ~ 10 fold compared to 2 L cultures, without reducing the 
purity.  
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Figure 3.29: FPLC fractions of α-syn produced from 10 L fermentation. 
NuPAGE gel showing a representation of the fractions produced from an FPLC run of a 10 L 
fermentation run of α-syn. Lane order; 1) Precision plus Protein unstained standards, 2) fraction 
14, 3) 15, 4) 16, 5) 17, 6) 18, 7) 19, 8) 20, 9) 21 10) 22, 11) 23, 12) 24, 13) 25 14) 29 15) 31. The 
majority of the α-syn is eluted in fractions 23, 24 and 25.  
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Figure 3.30: Mass spectrometry analysis confirming the presence of α-syn.  
The protein bands selected and removed from the NuPAGE gel for mass spectrometry are shown 
in the above panel, where the green arrow indicates the band confirmed to be α-syn.  The lower 
panel shows the mass spectrometry results which confirm the α-syn protein band.   
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3.8 Chapter 3 Summary. 
Within this chapter a successful method of generating purified recombinant α-syn 
protein was identified and optimised. Initially the expression of α-syn, A53T α-syn 
and β-syn was achieved using BL21 (DE3) cells and the pRK172 vector. However, 
protein expression was reduced due to selective rejection of the plasmid from the 
E.coli cell line. This was successfully addressed by constructing a new plasmid using 
a commercial pET-22b(+) vector and transferring the α-syn gene from the original 
pRK172 vector by PCR. The re-constructed α-syn plasmid best expressed α-syn 
protein in BL21 (DE3)pLysS, designed to reduce pre-induction or ‘leaky’ 
expression. Subsequently it was found that the yield of α-syn was significantly 
increased compared to the original pRK172 vector. Through our collaboration with 
Dr J. White we were successfully able to scale up expression from 2 L to 10 L 
fermentation cultures. The increased culture volume our optimised purification 
protocol, using anion exchange chromatography, gave an increased yield of purified 
α-syn of approximately 100 mg per fermentation run. Purified α-syn was identified 
by using western blotting and mass spectrometry.     
 
Though A53T α-syn and β-syn genes were not transferred to the new pET-22b(+) 
vector their expression within the original pRK172 vector was not diminished. The 
successful large scale expression and optimised purification protocol have allowed 
the reproducible production of large quantities of purified α-syn that will facilitate 
future experiments into the role of α-syn within PD in vitro model. 
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Chapter 4: Effects of α-syn in normal and disease conditions. 
4.1 Cytotoxic effects of α-syn. 
4.1.1 In-house wild-type α-syn did not induce cell death. 
As mentioned previously in section 1.1.3, there are may hypothesises about the effect 
of α-syn in cells. It has been speculated that soluble and aggregated forms of α-syn 
induce toxicity and subsequent cell death. As we have been able to produce soluble 
recombinant α-syn, we treated cells with either soluble or pre-aggregated 
recombinant (see section 2.4.4) protein at varying concentrations and incubated the 
cells for 24 h. The MTS assay contains a novel tetrazolium compound which is 
reduced by NAD(P)H released from metabolically active cells. A decrease in MTS 
reduction is an indication of cytotoxicity and cell death. 
 
SHSY-5Y cells were treated with vehicle (serum-free – medium containing 0.1 % 
water) (which was used as a measure of 100 % MTS reduction with treatments 
shown as percentage of vehicle), in-house produced soluble α-syn (0.1 – 10.0 µM) or 
in-house α-syn aggregated (0.1 – 10.0 µM) and incubated for 24 h. Cells treated with 
soluble α-syn (0.1 1.0 and 10.0 µM) for 24 h did not alter MTS reduction levels (99.1 
± 10.1, 100.5 ± 11.3 and 89.8 ± 7.4 % respectively) compared to vehicle (figure 
4.1A). Similarly SHSY-5Y cells treated with aggregated α-syn (0.1, 1.0 and 10.0 
µM) showed no significant alteration of MTS reduction (84.1 ± 6.2, 81.8 ± 13.8 % 
and 70.3 ± 12.9 % respectively) (figure 4.1B). 
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Figure 4.1: In-house produced α-syn did not induce cell death. 
SHSY-5Y cells were incubated for 24 h with vehicle (serum-free media with 0.1 % water), in-
house soluble α-syn (0.1 – 10.0 µM) or in-house aggregated α-syn (0.1 – 10.0 µM) with MTS 
reduction shown as a percentage of vehicle. (A) Soluble α-syn: Soluble α-syn did not lower or 
increase MTS reduction significantly. (B) Aggregated α-syn: Aggregated α-syn did not 
significantly lower MTS reduction, although there may be a trend towards a decrease in the 
percentage of MTS reduction with the highest concnetrations of α-syn. For all treatments N = 3. 
A B 
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This study showed that α-syn did not alter MTS reduction irrespective of 
aggregation state. However the highest concentration of aggregated α-syn may 
suggest a decrease in MTS reduction and possibly expanding the concentration range 
to include higher concentrations α-syn may induce a cytotoxic effect. 
 
4.1.2 Validation of in-house wild-type α-syn with commercial α-syn. 
A commercial source (rPeptide, USA) of wild-type α-syn was used to validate the 
results observed with previous in-house toxcity assay whether the same toxicity 
stands (section 4.1.1). 
  
SHSY-5Y cells were treated as previously with vehicle (serum-free media with 0.1 
% water), commercially soluble α-syn (0.1 – 10.0 µM) or aggregated commercial α-
syn (0.1 – 10.0 µM) for 24 h. Soluble α-syn (0.1, 1.0 and 10.0 µM) did not 
significantly affect MTS reduction (99.2 ± 6.8, 96.6 ± 5.8 and 87.1 ± 10.1 % 
respectively) (figure 4.2A). Similarly with aggregated α-syn (0.1, 1.0 and 10.0 µM) 
did not significant change MTS reduction compared to vehicle (93.0 ± 6.1, 86.5 ± 8.6 
and 76.8 ± 7.7 % respectively) (figure 4.2B).  
 
This study provides validation for our previous study, showing that commercially 
produced wild-type α-syn (soluble or aggregated), failed to induce toxicity in  
SHSY-5Y cells. The results for commercial wild-type α-syn are very similar to the 
results for the in-house produced α-syn (figure 4.1B and 4.2B). 
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Figure 4.2: Commercially produced α-syn did not induce cell death. 
SHSY-5Y cells were incubated for 24 h with vehicle (serum-free media with 0.1 % water), soluble 
commercial α-syn (0.1 – 10.0 µM) or aggregated commercial α-syn (0.1 – 10.0 µM). MTS 
reduction was shown as percentage of vehicle. (A) Soluble α-syn: Soluble α-syn did not 
significantly effect MTS reduction. (B) Aggregated α-syn: Aggregated α-syn did not significantly 
lower MTS reduction. For all treatments N = 3. 
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4.1.3 In-house A53T mutant α-syn does not induce cell death. 
Further to investigating the toxicity of wild-type α-syn, we similarly examined the 
putatively more toxic A53T mutant form of α-syn. 
  
SHSY-5Y cells were incubated for 24 h with vehicle (serum-free media with 0.1% 
water), in-house soluble A53T α-syn (0.1 – 10.0 µM) or aggregated in-house A53T 
α-syn (0.1 – 10.0 µM). Soluble A53T α-syn (0.1, 1.0 and 10.0 µM) showed no 
statistical significant change in MTS levels compared to vehicle (94.9 ± 3.9, 94.6 ± 
10.0, and 82.7 ± 15.0 % respectively) (figure 4.3A). Aggregated A53T α-syn at 0.1 
µM significantly decreased MTS reduction to 78.4 ± 4.4 % compared to vehicle. 
However, 1.0 µM aggregated A53T α-syn did not alter MTS reduction compared to 
vehicle (96.1 ± 9.1 %) and surprisingly, 10.0 µM aggregated A53T α-syn increased 
MTS reduction further to 122.4 ± 16.8 %, though no significance was determined 
compared to the vehicle (figure 4.3B). However it is important to note that the 
increase in MTS reduction observed for 10.0 µM aggregated A53T α-syn is due to 
one out lying point of 168 % of vehicle, which if removed lowers MTS reduction 
mean to 107.5 ± 11.1 %.  
 
In this study, soluble A53T α-syn did not alter MTS reduction whereas aggregated 
A53T α-syn at 0.1 µM decreased MTS reduction, suggesting a cytotoxic effect 
within the cells. However, the cytotoxic effect of 0.1 µM aggregated A53T α-syn 
was reversed by increasing the concentration of aggregated A53T α-syn (1.0 and 
10.0 µM) (figure 4.1B and 4.3B). 
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Figure 4.3: In-house A53T α-syn induced state- and concentration-dependent cell death. 
Cells were incubated for 24 h with vehicle (serum-free media with 0.1 % water), in-house soluble 
A53T α-syn (0.1 – 10.0 µM) or in-house aggregated A53T α-syn (0.1 – 10.0 µM). Levels of MTS 
reduction are shown as percentage of vehicle. (A) Soluble A53T α-syn: Soluble A53T α-syn did 
not significantly alter MTS reduction. (B) Aggregated A53T α-syn: Aggregated 0.1 µM A53T α-
syn significantly lowered MTS reduction compared to vehicle. A53T α-syn (1.0 and 10.0 µM) did 
not significantly alter MTS reduction. For all treatments N = 4 and significance was determined by 
one-way ANOVA with Student-Newman-Keuls post-hoc test where * P < 0.05 verses vehicle.  
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4.1.4 Validation of in-house A53T α-syn with to commercial A53T α-syn. 
As with wild-type α-syn, a commercial source (rPeptide, USA) of A53T α-syn was 
used to validate the previous results with an alternative source of A53T α-syn within 
SHSY-5Y cells in a manner similar to the previous study. 
 
As described earlier, SHSY-5Y cells were incubated for 24 h with vehicle (serum-
free media with 0.1 % water), commercially produced soluble A53T α-syn (0.1 – 
10.0 µM) or pre-aggregated A53T α-syn (0.1 – 10.0 µM). Soluble A53T α-syn at 0.1 
and 1.0 µM did not effect MTS reduction (101.1 ± 3.4 % and 102.9 ± 2.5 % 
respectively). 10.0 µM soluble A53T α-syn significantly decreased MTS reduction to 
81.4 ± 12.6 % compared to vehicle (figure 4.4A). Aggregated commercial A53T α-
syn (0.1, 1.0 and 10.0 µM) also did not alter MTS reduction compared to vehicle 
(95.7 ± 2.8 %, 102.8 ± 3.7 and 94.4 ± 4.0 % respectively) (Figure 4.4B).  
 
In constrast to in-house soluble A53T α-syn, the commerical protein induced slight 
cytotoxicity at the highest concentration (figure 4.3B and 4.4B). Aggregated α-syn 
from a commerical source showed no toxic effects, in a slight discrepancy with in-








































































Figure 4.4: Commercially produced A53T α-syn induced state- and concentration-dependent 
cell death. 
Cells were incubated for 24 h with vehicle (serum-free media with 0.1 % water), soluble 
commercial A53T α-syn (0.1 – 10.0 µM) or aggregated commercial A53T α-syn (0.1 – 10.0 µM) 
with MTS reduction are shown as percentage of vehicle. (A) Soluble A53T α-syn: Soluble α-syn 
(0.1 or 1.0 µM) had no effect on MTS reduction compared to vehicle whereas 10.0 µM soluble 
A53T α-syn significantly lowered MTS reduction compared to vehicle. (B) Aggregated A53T α-
syn: Aggregated A53T α-syn had no effect on MTS reduction compared to vehicle. Soluble A53T 
α-syn decreased MTS reduction in concentration-dependent manner, whereas aggregation of A53T 
α-syn had no effect MTS reduction. Significance was determined by one-way ANOVA with 
Student-Newman-Keuls post-hoc test where * P < 0.05 verses vehicle. For all treatments N = 4.  
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4.1.5 Validation of MTS assay by Staurosporine. 
To ensure that the results of previous section were not due to the inablity of the assay 
to detect cell death in these cells the effectiveness of the MTS assay at measuring 
toxicity was validated with staurosporine (STS). Staurosporine is a protein kinase C 
inhibitor which induces concentration-dependent apoptosis, making it ideal for 
validating the MTS assay (Koh et al., 1995; Boix et al., 1997; Posmantur et al., 
1997; Gescher 1998; Ha et al., 2004) 
 
Two validation studies were performed; examining the concentration-dependent and 
time-dependent toxicity of STS. In the first cells were treated with either vehicle 
(serum-free media with 0.1 % DMSO) or STS (0.003 – 10.0 µM) and incubated for  
5 h. STS (0.1 - 10.0 µM) induced a significant decrease in MTS reduction in a 
concentration-dependent manner. Within this range, STS lowered MTS reduction to 
50 % of vehicle between 0.3 and 1.0 µM (57.6 ± 23.9 and 33.3 ± 6.8 % respectively). 
Increasing the STS concentration to 10.0 µM significantly decreased MTS reduction 
to less than 20 % MTS reduction indicating almost total cells death (15.7 ± 1.4 %) 
(figure 4.5). At the lower concentrations of STS (0.003 – 0.03 µM) did not affect 
MTS reduction levels. STS induced concentration-dependent decrease in cell 







































Figure 4.5: Staurosporine induced cell death in a concentration-dependent manner. 
SHSY-5Y cells were incubated for 5 h with vehicle (serum-free media with 0.1 % DMSO) or 
Staurosporine (0.003 – 10.0 µM) with MTS reduction shown as percentage of vehicle. STS (0.003 
– 0.03 µM) did not alter MTS reduction. However higher concentration of STS (0.1 – 10.0 µM) 
significantly decreased MTS reduction in a concentration-dependent manner. Significance was 
determined by one-way ANOVA with Student-Newman-Keuls post-hoc test where * P < 0.05 
verses Vehicle. For all treatment N = 3. 
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For the temporal study SHSY-5Y cells were treated with either vehicle 
(serum-free media with 0.1 % DMSO) or STS (1.0 µM) and incubated for 1 – 7 h. 
The level of MTS reduction was presented as percentage of vehicle at 1 h. The 
vehicle did not significantly alter MTS reduction over the 7 h incubation (91.2 – 
126.8 % MTS reduction). In contrast STS (1.0 µM) induced a time-dependent 
decrease in MTS reduction with significance (compared to vehicle) after 3 h (69.4 ± 
7.9 %). At 4 h, STS induced ~ 50 % MTS reduction cell death (48.3 ± 6.4 %) before 
plateaoing between 5 – 7 h (figure 4.6). 
 
This study shows STS-induced cell death can be monitored overtime by the MTS 
assay (figure 4.6). As well as validating the MTS assay the two STS studies show 
consistentcy, where 1.0 µM STS decreased MTS reduction to 33.3 ± 6.8 % in the 
concentration-dependent study and to 27.7 ± 3.8 % at 5 h in the time course study 
(figure 4.5 and 4.6). 
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Figure 4.6: Staurosporine induced decrease in cell viability in a time-dependent manner. 
Cells were incubated with either vehicle (serum-free media with 0.1 % DMSO) or STS (1.0 µM) 
for 1 - 7 h. MTS reduction is shown as percentage of vehicle at 1 h. Vehicle alone did not 
significantly alter MTS reduction over the 7 h. STS induced time-dependent decrease in MTS 
reduction with STS inducing a significant decrease MTS reduction at 3 h, compared to vehicle at 3 
h. STS induced decrease in MTS reduction plateaued at 6 h and 7 h with less than 20 % MTS 
reduction observed compared to relevant vehicle. Significance was determined by one-way 
ANOVA with Student-Newman-Keuls post-hoc test where * P < 0.05 verses vehicle (at relevant 
time point). For all treatments N = 3. 
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4.1.6 α-Syn concentration-dependent decrease in MTS reduction.  
Soluble α-syn did not induce significant cell death after 24 h incubation at the 
concentration previously used (figure 4.1A and 4.2A). However, the results 
implicated a potential trend towards cytotoxicity with increasing concentrations. 
Increasing concentration range used for α-syn might therefore induce cytotoxicity of 
the cells. Increasing α-syn incubation time similarly increase any toxic effects. 
 
α-Syn (0.001 – 30.0 µM) was incubated for 48 h with SHSY-5Y cells. α-Syn induced 
a concentration-dependent decrease in MTS reduction. This was not significant at 
lower concentrations (0.001 – 3.0 µM), but α-syn at 10 and 30 µM did  significantly 
decrease MTS reduction compared to vehicle (56.6 ± 8.5 % and 47.2 ± 9.3 % 
respectively) (figure 4.7).  
 
The study has shown that increasing incubation time to 48 h and the concentration 
range of α-syn, has identified that α-syn induces concentration-dependent decrease in 
MTS reduction, indicative of a cytotoxicity effect. 
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Figure 4.7: α-Syn concentration-dependent decrease in MTS reduction. 
Cells were treated with either vehicle (serum-free media with 0.1 % water) or in-house soluble α-
syn (0.001 – 30.0 µM) and incubated for 48 h MTS reduction is shown as percentage of vehicle.  
α-Syn decreased MTS reduction ina concentration-dependent manner with significancy compared 
to vehicle at higher concnetrations (10.0 and 30.0 µM). For all treatments N = 3 and significance 
was determined by one-way ANOVA with Student-Newman-Keuls post-hoc test where * P < 0.05 
verses vehicle. 
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4.1.7 α-Syn does not induce cell death. 
α-Syn (10.0 and 30.0 µM) induced a significant decrease in MTS reduction at 48 h, 
suggesting that α-syn was cytotoxic. To confirm these results an alternative cell 
death assay was employed. This secondary assay analysies the release of lactate 
dehydrogenase (LDH), a stable cytosolic enzyme that is only released from lysed 
cells. 
 
As described previously, SHSY-5Y cells were treated with α-syn (0.1 – 30.0 µM) 
and incubated for 24 h or 48 h. Cell death was presented as a percentage to vehicle 
(serum-free media). At 24 h α-syn (0.1 – 30.0 µM) did not induce any cell death 
compared to vehicle. The maximum cell death observed was 0.975 ± 0.975% with 30 
µM α-syn (figure 4.8A). With increasing incubation time (48 h), α-syn still did not 
induce any cell death, with a maximum cell death observed of 4.0 ± 3.2 % using 0.1 
µM α-syn (figure 4.8B).  
 
This shows α-syn does not induce cell death within SHSY-5Y and is therefore not 
inherently toxic to cells (figures 4.8A and 4.8B). This would imply that the previous 
MTS experiments are detecting a decrease in cellular metabolism (as the MTS asssay 

















































Figure 4.8: α-Syn did not induce cell death. 
α-Syn (0.1 – 3.0 µM) was used to treat SHSY-5Y cells for 24 and 48 h and used on the LDH 
asaay with cell death determined as a percentage to vehicle (serum-free media) (A) 24 h: α-Syn 
(0.1 – 30.0 µM) did not induce cell death compared to vehicle. (B) 48 h: α-syn did not cell death 
with increased incubation. For all treatments N = 3 
: 24 h : 48 h 
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4.1.8 Summary of Section 4.1  
In summary, α-syn induces a reduction in SHSY-5Y cell metabolic output in a 
concentration- and time-dependent manner but does not, however, induce cell death. 
The reduction in MTS would appear to be dependent on the addition of soluble α-syn 
rather than aggregated α-syn, as aggregated α-syn had no significant effect on cell 
metabolic output after 24 h incubation. This would suggest that either the soluble, or 
protofibril, form of α-syn is affecting the cells rather than the aggregated form. Of 
these two forms the most likely candidate is the protofibril for a number of reasons. 
Firstly, soluble α-syn can be taken up into the cells within 60 seconds after addition 
to the media (Sung et al., 2001).  It could be speculated that such a fast uptake of 
soluble protein would result in a more rapid affect on the cells than is actually 
observed. Secondly, the reduction of total metabolic output is concentration- and 
time-dependent, two factors known to be important in the aggrgation of the protein. 
While this may suggest that aggregated form of α-syn is responsible for the 
metabolic effect, our studies show that the fully aggregated α-syn does not mediate a 
similar response. Therefore, the protofibril, the intermediate between soluble and 









4.2 Metabolic effects of α-syn. 
4.2.1 Effects on the translocation of cytochrome c into the cytosol by α-syn. 
We showed previously (section 4.1) that α-syn induced a concentration-dependent 
decrease in total metabolic content, which was not due to cell death (figures 4.7 and 
4.8). To investigate whether this decrease was due to mitochondrial dysfunction, we 
monitored the translocation of cytochrome c (cyt c) to the cytosol by ELISA. 
Mitochondrial dysfunction causes the translocation of cyt c from the mitochondrial to 
the cytosol through the mitochondrial permeable transition pore (mitochondrial pore) 
which can be inhibited with cyclosporine A (CsA). 
 
SHSY-5Y cells were treated with vehicle (serum-free media with 0.1 % DMSO), α-
syn (30.0 µM), CsA (10.0 µM) or CsA (10.0 µM) with α-syn (30.0 µM) and 
incubated for 6 h. N = 3 for all treatments and cells cytosol analysed by cyt c ELISA. 
Cytosolic concentrations of cyt c in control cells were 23.7 ± 2.0 ng/ml. With the 
addition of α-syn (30.0 µM) cytosolic cyt c levels rose to 38.2 ± 5.7 ng/ml, which 
although caused a 62 % increase, was not significantly different from vehicle. Cells 
treated with CsA (10.0 µM), the mitochondrial pore inhibitor, showed no alteration 
in cytosolic cyt c levels compared to vehicle (21.2 ± 3.5 ng/ml). However, the 
addition of CsA (10.0 µM) and α-syn (30.0 µM) significantly reduced the 
concentration of cytosolic cyt c to 12.2 ± 1.1 ng/ml compared to vehicle (figure 4.9).  
 
This study shows that α-syn (30.0 µM) or CsA (10.0 µM) do not significantly alter 

































Figure 4.9: Effect of the mitochondrial transition pore inhibitor, cyclosporine A, and α-syn 
on the translocation of cyt c to the cytosol. 
SHSY-5Y cells treated with vehicle (serum-free media with 0.1 % DMSO) saw a concentration of 
cytosolic cyt c at 23.7 ± 3.5 ng/ml. Treating cells with α-syn (30.0 µM) cytosolic cyt c 
concentrations rose to 38.2 ± 5.7 ng/ml, a 62 % increase, though not significant. Cytosolic cyt c 
levels of cells treated with CsA (10.0 µM) alone were unaltered compared to vehicle.  However, 
the addition of both CsA (10.0 µM) and α-syn (30.0 µM) significantly reduced cytosolic levels of 
cyt c compared to vehicle. All treatments were incubated with cells for 6 h (N = 3). Significance 




(30.0 µM) in combination, significantly reduces cytosolic levels of cyt c after 6h 
incubation. 
 
4.2.2 No translocation of cytochrome c to the cytosol after increased exposure to 
α-syn.  
The previous study suggests that incubation with α-syn for 6 h increased cytosolic 
cyt c levels, though not significantly. We speculated that increasing the incubation 
time would further increase α-syn induced translocation of cyt c to the cytosol. In 
this study therefore, incubation duration was increased to 48 h as α-syn significantly 
decreased SHSY-5Y cells total metabolic output at this time point in our previous 
studies (figure 4.7).  
 
SHSY-5Y cells were treated with vehicle (serum-free media with 0.1 % DMSO) or 
α-syn (30.0 µM) and incubated for a total of 48 h. After 36 h CsA (10.0 µM) was 
added to both α-syn and vehicle cells. The cytosol was analysed by cyt c ELISA. 
Control levels of cytosolic cyt c in the presence of vehicle were 21.3 ± 3.2 ng/ml 
after 48 h incubation (figure 4.10). Cells treated with α-syn did not alter the 
translocation of cyt c to the cytosol compared to vehicle (19.9 ± 1.2 ng/ml). CsA (10 
µM) showed a significant loss of cyt c from the cytosol (decreased to 5.7 ± 0.7 ng/ml 
compared to vehicle). Similarly with the addition of CsA (10 µM) to α-syn treated 
cells cytosolic cyt c levels significantly dropped to 4.1 ± 1.4 ng/ml compared to 
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Figure 4.10: Cytosolic cyt c was not increased with increase incubation with α-syn. 
SHSY-5Y cells were treated with vehicle (serum-free media with 0.1 % DMSO) or α-syn (30.0 
µM) and incubated for 48 h. CsA (10.0 µM) was added to cells at 36 h. N = 3 for all treatments. 
Vehicle treated cells showed 21.3 ± 3.2 ng/ml cytosolic cyt c. α-Syn treated cells did not increase 
cytosolic cyt c compared to vehicle. CsA (10.0 µM) significant lowered cytosolic cyt c levels 
compared to vehicle. CsA (10.0 µM) co-treated with α-syn significantly lowered cytosolic cyt c 
levels compared to vehicle and α-syn alone. Significance was determined by one-way ANOVA 
with Student-Newman-Keuls post-hoc test where * P < 0.05 verses vehicle 
 202 
Our results presented here suggest that the addition of α-syn alone (30.0 µM 
for 48 h) had no overall effect on the translocation of cyt c to the cytosol (figure 
4.10). However, the addition of 10.0 µM CsA alone produced a significant reduction 
in the concentration of cytosolic cyt c, a result mirrored when CsA was also added to 
the α-syn treated cells. However, this result may be misleading as the presence of 
CsA in these experiments should not alter the concentration of cytosolic cyt c in 
normal cells. The fact that a significant reduction is seen in cyt c concentration may 
be an indication that the addition of CsA at this concentration is inducing cell death. 
As previous experiments (sections 4.2.1 and 4.2.2) showed no significant reduction 
in cytosolic cyt c after 6 h incubation, this effect may be time dependent. 
 
4.2.3 Temporal profile of CsA induced cell death by the LDH assay. 
The previous data (sections 4.2.1 and 4.2.2) implied that CsA may be inducing a 
time-dependent decrease in cytosolic cyt c concentration that is independent of α-syn 
(figure 4.9 and 4.10). However, it may be the case that the reduction in cytosolic cyt 
c concentrations may be a result of cell death. To investigate this further we 
investigated CsA-induced cell death using the LDH assay. 
 
Cells were treated with either vehicle (serum-free media with 0.1 % DMSO) or CsA 
(0.1 - 10.0 µM) and incubated for 6, 12, 24 or 48 h. CsA at 0.1 and 1.0 µM did not 
show induced cell death between 6 – 24 h. However, after 48 h incubation, CsA (0.1 
and 1.0 µM) significantly increased cell death compared to the earlier time points 
(15.2 ± 7.7 % and 41.3 ± 12.8 % respectively) (figure 4.11). In contrast, CsA at 10.0 
µM significantly increased cell death at all time points (i.e. 6, 12 and 24 h saw an 
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Figure 4.11: Temporal profile of CsA concentrations.  
Cells were treated with either vehicle (serum-free media with 0.1 % DMSO) or CsA (0.1-10.0 
µM) and incubated for 6, 12, 24 or 48 h with cell death presented as a percentage to the vehicle (n 
= 3). CsA at 0.1 and 1.0 µM did not increase cell death at 6, 12 or 24 h, but significantly increased 
cell death at 48 h, where 1.0 µM CsA induced significantly higher cell death than 0.1 µM CsA. 
Increasing CsA to 10.0 µM significantly increased cell death at all time points when compared to 
lower concentrations. CsA (10.0 µM) induced a time-dependent increase in cell death with each 
time point significantly higher than the previous one. Significance was determined on ranks as 
normality test failed by two-way ANOVA with Student-Newman-Keuls post-hoc test where  
* P < 0.05 verses earlier time point (within specified concentration) and † P < 0.05 verses lower 
concentrations (within specified time point).  
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increase to 23.2 ± 1.1 %, 58.8 ± 4.3 % and 105.3 ± 3.6 % compared to the lower 
concentrations respectively). It is worthy to note that 10 µM CsA (and MPP+ in 
subsequent experiments using LDH assay) appears to be more efficient at inducing 
cell death than the commercial lysis buffer used here to induced ‘total’ cell death 
(figure 4.11).   
 
This study shows that CsA induces cell death in a time- and concentration-dependent 
manner (figures 4.11). Therefore, the reduction in the concentration of cyt c in the 
cytosol induced by CsA seen previously (figure 4.10), was due to CsA inducing cell 
death. 
 
4.2.4 The effect of α-syn on CsA induced cell death. 
Previously, we have shown that CsA significantly increases cell death in a 
concentration and time-dependent manner (section 4.2.3, figure 4.11). This would 
imply that the decrease in the cytosolic concentrations of cyt c seen previously 
(section 4.2.2, figure 4.10) was due to CsA induced cell death. The previous 
experiments also included the use of α-syn in combination with CsA that also saw a 
reduction in cyt c concentrations. It may be assumed that the reduction of cyt c in this 
case was solely due to the CsA induced cell death irrespective of α-syn. It may also 
be the case that the concentration of CsA used in the cytosolic cyt c ELISA was 
excessive, causing inappropriate cell death rather than just inhibiting the 
mitochondrial pore. To confirm that α-syn did not contribute to CsA-induced cell 
death we used the LDH assay as described previously (section 4.2.3). 
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Cells were treated with vehicle (serum-free media with 0.1 % DMSO), CsA 
alone or CsA with α-syn at varying concentrations for 6, 12, 24 or 48 h. Here, we 
show that a low CsA concentration (0.1 µM) resulted in an increase in cell death only 
when either 10.0 or 30.0 µM α-syn is added (figure 4.12A). However, at a higher 
concentration of CsA (1.0 µM) only 10.0 µM α-syn appears to have a significant 
effect on cell death (figure 4.12B). However, neither 0.1 nor 1.0 µM CsA 
concentrations showed an increase in cell death as high as observed with 10.0 µM 
CsA alone. Furthermore, the level of cell death caused by 10.0 µM CsA is not 
affected by any of the α-syn concentrations used (figure 4.12C).   
 
This would imply that the use of 10.0 µM CsA in the cytosolic cyt c ELISA 
experiments (section 4.2.2) was indeed too high and induced inappropriate cell death, 
but that a lower concentration (0.1 – 1.0 µM) could be used in future experiments. It 
is also important to note that the combination of CsA (0.1 – 1.0 µM) and α-syn (10.0 
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Figure 4.12: Concentration–dependent toxicity of CsA in the presence of α-syn. 
Cells were incubated for 6, 12, 24 or 48 h with vehicle (serum-free media with 0.1 % DMSO), 
CsA (0.1 – 10.0 µM) or CsA (0.1 – 10.0 µM) with α-syn (0.1 - 30.0 µM). N = 3 for all treatments 
with cell death presented as percentage to vehicle. (A) 0.1 µM CsA: CsA alone does not cause cell 
death. CsA co-treated with α-syn (10.0 or 30.0 µM) significantly increase cells death compared to 
CsA alone. CsA and α-syn (10.0 and 30.0 µM) induced cell death did not increase with time. (B) 
1.0 µM CsA: again, CsA alone does not increase cell death. Significant cell death is only seen in 
the presence of α-Syn at 10.0 µM at 12 and 48 h time points when compared to 1.0 µM CsA alone. 
(C) 10.0 µM CsA: CsA alone increased cell death independently of α-Syn. No concentration of α-
syn studied (0.1 – 30.0 µM) effected the level of cell death observed. For graphs A and B 
significance was performed on the data ranking because data failed normality and equal variance 
tests. All significance was determined by two-way ANOVA with Student-Newman-Keuls post-
hoc test where * P < 0.05 verses 6 h (specified concentration, and black stars specifying all 
concentrations), ‡ P < 0.05 24 h verses 12 h (within specified concentration), † P < 0.05 verses 
CsA µM (within specified time point). 
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4.2.5 Induced changes in cytosolic Ca
2+
 levels. 
Calcium can be released through the opening of the mitochondrial pore similar to the 
release of cyt c, but also through the changes in the mitochondrial membrane 
potential. Furthermore, mitochondrial dysfunction can also be identified through an 
increase in cytosolic calcium (Ca2+) levels. In contrast to the cyt c ELISA, the FLIPR 
Plus Ca2+ assay is able to measure the Ca2+ concentrations within live cells using a 
cytoplasmic fluorescent dye and so therefore is not as invasive as the cytosolic cyt c 
ELISA (which requires the lysing of the cells). The lack of cell disruption involved 
in the FLIPR Plus Ca2+ assay leads to more accurate and consistent results being 
obtained. With this in mind, we employed the FLIPR Plus Ca2+ assay to elucidate α-
syn-induced intracellular effects within live cells. 
 
Cells were incubated for 6, 12, 24 or 48 h with either vehicle (serum-free media) or 
α-syn at varying concentrations (0.1 – 30.0 µM). In each case the fluorescence was 
measured at 527 nm. Lower concentrations of α-syn (0.1 and 1.0 µM) did not alter 
cytosolic Ca2+ concentrations compared to vehicle controls (figure 4.13 A and B). 
However, α-syn at 10.0 and 30.0 µM induced an increase in the concentration of 
Ca2+ (figure 4.13 C and D). α-Syn at 10.0 µM induced a significant increase in Ca2+ 
concentration at 6 and 12 h (2.4 ± 0.25 x 104 A.U. and 3.0 ± 0.12 x 104 A.U. 
respectively), which fell to concentrations comparable with the vehicle at 24 and 48 
h (figure 4.13 C). Similarly, 30.0 µM α-syn induced a significant increase in Ca2+ 
concentration at 12 and 24 h (with an increase of 3.4 ± 0.20 x 104 A.U. and 3.6 ± 
0.18 x 104 A.U. respectively). Again, the increase in Ca2+ concentration returned to 
vehicle levels by 48 h (figure 4.13 D).   
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Figure 4.13: Temporal profile of varying concentrations of α-syn on cytosolic Ca
2+
. 
α-Syn induced a concentration- and time-dependent increase in cytosolic Ca2+ measured by 
increase in fluorescence at 527 nm. Cells were treated with either vehicle (serum-free media) or α-
syn (0.1 – 30.0 µM) and fluorescence measured after 6, 12, 24 or 48 h incubation. (A) 0.1 µM α-
syn and (B) 1.0 µM α-syn: α-Syn (0.1 or 1.0 µM) did not alter the cytosolic Ca2+ concentrations 
compared to their respective vehicle control at any time point. (C) 10.0 µM α-syn: α-Syn 
significantly increased fluorescence compared to vehicle at both 6 and 12 h, where a significantly 
higher fluorescence was observed for the 12 h time point (when compared to the other time 
points). (D) α-Syn 30.0 µM: α-Syn significantly increased fluorescence at 12h and 24 h when 
compared to vehicle and the other time points. Significance performed on ranks for the data 
presented in graph B (data failed normality test). Significance was determined by two-way 
ANOVA with Student-Newman-Keuls post-hoc test where * P < 0.05 verses 24 and 48 h (within 
specified concentration), ‡ P < 0.05 verses 6 and 48 h (within specified concentration), § P < 0.05 
verses 6 h, and † P < 0.05 verses vehicle (within specified time point). 
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These data shows that α-syn causes a concentration- and time-dependent increase in 
the concentration of cytosolic Ca2+. At present, it is not clear whether this change in 
Ca2+ concentration is due to α-syn inducing the opening of the mitochondrial pore or 
causing disruption of the mitochondrial membrane potential. Interestingly, the 
pattern of Ca2+ concentration increase shown by 30.0 µM α-syn is similar to that 
suggested by the increase of cytosolic cyt c translocation by 30.0 µM α-syn (sections 
4.2.1 and 4.2.2). In both cases an increase was indicated for the 6 h time point that 
had dissipated by 48 h.  It may be the case that both Ca2+ and cyt c release into the 
cytosol is via the same mechanism. 
 
4.2.6 CsA does not prevent α-syn induced cytosolic Ca
2+
 increase. 
As we have shown previously (section 4.2.5) α-syn increases the concentration of 
cytosolic Ca2+ in a concentration- and time-dependent manner. However, the 
mechanism by which this is mediated is not currently known. It may be the case that 
α-syn is inducing mitochondrial dysfunction by opening the mitochondrial pore or by 
disrupting the mitochondrial membrane potential. To examine this further, we 
utilised the CsA-induced inhibition of the mitochondrial pore to ascertain whether 
this prevented α-syn-induced increase in cytosolic Ca2+ concentration.  
 
Cells were treated with vehicle (serum-free media with 0.1 % DMSO), 30.0 µM α-
syn alone, CsA (0.1-10.0 µM) alone or 30.0 µM α-syn with CsA (0.1-10.0 µM). 
Cells were incubated for 6, 12, 24 or 48 h and the fluorescence was measured at 527 
nm, where an increase in fluorescence represented an increase in cytosolic Ca2+ 
concentration. CsA at 0.1 µM and 1.0 µM did not alter the fluorescence compared to 
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vehicle at any time point (figure 4.14A and B). However, cells treated with both CsA 
(0.1 µM) and α-syn (30.0 µM) significantly increased fluorescence at 48 h compared 
to vehicle. This increase in fluorescence was mirrored by cells treated with α-syn 
(30.0 µM) alone, which also significantly increased fluorescence after 48 h 
incubation compared vehicle (figure 4.14 A). The addition of CsA at 10.0 µM did 
not alter fluorescence compared to α-syn (30.0 µM) alone at 6, 12 or 24 h. However, 
CsA (10.0 µM) with α-syn (30 µM) did significantly decrease fluorescence at 48 h 
(2.5 ± 0.12 x 104 A.U.) compared to vehicle and α-syn (30 µM) alone (figure 4.15 
C).  
 
Our data presented here shows that CsA at either 0.1 or 1.0 µM does not reduce the 
α-syn- (30.0 µM) mediated increase in cytosolic Ca2+ (figure 4.14 A and B). It is also 
implied that increasing CsA to 10.0 µM inhibited the α-syn-induced increase in 
cytosolic Ca2+. However, it is important to recall that CsA (10.0 µM, alone or in 
combination with α-syn), previously induced total cell death at 24 h and 48 h (figure 
4.11 and 4.12). It may therefore be assumed that the lower fluorescence observed at 
24 h and 48 h induced by CsA at 10.0 µM alone and with α-syn (30.0 µM) is due to 
cell death and not inhibition of the mitochondrial pore. Similarly, results from 
preliminary experiments suggest cells treated with bongkrekic acid, an inhibitor of 
adenine nucleotide translocase and a component of the mitochondrial pore, did not 
reduce α-syn increase in cytosolic Ca2+ (data not shown). 
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Figure 4.14: Inhibitory effect of CsA on α-syn induced increase in cytosolic Ca2+. 
Ca2+ levels were measured by fluorescence at 527 nm. Cells were treated with vehicle (serum-free media with 
0.1% DMSO), α-syn (30 µM) or CsA (0.1 - 10.0 µM) with and without α-syn (30.0 µM) and the fluorescence 
measured at 6, 12, 24 or 48 h. (A) 0.1 µM CsA: α-Syn (30.0 µM) significantly increased fluorescence at 6 
and 48 h compared to vehicle. CsA at 0.1 µM has no significant effect on the fluorescence levels compared to 
vehicle. When CsA (0.1 µM) is treated with α-syn (30 µM) the fluorescence significantly increases at 48 h 
compared to vehicle and CsA (0.1 µM) alone, but does not significantly increase compared to α-syn (30.0 
µM) alone. (B) 1.0 µM CsA: The addition of α-syn (30.0 µM) alone significantly increased fluorescence at 6 
h compared to vehicle.  Similarly, an increase at 48 h is also seen. Furthermore, the addition of 1.0 µM CsA 
did not alter the effect of α-syn induced cytosolic Ca2+ concentration.  (C) 10.0 µM CsA: α-syn fluorescence 
significantly increases at 24 h and 48 h compared to vehicle. The addition of CsA alone and in combination 
with α-syn (30.0 µM) does not significantly change fluorescence compared to vehicle at 6, 12 or 24 h, 
however the fluorescence is significantly lower than vehicle or α-syn alone at 48 h. Significance performed 
on ranks for the data presented in graphs A and C as the data failed normality test. All significance was 
determined by two-way ANOVA with Student-Newman-Keuls post-hoc test where * P < 0.05 verses 6, 12 
and 24 h (within specified concentration), ‡ P < 0.05 verses 12 h (within specified concentration), § P < 0.05 
verses 6 and 12 h, and † P < 0.05 verses vehicle and CsA (within specified time point). 
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4.2.7 Loss of mitochondrial potential induced by α-syn. 
As α-syn causes an increase in cytosolic Ca2+, which can not be blocked using 
mitochondrial pore inhibitors. To determine whether the α-syn-induced 
mitochondrila dysfunction suggested above translates into a loss of mitochondrial 
membrane potential the MitoPT assay was used. MitoPT accumulates in the 
mitochondria in an aggregated form that fluoresces red. Loss of mitochondrial 
membrane potential causes the MitoPT to dissipate through the cell in a monomeric 
form, which itself fluoresces green. Therefore, a reduction in the level of red 
fluorescence is indicative of a loss of membrane potential. 
 
Cells were treated with either vehicle (serum-free media) or α-syn (30.0 µM) and 
incubated for 6, 12, 24 or 48 h, at which point MitoPT was added. Fluorescence was 
measured at 527 nm for green fluorescence (cytosolic) and 595 nm for red 
fluorescence (mitochondrial). α-Syn (30.0 µM) induced an increase in mitochondrial, 
red fluorescence at 6 h and 12 h (126.4 ± 27.2 % and 139.1 ± 23.8 % respectively), 
which decreased with longer incubation times. α-Syn lowered the mitochondrial 
fluorescence to 92.3 ± 11.5 % at 24 h and significantly decreased fluorescence to 
60.8 ± 6.1 % at 48 h when compared to 6 h and 12 h time points. This data shows 
that α-syn induces a time-dependent loss of mitochondrial membrane potential.  
Furthermore, cytosolic fluorescence was unaltered by treatment with 30.0 µM α-syn, 
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Figure 4.15: α-Syn induced time-dependent loss of mitochondrial membrane potential. 
α-Syn induces a time-dependent loss of mitochondrial membrane potential without increasing 
apoptosis. Cells were treated with either vehicle (serum-free media) or α-syn (30.0 µM) and 
incubated for 6, 12, 24 or 48 h. Fluorescence was measured at 527 nm for green fluorescence 
(cytosolic) and 595 nm for red fluorescence (mitochondrial). The data is presented as a percentage 
of vehicle (where vehicle = 100 % for both fluorescences). α-Syn (30.0 µM) initially increased 
mitochondrial (red fluorescence) at 6 h and 12 h. However, the mitochondrial fluorescence at 24 h 
appeared to be lower and by 48 h the mitochondrial fluorescence was significantly lower 
compared to the 6 h and 12 h time points. Cytosolic (green) fluorescence was unaltered by 
treatment with α-syn (30.0 µM), showing that α-syn was not increasing apoptosis. Significance 
was determined by one-way ANOVA with Student-Newman-Keuls post-hoc test where * P < 0.05 
verses 6 and 12 h. 
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4.2.8 Summary of Section 4.2 
From our studies we have shown that α-syn causes an increase in cytosolic Ca2+ in 
SHSY-5Y cells after 12 h incubation. This observed increase is not blocked by the 
addition of the mitochondrial pore inhibitor, CsA, which would suggest the observed 
increase in Ca2+ is either via α-syn affecting the mitochondria by a different 
mechanism other than the mitochondrial pore or α-syn is causing the release of Ca2+ 
from an alternative intracellular store. From the data it may be suggested that the 
cytosolic cyt c release mirrors Ca2+ release, however, this study is inconclusive. In 
the absence of data at 12 and 24 h incubation it may be that cytosolic cyt c levels are 
not affected (section 4.2.1 and 4.2.2). To investigate the method by which cytosolic 
Ca2+ concentrations were increasing we investigated the mitochondrial membrane 
potential. Our study found that upon addition of α-syn to cell media, mitochondrial 
membrane potential was lost after 48 h incubation. This could mean that the increase 
in cytosolic Ca2+ is due to mitochondrial membrane disruption resulting in 
mitochondrial dysfunction. Mitochondrial dysfunction would, of course, help explain 
the reduction in cellular metabolic output see in section 4.1.6. The reduction in 
cytosolic Ca2+ seen after 48 h incubation may be due to the sequestering of the 
cytosolic Ca2+ by other Ca2+ stores, e.g. the endoplasmic reticulum, perhaps leaking 
out of the cells altogether (see section 4.1).  
 
The study above suggests α-syn is forming independent pores in the membrane of the 
mitochondria, a mechanism which would not be possible if the α-syn protein 
involved was in its soluble form, but has been associated to the protofibril form 
(Volles et al., 2001; Lashuel et al., 2002; Volles and Lansbury, 2002; Furukawa et 
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al., 2006; Tsigelny et al., 2007). Furthermore, the fact that Ca2+ release was not 
prevented in the presence of the mitochondrial pore inhibitor CsA would suggest α-
syn is working independently of the mitochondrial pore.   
 
4.3: α-Syn within an in vitro model of Parkinson’s disease. 
Within our previous studies (sections 4.1 and 4.2), α-syn was shown to induce a 
concentration- and time-dependent reduction in total metabolic output without 
increasing cell death. This reduction in metabolic output (section 4.1.6) was 
speculated to be through α-syn inducing mitochondrial dysfunction via loss of 
mitochondrial membrane potential, resulting in an increase in cytosolic Ca2+ and 
possibly cyt c (sections 4.2.5 and 4.2.7). 
 
4.3.1 MPP+-induced cytotoxicity. 
α-Syn has been suggested to have both detrimental and protective effects within PD 
models. From our work described previously (sections 4.1 and 4.2), these data 
suggest increasing concentrations of α-syn, though not toxic independently, could 
cause an increase level of cellular sress. To investigate whether this stress is 
detrimental to cells under pathological conditions, the response to α-syn was 
investigated in the MPP+ model of PD. Intiall experiments aimed to establish the 
toxic concentration range of MPP+ within SHSY-5Y cells, using the LDH assay 
(Section 4.1.7) 
 
SHSY-5Y cells were incubated for 48 h with either vehicle (serum-free media with 
0.1 % water) or MPP+ (1.0 – 3000 µM). MPP+ (1.0 – 1000 µM) did not induce any 
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significant cell death compared to vehicle. MPP+ at 3000 µM, however, significantly 
increased cell death to 84.4 ± 6.9 % compared to vehicle (figure 4.16).  
 
From this study MPP+ did not significantly alter cell death at concentrations lower 
than 1000 µM after 48 h incubation. However, MPP+-induced a significant increase 
in cell death between 1000 and 3000 µM, which would imply that suitable 


























Figure 4.16: MPP+-induced a concentration-dependent increase in cell death. 
Cells were treated with vehicle (serum-free media with 0.1 % water) or MPP+ (1.0 – 3000 µM) 
and incubated for 48 h. Cell death is shown as a percentage to vehicle (N = 3). MPP+  
(1.0 – 1000 µM) did not significantly increase cell death compared to vehicle, with cell death 
ranging from 0 – 11.0 ± 6.4 % respectively. MPP+ at 3000 µM significantly increased cell death to 
84.4 ± 6.9 % compared to vehicle. Significance was determined by one-way ANOVA with 
Student-Newman-Keuls post-hoc test where * P < 0.05 verses 0 µM MPP+ 
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4.3.2 Study investigating the temporal profile of MPP
+ 
toxicity. 
In order to investigate whether α-syn is detrimental or protective against cell death in 
a MPP+ model, the model would require optimisation. To this end we investigated 
the effect of varying concentrations of MPP+ on cell death over time. This allows us 
to build a MPP+ temporal profile and to establish the LD50 of MPP
+, a concentration 
optimal for monitoring any changes induced by the addition of α-syn between 12 and 
48 h. 
 
The temporal profile was established by treating cells with either vehicle (serum-free 
media with 0.1 % water) or MPP+ (1.0 – 10.0 mM) and incubated for 0, 4, 6, 12, 24 
or 48 h. MPP+ at the highest concentration (10.0 mM) induced a rapid increase in cell 
death (from 7.3 ± 6.5 % at 6 h to 97.3 ± 10.6 % at 12 h) compared to lower 
concentrations (figure 4.17). Halving the concentration of MPP+ (5.0 mM) showed a 
similar pattern of cell death, although total cell death was not reached until 24 h and 
a slower initial increase in cell death was observed. MPP+ at 3.0 mM induced a 
steady increase in cell death from 12 h (11.2 ± 1.2 %) and total cell death was only 
just achieved at the final time point of 48 h. The two lowest concentrations of MPP+ 
used in this study (1.0 mM and 2.0 mM) both showed slow, progressive cell death 
after 12 h but neither reach total cell death by 48 h (38.5 ± 3.6 % and 78.7 ± 13.1 % 






































 Figure 4.17: Temporal profile of MPP
+
.  
SHSY-5Y cells were treated with either vehicle (serum-free media with 0.1 % water) or MPP+  
(1.0 – 10.0 mM) and incubated for 0, 4, 6, 12, 24 or 48 h. N = 3 for all treatments and cell death 
was shown as a percentage to vehicle. MPP+ (10.0 mM) induced low level cell death at 6 h, 
significantly increasing at 12 h compared to earlier time points. MPP+ at 5.0 mM slowly increased 
cell death up to 12 h and then significantly increased cell death at 24 h compared to earlier time 
points. MPP+ at 3.0 mM did not significantly increase cell death before 24 h, where at 24 h and 48 
h cell death significantly increased compared to all earlier time points. MPP+ (2.0 mM) 
significantly increased cell death at 24 and 48 h compared to all earlier time points, 2.0 mM MPP+ 
unlike 3.0, 5.0 and 10.0 mM MPP+ did not induce total cell death by 48 h. 1.0 mM MPP+ induced 
low level cell death with only a significant increase in cell death at 48 h. Significance was 
determined by two-way ANOVA with Student-Newman-Keuls post-hoc test where * P < 0.05 
verse earlier time points, † P < 0.05 verse 0, 4, 6 and 12 h, ‡ P < 0.05 verse 0, 4 and 6 h. 
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From this temporal profile of MPP+-induced cell death it may be concluded 
that a concentration of 2.0 mM MPP+ would provide an LD50 at 24 h, which would 
be the optimal concentration of MPP+ to use to monitor any changes in cell death 




-induced toxicity is exacerbated by α-syn. 
In our previous studies (section 4.1 and 4.2), α-syn was implicated in inducing 
mitochondrial dysfunction by causing loss of the mitochondrial membrane potential 
in SHSY-5Y cells, but without inducing cell death. MPP+ has been shown to induce 
cell death in a concentration- and time-dependent manner (section 4.3.2). In order to 
investigate potentially detrimental effects on cell survival by α-syn, we used the 
MPP+ in vitro PD model and the LDH assay with varying concentrations of α-syn. 
 
Cells were treated with vehicle (serum-free media with 0.1%), MPP+ (0.1 – 3.0 mM) 
or MPP+ (0.1 – 3.0 mM) with α-syn (0.1 – 30.0 µM) and incubated for 24 h. Where 
either 0.1 or 1.0 mM MPP+ was treated with α-syn at < 1.0 µM no significant cell 
death was observed when compared to the MPP+ alone (figure 4.18 A and B). 
However, the addition of α-syn at 10.0 and 30.0 µM to 0.1 mM MPP+ saw a 
significant increase in cell death (23.2 ± 3.3 % and 16.7 ± 1.8 % respectively) (figure 
4.18 A). This trend was matched with the 1.0 mM MPP+ experiment but here the 
30.0 µM α-syn data was found to not be significantly higher than the MPP+ control, 
where 10.0 and 30.0 µM α-syn lead to an increase in cell death of 67.0 ± 12.5 % and 
42.6 ± 8.1 % respectively (figure 4.18 B). At 2.0 mM MPP+ only the addition of 30.0 
µM α-syn induced a significant increase in cell death to 65.2 ± 2.6 % (figure 4.18 C).  
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MPP+ (3.0 mM) alone induced 96.6 ± 4.5 % cell death, producing a ceiling effect on 
the data. Therefore, it is unsurprising that the co-treatment of α-syn (0.1 – 30.0 µM) 
with 3.0 mM MPP+ resulted in 100 % cell death for all α-syn concentrations (figure 
4.18 D).  
 
This study shows that MPP+-induced cell death, independent of MPP+ concentration, 
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Figure 4.18: MPP+-induced toxicity is exacerbated by α-syn in a concentration-dependent manner. 
Cells were treated with vehicle (serum-free media with 0.1%), MPP+ (0.1 – 3.0 mM) or MPP+  
(0.1 – 3 mM) with α-syn (0.1 – 30.0 µM) and were incubated for 24 h. Cell death is shown as a percentage to 
the vehicle control (N = 4). (A) 0.1 mM MPP+: the MPP+ control induced 8.2 ± 2.8 % cell death at 24 h. 
MPP+ co-treated with α-syn at either 0.1 or 1.0 µM did not change the of level cell death. Treating the cells 
with MPP+ and either 10.0 or 30.0 µM α-syn significantly increased MPP+-induced cell death compared to the 
MPP+ control. (B) 1.0 mM MPP+: the MPP+ control here increased cell death to 16.3 ± 2.0 % cell death. 
Again, co-treatment of MPP+ and α-syn (0.1 or 1.0 µM) did not affect the level of MPP+-induced cell death. 
Whereas, MPP+ with 10.0 µM α-syn significantly increased cell death compared to MPP+ alone. MPP+ with 
30.0 µM α-syn increased cell death, but not significantly (P = 0.093). (C) 2 mM MPP+: the MPP+ control 
induced 51.6 ± 1.3 % cell death. MPP+ co-treated with 30.0 µM α-syn significantly increased cell death 
compared to the MPP+ control. (D) 3 mM MPP+: the MPP+ control induced almost complete cell death after 
24 h; co-treatment with α-syn (0.1 – 30.0 µM) did not decrease MPP+-induced toxicity. Significance was 




4.3.4 α-Syn and MPP
+
-induced toxicity over time. 
Our previous study (section 4.3.3) showed that α-syn exacerbated MPP+-induced cell 
death in a concentration-dependent manner in SHSY-5Y cells with 24 h incubation. 
This time point coincides with earlier data (section 4.2.5) that identified an α-syn-
induced increase in cytosolic Ca2+. To further investigate the enhancement of MPP+-
induced cell death by α-syn, the incubation time was increased to 48 h as α-syn was 
shown to reduce SHSY-5Y cells total metabolic output at 48 h (section 4.1.6).   
 
Cells were treated as in the previously study, with vehicle (serum-free media with 
0.1%), MPP+ (0.1 – 2.0 mM) alone or MPP+ (0.1 – 2.0 mM) with α-syn (0.1 – 30.0 
µM) for 48 h incubation. Cells treated with α-syn (0.1 – 30.0 µM) in combination 
with MPP+ at 0.1 mM did not significantly change the level of cell death compared 
to MPP+ alone (figure 4.19A). Whereas treatment with 1.0 mM MPP+ in combination 
with either 10.0 or 30.0 µM α-syn significantly increased cell death compared MPP+ 
alone, increasing cell death to 53.7 ± 7.3 % and 45.0 ± 9.8 % respectively (figure 
4.19B). Surprisingly, 2.0 mM MPP+ treated with α-syn (1.0 – 30.0 µM) did not 
significantly increase cell death compared to MPP+ alone (figure 4.19C). However, 
10.0 and 30.0 mM α-syn, in combination with 2 mM MPP+, do increase cell death to 
show complete cell death (110.1 ± 22.3 and 103.8 ± 19.7 % respectively) though not 
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Figure 4.19: α-Syn exacerbates MPP+-induced toxicity.  
Cells were incubated for 48 h with vehicle (serum-free media with 0.1%), MPP+ (0.1 – 2.0 mM) or 
MPP+ (0.1 – 2.0 mM) with α-syn (0.1 – 30.0 µM). Cell death was presented as a percentage to the 
vehicle control (N = 3). (A) 0.1 mM MPP+: the MPP+ control induced 6.2 ± 3.9 % cell death at 48 h. 
MPP+ co-treated with α-syn (0.1 – 30.0 µM) did not level of cell death. (B) 1.0 mM MPP+: the 
MPP+ control induced 22.0 ± 1.8 % cell death at 48 h. MPP+ treated in combination with α-syn at either 
0.1 or 1.0 µM did not induce a change in cell death. Whereas α-syn at either 10.0 or 30.0 µM with 
MPP+ significantly increased cell death compared to MPP+ alone. (C) 2.0 mM MPP+: the MPP+ 
control induced 84.2 ± 2.4 % cell death at 48 h, which was not changed with co-treatment of α-syn 
(0.1 – 30.0 µM) though an increase is implied with both 10.0 or 30.0 µM α-syn, though not 
significant. Significance was determined by one-way ANOVA with Student-Newman-Keuls post-
hoc test where * P < 0.05 verses MPP+ (mM) 
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In agreement with the previous studies (section 4.3.3) these data previously 
indicate that α-syn exacerbates MPP+-induced toxicity in a concentration-dependent 
manner. However, this exacerbation did not appear to be augmented by an increase 
in incubation time (figure 4.18 and 4.19). 
 
4.3.5 Potentiation of MPP
+
-induced cell death by CsA. 
As described previously (chapter 1.3), MPP+ is a mitochondrial complex I inhibitor 
which induces mitochondrial dysfunction. Through our previous studies, 2.0 mM 
MPP+ has been shown to induce ~ 50 % cell death of SHSY-5Y cells after 24 h 
(section 4.3.2 and 4.3.3). To examine whether inhibition of the mitochondrial pore 
reduces the toxicity of MPP+ (an inhibitor of the electron transport chain), the effects 
of CsA on MPP+-induced toxicity was characterised.  
 
As previously, cells were treated with vehicle (serum-free media with 0.1 % DMSO 
and 0.1 % water), MPP+ (2.0 mM) alone or with MPP+ (2.0 mM) in combination 
with CsA (0.1 – 10.0 µM) and incubated for 6, 12, 24 or 48 h. At short incubation 
times (6 and 12 h) CsA at 0.1 and 1.0 µM in combination with 2 mM MPP+ did not 
alter cell death compared to MPP+ alone. On increasing the incubation time to 24 and 
48 h, CsA, at all concentrations (0.1 – 10.0 µM), significantly increased 2.0 mM 
MPP+-induced cell death (figure 4.20). CsA at 0.1 µM with MPP+ (2.0 mM) 
increased cell death to 26.0 ± 1.7 % at 24 h which was further increased to induce 
complete cell death at 48 h incubation (101.8 ± 8.3 %) (figure 4.20). This increase in 
cell death was amplified by CsA at 1.0 µM with MPP+ (2.0 mM) at 24 and 48 h (58.0 
± 4.9 and 143.1 ± 11.8 % respectively). CsA at 10.0 µM in combination with 2 mM 
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 Figure 4.20: Temporal profile of CsA effect on MPP
+
-induced toxicity. 
SHSY-5Y were treated with vehicle (serum-free media with 0.1 % DMSO and 0.1 % water), 
MPP+ (2.0 mM) alone or with MPP+ (2.0 mM) with CsA (0.1-10.0 µM) and incubated for 6, 12, 
24 or 48 h. Cell death was show as a percentage to vehicle control (N = 3). MPP+ (2.0 mM) 
significantly increased cell death at 48 h compared to all earlier incubation times. Co-treatment 
with CsA (0.1 µM) did not increase cell death at 6 and 12 h, but significantly increased cell death 
at 24 and 48 h compared to MPP+ alone at relevant time points. The trend in cell death was 
followed with MPP+ (2.0 mM) treated with 1.0 µM CsA, where significant increased cell death 
was seen at 24 and 48 h compared MPP+ alone and MPP+ (2.0 mM) with CsA (0.1 µM) at 
relevant time points. CsA (10.0 µM) significantly increased cell death at 12 compared to all other 
treatment and induced total cell death at 24 h. Significance was determined by two-way ANOVA 
with Student-Newman-Keuls post-hoc test where * P < 0.05 verse earlier time points, † P < 0.05 
verse MPP+ (2.0 mM). 
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MPP+ significantly increased cell death after 12 h, inducing total cell death by 24 h 
(figure 4.20). However, CsA at 10.0 µM increased cell death as expected (previously 
shown in section 4.2.3). 
 
CsA (0.1 – 10.0 µM) treated in combination with MPP+ (2.0 mM) significantly 
increased cell death in a concentration- and time-dependent manner. These results 
show the addition of mitochondrial pore inhibitor is not protective against MPP+-
induced mitochondrial dysfunction, augmenting cell death. 
 
4.3.6 α-Syn effect on CsA enhanced MPP
+
-induced toxicity. 
In the previous study CsA was shown to potentiate MPP+-induced cell death (figure 
4.20). CsA enhancement of MPP+-induced cell death could possibly be via 
increasing oxidative stress and ROS levels within the mitochondria resulting in an 
increased rate of mitochondrial dysfunction and cell death (Fall and Bennett., 1998). 
α-Syn- (30.0 µM) induced increase in cytosolic Ca2+ was shown not to be blocked by 
CsA (figure 4.14). With this in mind our data would suggest that α-syn affects 
mitochondria via another mechanism other than the mitochondrial pore (section 4.2), 
potentially by the formation of an α-syn protofibril pore, in the mitochondra 
membrane. This is supported by our data that shows α-syn caused a reduction in 
mitochondrial membrane potential (section 4.2.7). Therefore we speculate that the 
CsA effect of increasing MPP+-induced cell death may be reduced by the addition of 
α-syn, possibly through α-syn ablity to form an altenerative pore to the mitochondrial 
pore which is blocked by the CsA. 
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To examine this hypothesis cells were treated with vehicle (serum-free with 
0.1 % DMSO and 0.1 % water), MPP+ (2.0 mM) alone, MPP+ (2.0 mM)  with α-syn 
(30.0 µM), MPP+ (2.0 mM) with CsA (0.1 – 10.0 µM), or  MPP+ (2.0 mM) with  α-
syn (30.0 µM) and  CsA (0.1 – 10.0 µM) and incubated for 24 h. Cells treated with 
CsA (0.1 µM) and MPP+ (2.0 mM) did not alter cell death compared to MPP+ (2.0 
mM alone) (figure 4.21 A). Whereas co-treating with α-syn (30.0 µM), MPP+ (2.0 
mM) and CsA at 0.1 µM significantly increased cell death compared to MPP+ alone 
increasing cell death to 81.7 ± 6.5 % (figure 4.21 A). Increasing CsA to 1.0 µM in 
combination with either MPP+ (2.0 mM) alone or MPP+ (2.0 mM) with α-syn (30.0 
µM) significantly increased cell death to 90.0 ± 7.9  and 104.6 ± 9.3 % respectively 
compared MPP+ alone (figure 4.21 B). Interestingly, CsA at 1.0 µM in combination 
with α-syn and MPP+ also resulted in an increase in cell death compared to α-syn and 
MPP+, although not significantly (P = 0.077) (figure 4.21 B). As previously shown 
(section 4.3.5) increasing CsA to 10.0 µM induced total cell death when (with MPP+ 
increased cell death to 101.2 ± 7.8 % and in combination with MPP+ and α-syn 
increased cell death to 96.5 ± 4.1 % respectively) (figure 4.21 C). CsA (10.0 µM) 
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 Figure 4.21: CsA enhances MPP+ and MPP+-α-syn induced toxicity in a concentration-dependent 
manner. 
Cells were incubated for 24 h with vehicle (serum-free with 0.1 % DMSO and 0.1 % water), MPP+ (2 mM), 
MPP+ (2 mM)  with α-syn (30 µM), MPP+ (2 mM) with CsA (0.1 - 10.0 µM), or  MPP+ (2 mM) with  α-syn 
(30 µM) and  CsA (0.1 or 1.0 µM). Cell death is present as a percentage to the vehicle  
(N = 3). (A) 0.1 µM CsA: MPP+ induced ~ 50 % cell death. Co-treatment with α-syn (30 µM) increased cell 
death to ~ 68 % without significance. MPP+ (2 mM) induced cell death did not increase when co-treated with 
CsA (0.1 µM). MPP+ with α-syn and CsA significantly increased cell death compared to MPP+ alone. (B) 1.0 
µM CsA: MPP+ induced 42 % cell death. Co-treating MPP+ (2 mM) with α-syn (30 µM) increased cell death 
induced by MPP+ (2 mM) to ~70 %, though no significance determined. MPP+ (2 mM) and CsA (1.0 µM) 
significantly increased MPP+-induced cell death compared to MPP+ alone. MPP+ (2 mM) with α-syn (30 µM) 
and CsA (1.0 µM) increased cell death compared to MPP+ (2 mM) and α-syn (30 µM) though not significant 
(P = 0.077) and significantly compared to MPP+ (2 mM). (C) 10.0 µM CsA: MPP+ induced 46 % cell death 
consistent with graphs A and B. MPP+ (2 mM) with α-syn (30 µM) significantly increased cell death 
compared to MPP+ (2 mM). CsA (10.0 µM) treated with either MPP+ or MPP+ with α-syn (30 µM) 
significantly increased cell death compared to MPP+ (2 mM) and MPP+ (2 mM) with α-syn (30 µM) inducing 
complete cell death. CsA at 1.0 and 10.0 µM significantly increases MPP+ and MPP+-α-syn induced toxicity. 
Significance was determined by one-way ANOVA with Student-Newman-Keuls post-hoc test where * P < 
0.05 verse MPP+ (2 mM) and † P < 0.05 verse MPP+ (2 mM) with α-syn (30 µM). 
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From these data the addition of α-syn (30.0 µM) increases CsA and MPP+-
induced cell death compared to MPP+ alone. This shows that α-syn induced effects 
are not protective within in a PD in vitro model, but detrimental increasing cell death 
after 24 h incubation. 
 




Our previous study (section 4.3.6) identified that the addition of α-syn (30 µM) in 
combination with CsA and MPP+ and incubated for 24 h, increased cell death. 
However, our previous data (described in sections and 4.1 4.2) identified that α-syn’s 
primary effects were more pronounced after 48 h incubation. This study examined 
the effect with the incubation time extended to 48 h.  
 
Cells were treated as in the previous study with the exception of using 10 µM CsA, 
as 10 µM CsA has been previously identified to induce total cell death after 48 h 
incubation (section 4.2.3) and the incubation time was extended to 48 h.  
 
MPP+ (2 mM) incubated for 48 h increased cell death to between 85 - 89 % 
compared to MPP+ cell death at 24 h (42 – 50 %). MPP+-induced cell death is 
comparable to MPP+ (2 mM) induced cell death at 48 h, as shown previously in 
figure 4.18 and 4.20 C. Previously, it was determined that the co-treatment of α-syn 
(30 µM) potientated MPP+ (2 mM) induced cell death increasing cell death to 101.0 
± 10.4% and 93.7 ± 6.4 % (figure 4.22 A and B). Cells which were co-treated with 
MPP+ and CsA (0.1 µM) saw no change in the level of MPP+-induced cell death of 
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91.2 ± 4.0 % (figure 4.22 A). As with the 24 h incubation, CsA (0.1 µM) with MPP+ 
(2 mM) and α-syn (30 µM) at 48 h increased cell death compared to 2 mM MPP+ 
(108.2 ± 9.1 %) though not significantly (figure 4.22 A). Increasing the CsA 
concentration to 1.0 µM increased MPP+ (2 mM) cell death to 106.1 ± 8.7 %, though 
this was not significant compared to 2 mM MPP+ (figure 4.22 B). CsA (1.0 µM) with 
MPP+ (2 mM) and α-syn (30 µM) induced total cell death increasing cell death to 
108.2 ± 5.7 % compared to 2 mM MPP+, though no significance (figure 4.22 B). 
CsA (1.0 µM) potentiation of MPP+ cell death is consistent with figure 4.21, where 
CsA (1.0 µM) was shown to significantly increase MPP+ cell death at 24 and 48 h. 
Furthermore, in figure 4.21B CsA (1.0 µM) was shown to significantly increase 
MPP+ and α-syn (30 µM) after 24 incubation. CsA shows no protection against 
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Figure 4.22: CsA increases MPP+-induced toxicity in a concentration-dependent manner.  
Cells were treated with vehicle (serum-free with 0.1 % DMSO and 0.1 % water), 2 mM MPP+ 
(light blue bars), 2 mM MPP+ with 30 µM α-syn (dark green bars), 2 mM MPP+ with 0.1 or 1.0 
µM CsA (dark red bars), or 2 mM MPP+ with 30 µM α-syn or 0.1, 1.0 µM CsA (dark blue bars) 
for 48 h. N = 3 for all treatment and cell death is presented as a percentage of the vehicle.  
(A) 0.1 µM CsA: MPP+-induced ~ 89 % cell death. MPP+ with CsA (0.1 µM) did not increase or 
decrease cell death. MPP+ (2 mM) co-treated with α-syn (30 µM) or α-syn (30 µM) with CsA (0.1 
µM) increase cell death inducing total cell death, though not significant. (B) 1.0 µM CsA: MPP+ 
induced ~ 85 % cell death. Co-treatment with α-syn indicates an increased cell death, without 
significance. MPP+ with CsA (1.0 µM) increased cell death compared to MPP+ and compared to 
MPP+ with α-syn though no significance. MPP+ (2 mM) with α-syn (30 µM) and CsA (1.0 µM) 
increased % of cell death higher compared other treatments, inducing complete cell death. 
Though no significance was determined, the results imply CsA increases MPP+ and MPP+ with  
α-syn induced toxicity in a concentration dependent manner.  
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4.3.8 α-Syn induced increase in cytosolic Ca
2+
 is independent of MPP
+
. 
From our previous studies, we have shown that α-syn decreases SHSY-5Y cells total 
metabolic out, possibly by disrupting the mitochondrial membrane potential resulting 
in an increase in cytosolic Ca2+ (section 4.2).  Though α-syn does not induce cell 
death (figure 4.8), when applied to our MPP+ in vitro PD model, α-syn augments 
MPP+-induced cell death. At this point it is important to remember that MPP+, a 
mitochondrial complex I inhibitor, induces cell death by causing mitochondrial 
dysfunction by inhibiting the production of ATP and increasing oxidative stress and 
ROS within cells. The previous studies have identified that α-syn induced 
mitochondrial dysfunction is independent of the mitochondrial pore (section 4.2) and 
speculate that α-syn induced mitochondrial dysfunction is also via a different 
mechanism than that induced by MPP+. To examine this hypothesis, the FLIPR Plus 
Ca2+ assay (section 4.2.5) was utilised to monitor the effect of MPP+ with and 
without α-syn on cytosolic Ca2+ levels. An increase of cytosolic Ca2+ levels by MPP+ 
alone would be an indication that MPP+ and α-syn may induce mitochondrial 
dysfunction by similar mechanisms. 
 
For this experiment, cells were treated with vehicle (serum-free with 0.1 % DMSO 
and 0.1 % water), MPP+ (2.0 mM), MPP+ (2.0 mM)  with α-syn (30.0 µM), MPP+ 
(2.0 mM) with CsA (0.1 µM), or  MPP+ (2.0 mM) with  α-syn (30.0 µM) and  CsA 
(0.1 µM). Fluorescence was measured at 527 nm after 24 h incubation of treatments 
with an increase in fluorescence indicating an increase in cytosolic Ca2+. Cells 
treated with either MPP+ (2.0 mM) alone or  MPP+ (2.0 mM) with CsA (0.1 µM) had 
no significant on fluorescence (1.8 ± 0.04 x 104 and 1.9 ± 0.05 x 104 A.U. 
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respectively) compared to the vehicle control (figure 4.23). Whereas cells treated 
with either α-syn (30.0 µM) with MPP+ (2.0 mM) or CsA (0.1 µM) with MPP+ (2.0 
mM) and α-syn (30.0 µM) fluorescence was significantly increased (2.1 ± 0.08 x 104 
and  2.0 ± 0.06 x 104 A.U.) compared to MPP+ (2.0 mM) alone (figure 4.23). 
 
From these data, MPP+ alone or in combination with CsA had no significant effect 
on cytosolic Ca2+ levels, whereas, the addition of α-syn significantly increased 
cytosolic Ca2+ which were not reduced by CsA, mitochondrial pore inhibitor. This 
shows α-syn and MPP+-induced mitochondrial dysfunction are through different 
mechanisms, which are both independent of the mitochondrial pore, with α-syn 
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Figure 4.23: α-Syn increased cytosolic Ca2+ is independent of MPP+.  
Cells were treated for 24 h with vehicle (serum-free with 0.1 % DMSO and 0.1 % water), MPP+ 
(2 mM), MPP+ (2 mM)  with α-syn (30 µM), MPP+ (2 mM) with CsA (0.1 µM), or  MPP+ (2 mM) 
with  α-syn (30 µM) and  CsA (0.1 µM). For all treatments, fluorescence at 527 nm was taken at 
24 h (N = 6). Increase in fluorescence shows an increase in cytosolic Ca2+. Vehicle fluorescence 
averaged 1.9 ± 0.01 x 104 A.U. MPP+ (2 mM) decreased fluorescence to 1.8 ± 0.04 x 104 A.U. 
compared to vehicle but not significantly. MPP+ with CsA (0.1 µM) increased MPP+ fluorescence 
to similar level to vehicle, though not significantly. α-Syn (30 µM) treated with MPP+ (2 mM) 
significantly increased fluorescence compared to MPP+ (2 mM), though significance was not 
tested MPP+ (2 mM) with α-syn (30 µM) increased fluorescence compared vehicle with P = 
0.041. MPP+ (2 mM) with CsA (0.1 µM) and α-syn (30 µM) increased fluorescence compared to 
vehicle and MPP+ (2 mM) with CsA (0.1 µM), significantly increasing fluorescence compared to 
MPP+ (2 mM). MPP+ (2 mM) does not increase cytosolic Ca2+ levels, co-treating with α-syn (30 
µM) significantly increased cytosolic Ca2+ which was not blocked by CsA (0.1 µM). Significance 
was determined by one-way ANOVA with Student-Newman-Keuls post-hoc test where * P < 
0.05 verses MPP+ (2 mM). 
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4.3.9 Summary of Section 4.3 
The study reported in this chapter has described our success at establishing an in 
vitro PD model utilising the mitochondrial complex I inhibitor MPP+. This MPP+ in 
vitro PD model allowed us to investigate the effects of α-syn on mitochondrial 
dysfunction in human neuroblastoma cells (SHSY-5Y) and to elucidate the potential 
role of α-syn in PD disease progression.  
 
Using our MPP+ PD model we show that the addition of α-syn alone does not cause 
cell death through mitochondrial dysfunction (also seen previously in section 4.1) but 
when added with MPP+, enhanced the MPP+-induced toxicity in a concentration-
dependent manner. The addition of MPP+ alone causes the mitochondrial pores to 
open.  To investigate whether the closing of the mitochondrial pores in the presence 
of MPP+ would offer protection from mitochondrial dysfunction we added the 
mitochondrial pore inhibitor CsA along with MPP+. Surprisingly, the inhibition of 
the mitochondrial pores by CsA did not reduce the level of MPP+-induced cell death, 
but in fact increased it in a concentration-dependent manner. Our previous 
experiments have shown that it may be possible that α-syn forms protofibril pores in 
the mitochondrial membrane independent of the mitochondrial pores (section 4.2). 
Therefore, it may be assumed that the addition of α-syn could replace the pores 
inhibited by CsA and therefore reduce the level of cell death to similar levels seen in 
the presence of MPP+ alone. However, the addition of α-syn in the presence of both 
CsA and MPP+ led to a further increase in cell death. This result would suggest that 
MPP+, CsA and α-syn all induce mitochondrial dysfunction by separate pathways.   
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To confirm that the mechanism of mitochondrial dysfunction by α-syn is 
independent of MPP+ we investigated the concentration of cytosolic Ca2+ with the 
addition of CsA, both in the presence and absence of α-syn, in our MPP+ model. Our 
results show that MPP+ alone did not affect the concentration of cytosolic Ca2+. The 
addition of α-syn, however, saw a significant increase in cytosolic Ca2+, an effect not 
inhibited by the addition of CsA. This result seems to confirm our belief that the 
mechanism of mitochondrial dysfunction by α-syn is different to that of MPP+.  
Furthermore, we have identified that α-syn does not have any protective effects 
against mitochondrial dysfunction, counter to the suggestions of other reports 




Chapter 5: Discussion and conclusion. 
The identification of α-syn as a major component of LBs, LNs and the identification 
of PD-associated mutations within the α-syn gene (discussed in section 1.2.1.1 and 
1.2.4), has led to the implication of the involvement of α-syn in the progression of 
PD and other neurodegenerative disorders. There are two differing theories on the 
role of α-syn in PD that α-syn may be directly involved in the cellular degradation 
process, or may merely be epiphenomenal with no role in disease progression 
(Manning-Boğ et al., 2003; Klivenyi et al., 2005; Quilty et al., 2006; Zhou et al., 
2006). 
 
PD is a progressive neurological disorder affecting 1 in 500 people 
(www.parkinsons.org.uk). While the majority of patients present with idiopathic PD, 
5 – 10 % of PD patients have a family history of a neurodegenerative disorder 
(Cordato and Chan, 2004; Gandhi and Wood, 2005). Regardless of idopathic or 
familial, there is a progressive loss of dopaminergic neurones, accumulation of LBs 
and LNs in the brain (especially in the  SN, LC and hypothalamus), with symptoms 
developing after approximately 50 % of the dopaminergic neurones are lost 
(especially within the SN, hypothalamus, LC, cerebral cortex and olfactory bulb) 
(section 1.2.1and 1.2.1.1) (Lowe et al., 1988; Cornford et al., 1995; Spillantini et al., 
1997; Mezey et al., 1998; Zhang et al., 2000; Wood-Kaczmar et al., 2006). 
 
α-Syn protein is found primarily in the aggregated state in LB leading to the 
hypothesis that it is the aggregated form of α-syn that is involved in causing PD-
associated toxicity (El-Agnaf et al., 1998). However, a number of alternative theories 
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have since been suggested. The fibril formation of α-syn could potentially be 
protective by sequestering a potentially toxic intermediate (protofibril) form of α-syn 
(Conway et al., 2000a). Integral to this theory is the concept that the protofibril form 
of α-syn is the pathogenic entity. Evidence for a toxic intermediate is suggested by 
studies correlating the aggregation rates of the mutant forms of α-syn with their 
toxicity. The A30P mutation form protofibrils quicker than WT α-syn (Narhi et al., 
1999; Greenbaum et al., 2005), although full aggregation appears to be at the same 
rate (i.e. A30P promotes the formation of protofibrils). In contrast, A53T α-syn has 
been shown to result in a more rapid formation of full fibrils. Rapid aggregation 
removes α-syn from the cellular system, one concequence of which is to increase α-
syn expression, inducing further aggregation and potentally the presence of 
protofibrils (Conway et al., 1998). Triplication of the α-syn gene increases α-syn 
protein expression (Miller et al., 2004) and has been linked to early-onset PD (Farrer 
et al., 2004; Singleton et al., 2004) as increased concentration of α-syn promotes 
aggregation, this further links the process of α-syn aggregation to PD progression 
(section 1.1.2.1 and 1.2.4) (Singleton et al., 2003; Farrer et al., 2004; Singleton et al., 
2004). α-Syn has the potential to self-aggregate, with the rate of aggregation rate 
potentiated by a number of environmental factors, such as heavy metals (Paik et al., 
1999), neurotoxins (the MPTP metabolite MPP+) (Kalivendi et al., 2004), as well as 
cellular components such as cyt c (Hashimoto et al.,1999) and DA (Cappai et al., 
2005). This has led to the hypothesis that the aggregated or protofibril forms of α-syn 
are the toxic forms of α-syn suggesting that the aggregation process of α-syn is an 
important component in the progression of PD, rather than the soluble form of α-syn 
(Ding et al., 2002; Lashuel et al., 2002; Volles et al., 2002; Tsigelny et al., 2007). In 
 240 
contrast, soluble α-syn has also been implicated as being toxic and inducing cell 
death through the use of inducable over-expression of α-syn in cell cultures (Iwata et 
al., 2001; Oluwatosin-Chigbu et al., 2003). Although toxicity of soluble α-syn has 
been suggested other reports show it to be protective. One potential protective 
mechanism may be the reduction of oxidative stress and inactivation of apoptotic 
agents (JNK) by interaction with JIP-1b/IB1 (Hashimoto et al., 2002). α-Syn has 
been shown to be up-regulated in response to increased oxidative stress, increasing 
cell survival (da Costa et al., 2000; Quilty et al 2006). From this evidence it could be 
suggested that α-syn plays a protective role under normal conditions, but under 
pathological conditions (excessive oxidative stress or breakdown of cellular process 
such as UPS) α-syn becomes toxic. By investigating the physiological effects of α-
syn in normal and PD-like conditions, we sought to elucidate α-syn role further.  
 
5.1 Chapter 3 discussion. 
The physiological effects of α-syn in a human neuroblastoma cell line were 
examined using exogenously applied α-syn. Exogenous application of α-syn has a 
number of advantages over an over-expressing system. For example, the duration of 
exposure of cells to α-syn protein is known and can be easily adapted. The 
aggregation state of α-syn protein can also be determined prior to application and 
concnentration also titrated. To establish such an approch a protocol to generate 
recombinant synuclein proteins had to be established. Within chapter three, initial 
experiments designed, established and validated a recombinant protein expression 
system for the generation of α-syn. The production of the recombinant α-syn protein 
was initially tested using the pRK172 vector. However within this system the 
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expression of the synuclein proteins (α-syn, A53T α-syn and β-syn) showed varying 
levels of expression, with both α-syn and A53T α-syn failing to generate suitable 
levels of recombinant protein (section 3.1). We showed that the synuclein genes were 
present within the plasmids and examined whether altering the media would induce 
expression. The growth media was changed from LB broth to peptone media to 
reduce the glucose source and increase the lag-phase of the growth cycle of BL21 
(DE3) cells, promoting protein expression. This did not, however, induce expression 
for α-syn, but did cause a reduction in the total level of proteins within the expression 
cultures. However for A53T α-syn expression cultures, low level expression was 
observed and confirmed by western blot. These results suggest that the varying 
expression between the synuclein plasmids (specifically α-syn plasmid) was more 
likely to be due to a problem within the pRK172 vector that effecting the induction 
of the target gene prior to protein expression.  
 
In an attempt to induce α-syn expression we transformed the original sample of α-syn 
plasmid (gifted from Prof. Buchman) directly into BL21 (DE3) expression cells. 
Upon induction of expression, α-syn protien generation was observed. This 
suggested that the amplification of the α-syn plasmid, by DH5α cells, inducing an 
alteration in the α-syn plasmid preventing the induction of α-syn expression.  
 
However, analysis showed that continuous use of the BL21 cells transformed with 
the original α-syn plasmid, decreased expression over time (section 3.4, table 3.1). 
We showed that the decline in expression was due to the BL21 (DE3) cells rejecting 
the plasmids containing the α-syn gene, as there was a decrease in the intensity of the 
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amount of α-syn gene without a similar reduction in the band intensity for pRK172 
vector (section 3.4.2). This result shows that the BL21 (DE3) cells were selecting the 
smaller empty plasmid over the α-syn containing plasmid.  
 
An attempt to increase the α-syn plasmid in propagating cells resulted in increasing 
the pRK172 vector without α-syn gene (section 3.5.2). Therefore, we decided to 
remove the α-syn gene from the pRK172 vector and re-insert it into a commercial 
vector (pET-22b(+) from Novagen). The commercial vector was selected over re-
using the pRK172 vector as the pRK172 is a relatively unknown expression vector 
(originally derived from the pAR3038 expression vector (Mcleod et al., 1987)). 
While the pRK172 vector is commonly used in synuclein expression systems 
(Goedert and Jakes, 1990; Jakes et al., 1994; Giasson et al., 1999), our problems 
imply that the pRK172 expression vector we are using may not be the same as the 
original pRK172 vector as the full sequence of pRK172 has not been published, we 
can not confirm the degree of alteration. 
 
The pET-22b(+) commercial vector was selected to replace the pRK172 vector for a 
number of reasons (table 3.2), but principally because the vector is designed to 
reduce pre-induction expression leakage, and allows the option of tagging the target 
protein. As for many commercial vectors a full DNA and restriction site map is 
available (figure 3.14). The pET-22b(+) vector is designed to reduce toxicity induced 
by toxic proteins by reducing leaky expression (Novagen pET Ststem Manual 
(TB055, 11th Edition)). This was important as we suspected the inherent protein 
expression (not related to deliberate experimental induction of expression) caused 
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toxicity within E.coli cells. We subsequently showed this to be the case as the newly 
constructed α-syn plasmid showed a reduction in α-syn yield in overnight cultures 
inoculations compared to single colony inoculation (section 3.6.2).  
 
Confirmation of the corruption of the pRK172 plasmid (possibly from the insertion 
and removal of gene inserts over time) was shown by our ligation studies. The 
restriction sites used to remove the α-syn gene from the plasmid did not cut 
effectively, though a number of methods were used to optimise the restriction digests 
(section 3.5), and prevented the ligation of the α-syn gene into the pET-22b(+) 
vector. This was resolved by using PCR with specifically designed primers that 
integrated new restriction sites into the terminals of the α-syn genes and amplified 
the α-syn gene removing the old restriction sites and any additional nucleotides 
around the α-syn gene when in the pRK172 vector. The α-syn gene was then 
successfully ligated into the pET-22b(+) vector. The new α-syn pET-22b(+) plasmid 
showed increased expression and α-syn protein yield compared the original α-syn 
pRK172 plasmid that was maintained with subsequent expression cultures. 
 
There are a number of purification protocols in the literature that produce varying 
quantities of pure recombinant α-syn ranging from 1 mg/L (Choi et al., 2002) to 80 
mg/L (Huang et al., 2005). Our purification protocols for β-syn, α-syn and A53T α-
syn were established by adapting previously published methods (Goedert and Jakes, 
1990; Jakes et al., 1994; Giasson et al., 1999). The expression cultures were induced 
for 4 – 5 h before harvesting the cells. The purification of the synuclein protein was 
divided into two main steps, extraction and anion exchange chromatography. 
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Synuclein protein was extracted by lysing the harvested cells (using a high salt lysis 
buffer) before heat treating. Synuclein proteins are heat resistant and are not 
denatured by the heat treatment and remain in the supernatant (Weinreb et al., 1996; 
Kim et al., 2000). The heat treatment was shown to significantly reduce the 
contaminants from the synuclein samples compared to whole cell lysate (section 
3.2.2, figure 3.6). The supernatant containing synuclein was dialysed into 
equilibration buffer (0.02M Tris pH 8.2) and the synuclein protein was isolated via 
anion exchange chromatography. The subsequently isolated α-syn was shown to be 
of a purity that could be used within future in vitro experiments by way of SDS-
PAGE (or NuPAGE) gel and mass spectrometry (through our collaboration with Dr 
D Short) analysis (figure 3.30).  
 
This protocol was shown to be consistent and could be utilised for purification of all 
the synuclein proteins. The protocol was also scaled up to deal with increased protein 
yield produced by scaling up α-syn expression from 2 L cultures to 10 L cultures 
grown by fermentation (through our collaboration with Dr J. White within the 
Edinburgh Protein Interaction Centre).  
 
Initially, purification protocols were established using recombinant β-syn protein. 
This was because the purification protocols were established at the same time as the 
issues with α-syn expression were being resolved. Initially a mono-Q anion exchange 
column was used for the fine purification. Although β-syn protein was primarily 
eluted into 2 fractions, a lot of β-syn was lost in contaminated fractions either side of 
those collected. By changing to a HiTrap Q HP column, a stronger anion exchange 
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column compared to mono-Q, and adding of a 20 % NaCl step prior to the gradient 
increase, we were able to elute the β-syn protein into fewer fractions with no 
contaminating bands (section 3.3.1 and 3.3.2). The HiTrap Q HP column and adapted 
protocol were used for the purification of α-syn and was scaled up (increasing 
column size and flow rate) at all stages to ensure maximum yield and purification of 
α-syn when α-syn expressions culture size was increased. With the plasmid 
reconstruction (using the pET-22b(+) expression vector) and the increase in culture 
volume we successfully increased our yield of purified recombinant α-syn from 2 
mg/L to 10 mg/L.  
 
The purification could have been done, as mentioned previously, by a number of 
different methods such as using a GST-tag to increase the efficiency of the 
purification procedure of the recombinant α-syn protein. However, the GST-tag 
reduces the α-syn expression level in comparison to other methods including our 
own, without significantly increasing the purity of the target protein (Choi et al., 
2002). Alternatively, we could have used the purification protocol described by 
Huang et al. (2005), which increased the yield of purified α-syn to 80 mg/L (Huang 
et al., 2005). The difference between our purification protocols and that of Huang et 
al. (2005) was they used osmotic shock to extract the α-syn protein expressed within 
the cells, rather than high salt lysis buffer and heat treatment utilised within our own 
study. After the extraction of the target protein from the cells, α-syn protein was 
purified by chromatography using a Sepharose Q column and NaCl gradient, which 
is very similar to our own protocol. Extraction of the protein by osmotic shock uses 
low temperatures and a high sucrose concentration to release the target protein from 
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the cells. However, although the protocol of Huang et al. (2005) increased the yield 
of protein per culture run, this may simply be due to the use of an alternative 
expression vector (pET-3a expression vector), rather than their use of osmotic shock. 
It is unlikely that the increased expression levels seen in Huang et al. are due to the 
protocol as the only difference between the protocols is the lysis of the cells (as 
described above) therefore, it is more likely the increase in yeild is through their use 
of an alternative expression vector (pET-3a). We found that to reduce the toxicity 
induced by the α-syn gene and expression of the protein, using the pET-22b(+) vector 
minimised α-syn effects and led to a constant expression between cultures, ensuring 
a stable plasmid that could be used in a number of cell lines. Though our expression 
levels are lower compared to Huang, the expression and protein yield is comparable 
with the more conventional protocols used which generally produced 5 to 10 mg/L 
(Goedert and Jakes, 1990; Jakes et al., 1994; Giasson et al., 1999; Kloepper et al., 
2006). Through our collaboration with Dr J. White (within the EPIC) we successfully 
increased our initial yield from 2 mg/L to approximately 10 mg/L upon scaling up 
the process to 10 L fermentation. 
 
5.2 Chapter 4 dissucsion. 
5.2.1 Section 4.1. 
Our studies reported in chapter four of this thesis details our investigation into the 
effects of α-syn on cellular mechanisms in an in vitro system. We utilised the MTS 
assay (measures the total metabolic output of cells) as a method of measuring cell 
viability validated by control experiments using STS, a bacterial toxin. These studies 
showed the expected concentration- and time-dependent cell death in SHSY-5Y cells 
 247 
(see section 4.1.5) Previous resports have shown similar toxicity in vitro (Koh et al., 
1995; Boix et al., 1997; Posmantur et al., 1997; Ha et al., 2004). We showed STS 
induced 50 % cell death at 1.0 µM after 5 h incubation and using this concentration, 
cell death was shown to increase with incubation time (section 4.1.5, figure 4.5 and 
4.6) This was also consistent with the results obtained by other members of our 
research group and through the literature (Boix et al., 1997; Ha et al., 2004; Koh et 
al., 1995; Posmantur et al., 1997). This showed that consistent results can be 
generated using the MTS assay and SHSY-5Y cells.   
 
Using the MTS assay, we showed that α-syn and A53T α-syn (0.1 – 10.0 µM), in 
soluble or aggregated form, had no significant effect on the total metabolic output of 
SHSY-5Y cells after 24 h incubation with either in-house or commercially produced 
recombinant α-syn protein. A small (non-significant) decrease in the MTS assay with 
24 h incubation of either soluble or aggregated α-syn suggested that subjecting the 
cells to an increase insult could induce a more significant loss in total metabolic 
output.  
 
Increasing the incubation duration to 48 h and widening the concentration range of 
soluble α-syn (0.01 – 30.0 µM), α-syn (10 and 30 µM) was shown to induce a 
significant decrease in the total metabolic output of SHSY-5Y cells. This showed 
that α-syn induced a concentration- and time-dependent effect in SHSY-5Y cells.  
 
Increased aggregation has been shown to occur with increased concentration and 
length of incubation. A study by Chen et al., (2007) has shown that aggregation of α-
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syn occurs within 12 h of incubation of high concentrations of α-syn (69.2 µM 
upwards) at 37 oC with continuous agitation (Chen et al., 2007). Full α-syn fibril 
formation occurs within 7 days of incubation at 37 oC (with or without agitation) as 
has been demonstrated in a number of studies (El-Agnaf et al., 1998; Miake et al., 
2002; Zhang et al., 2005). With this in mind, the observed reduction in metabolic 
output induced by α-syn (10.0 and 30.0 µM) after 48 h incubation could be suggested 
to be due to the generation of α-syn either fibrils or protofibrils within the cells. Our 
data argues that protofibrils are more likely responsible as soluble α-syn (10.0 µM) 
after 48 h incubation induced a decrease in metabolic output that was not reflected by 
aggregated α-syn (10.0 µM) after 24 h incubation. Although different incubations 
times were used, if the aggregated form was toxic, it would be anticipated that 
aggregated α-syn (10.0 µM) would induce a decrease in metabolic output with a 
shorter incubation (as the aggregation of soluble α-syn occurs relatively slowly, see 
above). However the lack of effect with aggregated α-syn could be due to a slower 
uptake into cells of aggregated α-syn (fibrils) compared to soluble α-syn. This not 
only has been shown not to be the case, but aggregated α-syn is taken up at a greater 
rate than soluble α-syn (Sung et al., 2001; Fortin et al., 2005). By observing this 
metabolic effect only with soluble α-syn only after prolonged incubation and not 
with aggregated α-syn, our data would suggest that the intermediary form, the 
protofibrils, maybe the cause.    
 
The observed decrease in metabolic output induced by α-syn should imply an 
increase in cell death. However, α-syn (0.1 – 30.0 µM) did not induce cell death at 
either 24 h or 48 h as determined by the LDH assay. This demonstrates that neither 
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soluble nor aggregated α-syn are inherently toxic. It also suggests that the decrease in 
total metabolic output, from the previous studies, are not due to cell death, but a 
reduction in metabolism (production of NAD(P)H) within cells and could be 
indicative of mitochondrial dysfunction. 
 
There are a number of further reasons as to why the protofibril form of α-syn, rather 
than the soluble form, maybe responsible for the decrease in metabolism. The 
addition of an oligomer form of α-syn (protofibril) at a low concentration (0.125 and 
0.25 µM) caused a reduction in the level of MTT activity (another marker of 
metabolism) after 3 h incubation (Chen et al., 2007). This effect is considerably more 
rapid than observed with soluble α-syn. Importantly the lower toxic concnetration 
suggests that the conversion of only a small amount of the soluble α-syn in our 
studies (10 – 30 µM) would be enough to observe a response. Secondly, the 
reduction of total metabolic output is concentration- and time-dependent, where 
increasing the concentration of α-syn results in a greater reduction in total metabolic 
output (see section 4.1). An effect linking the increased rate of aggregation with 
increased α-syn concentration. This hypothesis supported by the identification 
doubling α-syn expression (in family with a triplication of the α-syn gene) leads to an 
autosomal dominant form of PD (Singleton et al., 2003; Farrer et al., 2004; Miller et 
al., 2004). Miller et al. (2004) suggested that the doubling of expression promoted 
aggregation of all forms (including both fibrils and protofibrils) leading to a 
concentration dependent phenomenon, agreeing with the data reported in this thesis.  
 
 250 
Our data is consistent with a number of studies which also show α-syn is not 
inherently toxic (da Costa et al., 2000; Rathke-Hartlieb et al., 2001; Quilty et al 
2006). Many of the studies imply that toxicity of α-syn is dependent on the 
aggregation state of the protein through the use of ‘aged’ or aggregated α-syn on 
dopamaniergic cells line (e.g. SHSY-5Y or MES cells) and using the MTT and 
immunostaining to assess α-syn effects (El-Agnaf et al., 1998; Chen et al., 2007). 
This is indicative with our own data with the varying effects between the soluble and 
aggregated α-syn. This was also observed in studies using α-syn over-expression, 
where there was no effect on cell viability, but was an increae in mitochondrial 
dysfunction that correlated with expression levels (as ascertaind using the MTT 
assay) (Kanda et al., 2000; Iwata et al., 2001) (see section 4.1). In conclusion, α-syn 
did reduce total metabolic output of SHSY-5Y cells (see section 4.1), without 
causing cells death in, and this physiological effect was most likely atiributable to the 
protofibril form. 
 
5.2.2 Section 4.2. 
From the results presented in chapter 4 of this thesis, we have suggested that α-syn 
effects mitochondrial function by causing the release of cyt c and Ca2+ from 
mitochondria leading to mitochondrial dysfunction in SHSY-5Y cells, which cannot 
be blocked by using a mitochondrial pore inhibitor (CsA). This would suggest that 
either α-syn affects the mitochondria by a mechanism other than the mitochondrial 
pore, or induces the release of Ca2+ from an alternative intracellular store. We 
showed that α-syn induced a loss in mitochondrial membrane potential, impling that 
the increase in cytosolic cyt c and Ca2+ is through α-syn-induced mitochondrial 
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membrane disruption. This disruption to the mitochondria could explain the 
reduction in metabolic output of the cells discussed in the previous section. Diruption 
of the mitochondrial membrane would lead to the dyfunction of the E.T.C and 
therfore a decrease in the NAD(P)H, which was shown through the reduction in total 
metabolic output of SHSY-5Y cells and is indication of mitochondrial dysfunction 
(section 4.1.6). 
 
We showed that α-syn (30 µM) caused an increase in cytosolic cyt c after 6 h 
incubation which decreased after 48 h incubation. The α-syn induced cyt c increase 
was significantly reduced by co-treatment with the mitochondrial pore inhibitor CsA 
(10 µM). This implies that α-syn increase in cytosolic cyt c is linked to the 
mitochondrial pore. However, CsA significantly reduced cytosolic cyt c compared to 
the vehicle control independent of α-syn. The apparent mediated effect may simply 
be due to the presence of CsA. 
 
Investigation into the effects of CsA on cell viability using the LDH assay showed a 
concentration- and time-dependent induction of cell death. This cells death was 
independent of the presence of α-syn (with CsA at 10 µM). Lower concentration of 
CsA (0.1 – 1.0 µM) did not increase cells death and could still be justifiably used as 
a mitochondrial pore inhibitor at these concentrations. The experiment confirmed 
that the effect of α-syn in the presence of CsA above was almost certainly due to the 
toxicity of the pore inhibition. 
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To futher investigate α-syn induced mitochondial disruption we switched 
from using the cyt c ELISA to use the FLIPR Plus Ca2+ assay. Like cyt c, Ca2+ can be 
regulated by the mitochondria either via mitochondrial pores or disruption 
mitochondrial membrane (Albert et al., 1994; Gunter et al., 2000; Smaili et al., 2000; 
Smaili et al., 2003). Although cytosolic Ca2+ is regulated by a large number of 
mechanisms (e.g. intracellular stores, NMDA receptors (Albert et al., 1994; Rizzuto, 
2001)), changes in levels could also be indicative of mitochondrial disruption. This 
means that cytosolic Ca2+ could be used to identify mitochondrial dysfunction. As 
the cyt c ELISA used cell lysate, it could not identify subtle changes within the 
concentration of cytosolic cyt c. The Ca2+ assay used a cytoplasmic dye (Molecular 
Devices Limited) used in live cells, allowing a more sensitive measure that could 
take readings overtime. By using the Ca2+ assay we showed that α-syn caused 
concentration- and time-dependent increase in cytosolic Ca2+. α-Syn (30 µM) 
increase cytosolic Ca2+ after 6 h incubation. α-Syn (30 µM) significantly increased 
cytosolic Ca2+ at 12 and 24 h before decreasing after 48 h incubation. The decrease 
in cytosolic Ca2+ could be due to alternative Ca2+ stores sequestering the 
mitochondrial released Ca2+ or the Ca2+ could be being release from the cells. The 
decrease is similar to the decrease in cytosolic cyt c observed by ELISA after 48 h 
incubation with α-syn (30 µM). This would suggest that α-syn induces a similar 
release of cyt c and Ca2+ into the cytosol, and implies that they are released by the 
same mechanism.   
 
As cyt c ELISA data was inconclusive on whether α-syn release of cyt c was through 
a mechanism which involved the mitochondrial pores, CsA was used in combination 
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with α-syn and the Ca2+ assay. As CsA had no effect on α-syn induced increase in 
cytosolic Ca2+, the α-syn effect on cytosolic Ca2+ is independent of CsA-sensitive 
mitochondrial pores. This means that α-syn increase in cytosolic Ca2+ is either by an 
alternative mechanism involving the mitochondria or from an alternative Ca2+ store. 
 
α-Syn has been shown in a number of studies to form protofibril pores and has been 
implicated as the possible toxic form of α-syn. The protofibrils have been suggested 
to have the ability to permeablise cellular membranes in a similar manner to some 
bacterial toxins or detergents, by forming large pores within the membranes and 
disrupting membrane potential (Tanaka et al., 2001; Ding et al., 2002; Orth et al., 
2003; Furukawa et al., 2006). The pores are thought to be non-selective and allow 
the passage of cations (Furukawa et al., 2006; Tsigelny et al., 2007). It is also 
interesting to note that a study has shown that cyt c attenuates α-syn aggregation and 
promotes α-syn protofibril formation (Hashimoto et al.,1999). This suggests a 
mechanism by which α-syn could increase cytosolic cyt c and Ca2+ as seen in this 
thesis and that the release of cyt c could further promote protofibril formation and 
perpetuate the α-syn effect. 
 
To investigate if α-syn-induced release of cyt c and Ca2+ was due to mitochondria 
membrane dysfunction we established an assay to monitor the mitochondria 
membrane potential. Using this approach we showed that α-syn (30 µM) caused the 
loss of mitochondrial membrane potential over-time, with a significant decrease 
observed after 48 h incubation with α-syn. This correlates with the decrease in total 
metabolic output of SHSY-5Y cells seen previously (section 4.1.6).  
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From our observations we showed that soluble α-syn once taken up into the 
cells induces mitochondrial dysfunction causing a loss of membrane poteintal and an 
in flux of Ca2+ and cyt c in to the cytosol. We have also suggested that it is the 
formation of protofibrils, forming independent pores in the membrane of the 
mitochondria that is most likely responsible.  
 
5.2.3 Section 4.3. 
A number of in vitro PD studies have utilised the mitochondrial complex 1 inhibitor 
MPP+ (see section 1.3) in human neuroblastoma (SHSY-5Y) cells as a model of PD. 
However, a lower concentration range of MPP+ (µM concentrations rather an mM) 
was generally used in combination with over extend incubation times, such as 5 days 
(Gómez-Santos et al., 2002; Storch et al., 2000; Kalivendi et al., 2004), compared to 
our model which used a mM concentration with maximum incubation time of 48 h.   
 
In our model the addition of α-syn, together with MPP+, significantly enhanced 
MPP+-induced cell death in a concentration dependent manner (section 4.3.3), were 
α-syn alone did no induce toxicity. When mitochondrial pores were inhibited by the 
addition of CsA we found no reduction to the level of MPP+-induced cell death 
(section 4.3.5). In fact, the addition of CsA resulted in an increase in MPP+-induced 
cell death in a concentration dependent manner (section 4.3.5). This result is 
somewhat surprising given that two previous studies have described the addition of 
the same concentration of CsA as being protective against MPP+-induced apoptosis 
(Seaton et al., 1998; Chalmers-Redman et al., 1999). Fall and Bennett (1998) showed 
that 24 h incubation with 1 µM CsA and 5 mM MPP+ (also in SHSY-5Y cells) 
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doubled the MPP+ toxicity of the cells. This result may be misleading in that our 
study has shown the addition of 5 mM MPP+ alone is enough to induce total cell 
death after 24 h irrespective of the presence of CsA (see section 4.3.1, figure 4.16).   
 
We showed that CsA at low concentrations has no protective effect against MPP+ 
toxicity. This would imply that MPP+ toxicity is independent of mitochondrial pores, 
though the subsequent effects of MPP+-induced toxicity may lead to an opening of 
the mitochondrial pores and loss of membrane potential (Wong et al., 1999; Smeyne 
and Jackson-Lewis, 2005). It may be the case that the previous studies by Seaton et 
al. (1998) and Chalmers-Redman et al. (1999) observed a protective role for CsA 
because of the lower MPP+ concentrations used. This would lead to a prolonged 
exposure to MPP+ increasing the length of time needed to induce cell death. The 
higher concentrations of MPP+ used in our study allowed us to see the ultimate effect 
in a shorter time-span. 
 
To further investigate the role of α-syn in the progression of PD we included α-syn in 
our MPP+ in vitro PD model. As we showed previously, the inhibition of the 
mitochondrial pores with CsA increased MPP+-induced cell death. After addition of 
CsA which blocks the mitochondrial pore, we speculate the addition of α-syn would 
form an alternative pore to the inhibited mitochondrial pore. However, this was 
shown to not be the case (see section 4.3.6) in fact it appears to further increase the 
level of cell death observed, something which has never been reported before. Our 
results described above would suggest that MPP+, CsA and α-syn all induce 
mitochondrial dysfunction by separate pathways (section 4.3.5 and 4.3.8). 
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 To confirm that the effect of α-syn on mitochondrial dysfunction is by a 
mechanism difference to that of both MPP+ (ETC complex I inhibition) and CsA 
(mitochondrial pore inhibition), we investigated the level of cytosolic Ca2+ in our 
MPP+ in vitro PD model. We identified that MPP+ alone did not affect the 
concentration of cytosolic Ca2+, whereas the addition of α-syn with MPP+ 
significantly increased the concentration of cytosolic Ca2+ (see section 4.3.8). This 
increase was not reduced by the addition of CsA. This result and α-syn effect on 
cytosolic Ca2+ alone (section 4.2.5) seems to confirm our belief that the mechanism 
of mitochondrial dysfunction by α-syn is different to that of MPP+ (ETC complex I 
inhibition) and is independent of the mitochondrial pore. Furthermore, this implies 
that α-syn does not have any protective effects but instead increases mitochondrial 
dysfunction, a concequence that becomes toxic in pathologically compromised cells.  
 
5.3 Conclusion. 
In conclusion, we showed α-syn does not induce cell death, but has a detrimental 
effect on cells that would appear to be dependent on the formation of protofibrils. 
From our studies we show that α-syn causes an increase in cytosolic cyt c, Ca2+, 
disruption of the mitochondrial membrane and a reduction in total metabolic output 
in SHSY-5Y cells. This suggests that α-syn causes time- and concentration-
dependent mitochondrial dysfunction. We showed that α-syn-induced mitochondrial 
dysfunction was independent of mitochondrial pores, and have speculated that it 
could be via the formation of α-syn protofibrils. As we have shown α-syn does not 
induce cells death this would suggest the SHSY-5Y cells are able to compensate for 
the detrimental effects of α-syn or that these effects are part of the physiological role 
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of endogenous α-syn. However, when α-syn was exogenously added to our MPP+ PD 
model, it increased cell death. This shows that the MPP+ stressed cells can not 
compensate for mitochondrial dysfuction caused by α-syn. Therefore we have shown 
a possible mechanism by which the potentially physiological role of α-syn may be 
involved in the pathology of PD. 
 
This would suggest that that accumulation of soluble α-syn in cells plays an 
important role in the progression of neurodegenerative disorders like PD, though is 
not the initial factor. As we have shown under normal cellular conditions α-syn does 
induce abnormal effects at low concentrations (less 10 µM) (section 4.1). However 
the accumulation of α-syn induces mitochondrial dysfunction (possibly through the 
formation of protofibril pore) which is exacerbated by cellular stresses leading to cell 
death (section 4.2 and 4.3). In neurodegenerative disorders (such as PD) 
dopaminergic neurones, especially in the SN, are exposed to increased oxidative 
stress and ROS generation due to the synthesis of DA (Wersinger and Sidhu, 2003b). 
This may make the neurones more susceptible to the effects of accumulation of α-
syn. α-Syn could accumulate due to; build of protein overtime, disruption in the UPS 
and degradation pathways or increased expression and up-regulation due to increase 
oxidative stress (da Costa et al., 2000; Quilty et al 2006). The accumulation of α-syn 
would promote α-syn-induced mitochondrial dysfunction, possibly through 
protofibril pore formation, which in combination with the additional cellular stresses 




5.4 Future work. 
Interestingly, β-syn and γ-syn have been shown to inhibit the formation of α-syn 
protofibrils (Park and Lansbury Jr., 2003; Uversky et al., 2002; Tsigelny et al., 
2007), therefore it would be interesting to establish whether β-syn or γ-syn are able 
to prevent the effects of α-syn observed in SHSY-5Y cells. This would be best 
achieved by using our MPP+ PD model. In doing so we would also be able to 
investigate whether β-syn and γ-syn would be able to prevent the increase in 
cytosolic Ca2+ or the loss of mitochondrial membrane potential, indicating if either β-
syn or γ-syn are natural inhibitors of protofibril formation. It would also be 
advantageous to establish whether similar effects of α-syn were observed in primary 
culture and not a neuroblastoma cell line. 
 
In order to elucidate the mechanism of α-syn induced loss of mitochondrial 
membrane potential, further investigations into α-syn interactions with mitochondrial 
proteins would be advisable. This may be facilitated through the tagging of the α-syn 
protein in a manner to allow the visualisation and localisation of the protein within 
the cell. Further to this the tagged α-syn and bound ligand may be isolated and 
analysed by way of mass spectrometry. Such experiments may be able to identify 
potential protein ligands for α-syn and therefore allow us to develop therapeutic 
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